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This work hypothesizes that the molecular characterization of extracellular vesicles (EVs) 
and circulating tumor cells (CTCs), biomarkers found in peripheral blood draws, can be used to 
monitor, and predict, treatment efficacy and patient outcomes in lung cancer.  
First, microfluidic EV isolation technologies were developed, and EV protein 
characterization assays were adapted for use with these technologies.  Isolation strategies 
included (1) Annexin V-phosphatidylserine binding to capture tumor-derived EVs on the device 
surface and (2) isolating natural killer (NK) cell-derived EVs by first capturing NK cells 
followed by on-chip EV biogenesis. Western blot protein analyses were optimized for these 
technologies to verify the presence of EV-specific proteins (CD9, FLOT1, HLA-C) along with 
cell type-specific proteins (CD56). Finally, the DICE device was developed to both isolate EVs 
and characterize select EV-Proteins (CD9, Vimentin, EGFR) on-chip. 
Building off the developed EV characterization methods, EGFR mutations were detected 
longitudinally in both EV-RNA and EV-Protein from 10 metastatic NSCLC patients. For these 
patients, identifying the presence of sensitizing (exon 19 del, L858R) and resistance (T790M) 
EGFR mutations informs sensitivity to tyrosine kinase inhibitors. We demonstrated the presence 
of exon 19 del and L858R mutations within EV-Protein, marking the first study that 
demonstrates the presence of these mutations in patient-derived EVs. At the EV-RNA level, 
exon 19 del mutations were detected in 88% (n=7/8) patients and an increase in mutation burden 
mirrored disease progression and a decrease mirrored stable disease in 100% (n=5/5) of patients 
and in 86% (n=12/14) samples. We additionally profiled 2 patients for L858R and T790M 
xv 
 
mutations, however the detection was more modest at 60% (n=6/10) and 30% (n=3/10) samples, 
respectively. As such, EV-RNA exon 19 del mutation burden has the potential to inform 
treatment decisions in a subpopulation of metastatic NSCLC patients.  
In a cohort of 26 stage III NSCLC patients, CTCs were isolated from all 26 patients using 
the microfluidic graphene oxide (GO) chip at six timepoints during radiation and immunotherapy 
therapies.  Significantly, it was found that having a decrease in CTCs of less than 75% between 
pre-treatment and week 4 of radiation therapy is predictive of significantly shorter progression 
free survival time, 7 months vs 21 months stable monitoring time (p=0.005, log-rank test). 
Additionally, evaluation of PD-L1 expression on the CTCs demonstrated that having a higher 
proportion of PD-L1 CTCs before starting treatment was a potential indicator of metastatic 
potential (p=0.057, log-rank test). Finally, microarray mRNA analysis demonstrated that CTCs 
develop a more aggressive, proliferative phenotype during radiation treatment.   
Finally, to assess the heterogeneity of EV biogenesis for applications in NK-EV 
therapeutics, the droplet microfluidic CellMag-CARWash system was adapted to isolate single 
NK-92MI cells bound with anti-CD56 Dynabeads. It was found that the CellMag-CARWash 
isolates cells that have 3+ Dynabeads attached, with an overall efficiency of 58% ± 7 (n=4), 
while calculations indicate that 1.8 beads should be needed to isolate cells. From a mixed cell 
population, the CellMag-CARWash isolated NK cells with 95% ± 2 (n=4) purity, achieving an 
isolation efficiency of 42% ± 14 (n=3). Prolonged droplet stability was demonstrated, and cell 
viability is 50% after 24 hours in droplets.  
Taken together, these technological advancements represent necessary developments to 
move liquid biopsies from the lab to the clinic. These novel isolation and characterization 
strategies will need to continue to be tested in pilot cohorts and validated in larger cohorts.  
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Chapter 1 Introduction 
 
1. 1         Non-small cell lung cancer (NSCLC) 
Approximately 190,000 people were diagnosed with non-small cell lung cancer (NSCLC) 
in 2020. While localized, NSCLC has a survival rate of  63% and while regional, the survival 
rate is 35%, however when the cancer becomes metastatic the survival rate drops to 7%.1 
Personalized, precision treatment will revolutionize the way we treat cancer, allowing each 
patient to receive only the treatments most likely to lead to positive outcomes. Having highly 
personalized, precise treatments are particularly critical in lung cancers when patients most often 
are diagnosed with late-stage disease because early symptoms are mistaken for infection or 
effects of previous years of smoking.  
Current first line treatment for unresectable stage III, NSCLC patients is combination 
chemotherapy and radiation treatment, Figure 1-1.2 Recent advancements have led to the use of 
antibodies against programmed death ligand 1 (PD-L1) as a checkpoint inhibitor to stop the 
deactivation of T-cells associated with PD-1-PD-L1 interactions.3 The PD-1 cascade is the 
body’s pathway to turn off CD8 T-cells after their activation as a part of an immune response. 
Tumors, however, have high presentation PD-1, resulting in the inactivation of the very T-cells 
that would kill the tumor cells.4 In 2017, the PACIFIC Trials demonstrated that providing 
durvalumab, anti-PD-L1+ immunotherapy, following chemoradiation in stage III NSCLC 
patients led to an increase in progression free survival time from 5.6 months for patients 
receiving placebo to 16.8 months for patients receiving durvalumab.5 However, there is little 
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understanding as to which patients will benefit from durvalumab, as the PD-L1 expression on the 
primary tumor is not taken into account.  
In metastatic, or stage IV, NSCLC, patients qualify for targeted therapies if their primary 
lung tumor has specific mutations in the epidermal growth factor receptor (EGFR) or, less 
commonly, ALK, ROS1, or BRAF, Figure 1-2.2 Three EGFR targeting drugs are a set of small 
molecules termed tyrosine kinase inhibitors (TKIs), targeting tyrosine kinases, the class of 
enzyme to which EGFR belongs. These drugs, however, are either only effective or are 
Figure 1-2 Flowchart for stage IV NSCLC treatment from National Comprehensive 
Cancer Network Guidelines Version 3.2020 Non-Small Cell Lung Cancer.  
Figure 1-1 Flowchart for unresectable stage III NSCLC treatment from National 
Comprehensive Cancer Network Guidelines Version 3.2020 Non-Small Cell Lung Cancer 
3 
 
significantly more effective if the tumor has specific EGFR mutations, such as an exon 21 
L858R substitution mutation or an exon 19 deletion.6  For patients on the common targeted 
therapies erlotinib and gefitinib, drug resistance occurs in as little as nine months, with over half 
of those resistances coming as a result of the T790M mutation.7–9 In 2015, the FDA approved 
osimertinib, a third generation TKI therapy for patients who already have T790M mutations in 
their EGFR. Resistance, however, still occurs in the form of another acquired mutation in exon 
20, C797S.10  
In both stage III and stage IV NSCLC, there is a critical need for precise knowledge of a 
patient’s tumor to allow for the best possible treatment plans. In stage III, current treatment is not 
based on molecular information of the patient’s tumor, and there is an urgent need to determine 
which patients will benefit from the current standard treatments. Conversely, in stage IV, there 
are a myriad of treatment options based on the molecular profile of the tumor, however, 
monitoring methods, including tumor biopsy, are minimally repeatable, which means treatment 
can not accurately reflect changing tumors.  
1. 2         Liquid Biopsy: the role of biomarkers in NSCLC 
Monitoring and molecular characterization of patients’ disease allows clinicians to 
determine the best treatment options. Many groups have proposed a liquid biopsy to identify a 
biomarker in a peripheral blood draw which would be used for the early diagnosis and 
monitoring of cancer. Several potential targets have been identified for such a liquid biopsy, the 
most common of which are circulating tumor DNA (ctDNA), circulating tumor cells (CTCs),  
and extracellular vesicles (EVs).11,12,13 Information about CTCs and EVs can be found in detail 
below, but briefly, ctDNA is a subset of cell free DNA that has been shed from the primary 
tumor to circulate in the bloodstream. ctDNA is mainly released by apoptotic or necrotic tumor 
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cells and contains the genetic signature, including mutations, of their cancer cells of origin.14,15 
Elevated DNA fragment concentrations have been observed in the blood of cancer patients, 
suggesting that this metric may be useful for diagnosis.16 However, to precisely predict tumor 
behavior, assess treatment efficacy, and determine mutational load, it is necessary to determine 
the proportion of aberrant vs. wild-type DNA and thoroughly characterize the tumor-derived 
DNA.17 Additionally, because ctDNA is shed primarily by dying cells, ctDNA may not be shed 
from the most aggressive, invasive, or treatment resistant cells.  
We hypothesize that the molecular characterization of biomarkers, found in a simple 
peripheral blood draw, can be used to monitor, and predict treatment efficacy and patient 
outcomes in lung cancer. It is critical that we develop highly specific, accurate, low-cost testing 
techniques to allow for repeated testing and continued monitoring of NSCLC patients. 
1.2.1      Extracellular vesicles (EVs) 
The first biomarker of interest, extracellular vesicles (EVs) are group of nanovesicles, 
approximately 50-1000nm in diameter, that are released into the blood stream through 
exocytosis.18 While several subtypes of EVs that have been discovered, clear nomenclature is 
still being developed in the field.19 One of the most common subtypes, exosomes, have been 
recently renamed as smallEVs, sEVs, or simply EVs as defined by a specific size range of 50-
200nm for particle sizes.  
EVs are uptaken by distant cells after excretion, allowing for cell-cell communication and 
the transfer of cellular information.20–22 EVs have been found to play many roles in normal 
cellular communication, as well as in cancer. One of these roles is inhibiting normal immune 
response to allow for tumor growth or immune evasion.18 It has been demonstrated by Liu et al. 
in mice that EVs have the ability to increase tumor growth by inhibiting the cytolytic function of 
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natural killer (NK) cells.23  EVs have also been shown to mediate CD8+ T cell apoptosis through 
the expression of the Fas ligand, providing another route for tumor immune evasion.24  In 
addition to immune cell evasion, EVs have been implicated in the formation of the pre-metastatic 
niche. Costa-Silva et al. found that pancreatic ductal adenocarcinoma (PDAC) derived exosomes 
induced liver pre-metastatic niche formation in mice, followed by increased liver tumor burden. 
This cascade began with uptake of PDAC EVs by Kupffer cells, a macrophage in the liver, 
which caused the excretion of growth factors and the upregulation of fibronectin.25 
A second up-and-coming area of EV research, EV engineering for drug delivery, hasled 
to many groups developing novel EV engineering solutions to deliver standard anti-tumor drugs, 
such as chemotherapies or immunotherapies.26 For example, EVs extracted from NSCLC cells 
were embedded with doxorubicin (DOX), a well-known chemotherapy, and conjugated with 
gold nanoparticles. These ‘nanosomes’ were used to deliver drugs to lung cancer cell lines and 
non-tumorigenic lung fibroblasts. Compared with free DOX delivery, the nanosomes had higher 
toxicity against cancer cells, while the effects of DOX on healthy cells were reduced27. One 
group developed hyaluronic acid functionalized extracellular vesicles using lipid-grafting that are 
loaded with DOX to overcome multidrug resistance in breast cancer cell lines.28   
EVs have also been recently used to deliver novel therapeutics, including siRNA and 
CRISPR/Cas-9 to specifically induce cell death in vivo and in vitro, respectively.29,30 Modifying 
the exosomal surface, in addition to loading a therapeutic agent, allows researchers to target 
specific organs or cell type, such as the brain.31 One group genetically modified EVs to express a 
cardiac-targeting peptide on the surface, which increased EV delivery and uptake in the hearts of 
mice.32  A final therapeutic target for EV delivery are miRNAs.33 An exciting application of 
miRNA delivery is the potential to treat therapy-resistant tumors; it was found that delivery of 
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miR-21 inhibitor in conjunction with chemotherapy using engineered EVs reversed drug 
resistance in chemoresistant colon cancer cells.34  
Engineered EVs can either originate from cell culture cells, or donor cells from either 
patient or a specifically matched donor. Recently, groups have begun looking to other sources of 
EVs such as EV-like nanosomes derived from edible plants, because of their safety without the 
challenges of using human-derived EVs.35 These vesicles are isolated using ultracentrifugation 
with density gradient, loaded with therapeutics, and then validated using mouse models by 
delivering the nanosomes orally or intravenously.36 One group used grapefruit-derived 
nanovesicles to deliver chemotherapy and anti-inflammatory drugs and coated nanovesicles with 
activated leucocyte membranes to enter inflammatory sites.37 
Despite their promise, therapeutic applications of EVs are in the very early stages of 
development, and thus far, low production, purification, and recovery rates have hindered their 
widespread appreciation.38 To see EVs adopted in the clinic, it will be critical to thoroughly 
validate the methods for EV delivery and loading while further characterizing the off-target 
effects.  
Finally, EVs contain proteins, miRNA, mRNA, and DNA fragments, which play a role in 
the transfer of information from parent cell to distant cells.39 However, this also allows EVs to be 
used in diagnostic and prognostic assays, as they carry molecular cargoes from their cells of 
origins. Several groups have determined specific miRNA and protein compositions in EVs that 
have potential as diagnostic markers for non-small cell lung cancer. For example, in a cohort of 
stage I and II adenocarcinoma patients, there were similar signatures between exosomal miRNA 
and miRNA from the primary tumor. Additionally, it was found that from a peripheral blood 
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draw, cancer patients had an exosomal concentration of 2.85 mg/mL compared to only 0.77 
mg/mL in a comparable healthy control group.40  
While EVs offer the potential to indirectly profile their cells of origin, they can be 
challenging to isolate and characterize because of their size. For EVs to become clinically 
relevant, isolation workflows need to be developed that yield highly pure EVs and allow for 
highly sensitive downstream applications.  
1.2.2      Circulating tumor cells (CTCs) 
A second common biomarker, circulating tumor cells (CTCs) are cells shed from primary 
tumors that circulate in the bloodstream and may extravasate into peripheral locations in the 
body, causing metastasis.41 CTCs are incredibly rare cells, frequently only 10-100 per mL of 
blood, making it challenging to isolate and interrogate them. CTCs contain proteins, miRNA, 
and RNA that can be quantified, allowing for understanding of the originating tumor.42 It has 
been found for many cancers, including non-small cell lung cancer, that quantity of CTCs as well 
as contents of CTCs, such as mRNA and miRNA can be correlated to progression-free survival, 
overall survival, and disease stage. 42–45 For example, in metastatic breast cancer, it was found 
that patients with fewer than 5 CTCs per 7.5 mL of blood had a better prognosis than their 
counterparts with higher CTC counts.42 CTC isolation technologies have advanced rapidly since 
the discovery of CTCs in the 1960s, although the FDA has only approved one technology, 
CellSearch™, for clinical use. For research purposes, immunoaffinity microfluidic devices, 
inertial microfluidic devices, filtration, magnetic sorting and many other methods have been 
developed allowing for increased characterization opportunities.11 
Ultimately, there are many different biomarkers that could be used to populate a liquid 
biopsy for the early detection or characterization of cancers. Although there have been many 
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advances in technologies for CTC isolation and characterization that have allowed them to start 
to gain traction in clinical settings, the clinical applications of EVs are still in the early stages of 
discovery. 
1. 3         Extracellular vesicle (EV) isolation and characterization strategies  
1.3.1      Conventional isolation strategies 
Conventional EV isolation strategies include differential ultracentrifugation (UC),46 UC 
paired with density gradient,47 filtration,48,49 size exclusion chromotagraphy,50 and polymer 
precipitation kits.51 These methods are known to have different compatibility with downstream 
assays. For example, UC without a gradient has been shown to have lower EV yield, but high 
purity when performing protein analyses compared with polymer precipitation methods.52 
Conversely, polymer precipitation kits have been shown to lead to high contamination but also 
high yield of small RNAs compared to UC.47,52 Conventional strategies have many common 
challenges, including yield, purity, specificity, cost of machinery, and processing time.  
1.3.2      Microfluidic EV isolation technologies 
There is great interest in the development of microfluidic-based platforms for EV 
isolation and profiling to address many of the challenges of conventional isolation strategies. 
These technologies commonly take one of two forms: (1) on-chip EV isolation followed by off-
chip EV characterization or (2) on-chip EV isolation along with on-chip EV profiling. These two 
types of technologies have different uses and applications. For example, on-chip analysis is 
commonly used to profile EVS for a small panel of proteins or RNAs, whereas off-chip analyses 
allow for high-throughput assays such as RNA-seq or proteomics.  
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Technologies that feature on-chip isolation and characterization have become more 
common in recent years, but they are still much less common than purely isolation devices. The 
benefit of this type of device is in their potential ease of use along with decrease loss of sample 
during sample process. In one example, Wu et al. deployed a novel nanomaterial and 
microfluidic based EV characterization technology coined “templated plasmonics for exosomes 
(TPEX).”53 In this method, samples were introduced into the device, followed by incubation and 
dual labeling of samples with fluorescent aptamers and gold nanoparticles. After the 
development of in situ gold nanoshells, changes in fluorescence intensity and absorbance signal 
are monitored. For in situ profiling of EV markers, EVs derived from six cancer cell lines were 
spiked into human serum, and analyzed the expression of CD63, CD24, MUC1, and EpCAM. 
The output from the TPEX compared to conventional ELISA showed to be a better match to pure 
exosomes. In a second, unique approach to on-chip EV analysis, Liu et al. introduced their 
droplet-based single-exosome-counting enzyme-linked immunoassay (droplet digital 
ExoELISA).54 Their device encapsulates antibody-conjugated bead complex with exosomes 
inside a mineral oil droplet. After incubation, an enzyme reporter on catalyzes the substrate 
(fluorescein-di-β-D-galactopyranoside) and produces a fluorescent signal, leading to the 
quantification of a single exosome. As the output result of clinical samples from this device is in 
accordance with other studies, it has been proposed that it can be used as diagnostic device.  
EV capture on-chip followed by off-chip characterization is still the most common 
strategy for EV analysis. Immunoaffinity-based approaches are the most frequent methods used 
in these devices for EV capture. These technologies capture EVs on a surface based on the 
presence of specific EV-proteins or lipids.  The substrate for isolation can be either magnetic 
beads or internal surfaces functionalized with antibodies or aptamers targeting exosomal markers 
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like CD9,55 EPCAM,55–58 CD63,57–61 CD81,62 phosphatidylserine (PS),63 and other markers.64 
For example, Hisey et al developed a device using anti-EpCAM and anti-CD9 coated onto 
herringbone structures to isolate and release exosomes from ovarian cancer.55 Their results show 
a nearly 5-fold higher yield compared to UC. A common challenge of these technologies is that 
it can be problematic to remove EVs from the device, such as would be necessary to perform 
functional studies.  
Microfluidics offer exciting platforms for EV isolation and characterization. However, it 
is critical to thoroughly validate these novel technologies. Because of their small size and low 
cargo concentrations, EV characterization methods following isolation using microfluidics need 
to have high sensitivity. 
1.3.3      Unmet need for approaches to characterize EVs 
The number of EV isolation and characterization workflows have skyrocketed in the last 
number of years. However, for these assays to become clinically relevant, it is critical to 
thoroughly characterize the isolated EVs. While EV classification has become an active area of 
research in recent years, there is still much debate about how the field classifies different 
populations of vesicles. Of the EV excreted by cells, exosomes or sEVs are 50-200 nm in 
diameter, whereas microvesicles or apoptotic bodies are larger, >500nm.65 Other identifying 
features of different EV subtypes are their cargo, including RNA, DNA, proteins, and other 
molecules.  Commonly, EVs between 50-200 nm are isolated and tested for purity as defined by 
a series of characterizations, including morphology, size, concentration, and protein 
composition.66  
The most frequent methods to probe EV morphology and overall purity are microscopy-
based, including atomic force microscopy,67 transmission electron microscopy,68 and field 
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emission scanning electron microscopy.67 These assays are looking to find EVs that are spherical 
in shape and of a consistent size—finding vesicles of a wide range of sizes can indicate less pure 
isolations. Additionally, imaging scans can show other contaminants like protein aggregates, 
which are common in poorly isolated EVs. 
To study EV size distribution, optical methods such as dynamic light scattering and 
nanoparticle tracking analysis (NTA) are performed.69 The most common tool to perform NTA is 
the Nanosight technology (Malvern), however the ZetaView (Particle Metrix) has become more 
popular recently. These technologies are based on measuring the size and concentration of 
nanoparticles based on their Brownian motion. The Nanosight has been found to yield more 
accurate particle sizes, whereas the ZetaView yields a more accurate and repeatable particle 
concentration.70  
Finally, researchers need to demonstrate the presence of specific proteins to validate 
purity and type of vesicles isolated.19 These assays look for specific sets of proteins, including 
elevated expression of several tetraspanins (CD9, CD63, CD81) to demonstrate the presence of 
EVs.  Additionally, EVs need to be probed for cell type-specific proteins along with secondary 
and tertiary EV purity proteins. Protein analysis is frequently achieved through antibody-based 
assays like ELISA and western blotting.69 These assays need fairly high protein concentrations, 
which can be challenging to achieve from EVs. It is critical to validate all EV-protein workflows 
for novel isolation devices to ensure that the isolated EVs are pure and of the correct size and 
morphology.  
1.3.4      Downstream strategies for EV profiling 
Outside of determining the presence and purity of exosomes in a sample, common 
downstream applications of EV isolation include RNA,40,71,72 DNA,73 protein,74,75 and metabolite 
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profiling.76 RNA characterization is commonly performed using reverse transcription-qPCR, 
microarrays, or RNA-sequencing. While standard protein profiling techniques are commonly 
used, increased technological capacities have led to a rise of flow cytometry-based profiling 
techniques.77 Other proteomics strategies such as sodium dodecyl sulfate-polyacrylamide (SDS-
PAGE) gel electrophoresis followed by liquid chromatography-tandem mass spectrometry 
(GeLC–MS/MS),78 and matrix-assisted laser desorption ionization time-off-light (MALDI-
TOF),79,80 have become more prevalent.  
While many novel applications and profiling techniques are being developed for EVs, 
many of these techniques have yet to be applied to microfluidic isolation workflows. There is a 
need to validate many of these more complex analysis methods in conjunction with microfluidic 
EV isolation to ensure the EVs and EV cargoes are not damaged during isolation or isolated in 
too low of a quantity for downstream use.  
1. 4         EVs as potential biomarkers for NSCLC 
As previously stated, EVs originate from all cell types—including tumor cells. These 
tumor derived EVs have been suggested as biomarkers for cancer by many groups. EVs are 
profiled largely for two purposes, diagnostics, and prognostics (or treatment monitoring). For 
clinical diagnostic and prognostic studies, various EV metrics have been proposed, ranging from 
the quantity of EVs to the presence of specific cargoes within the EVs. A critical benefit of EVs 
compared to circulating tumor DNA (ctDNA), another common biomarker, is their various 
cargoes; where ctDNA is restricted to DNA analyses, EVs carry an array of cargoes, including 
RNA, DNA, protein, and lipids.81  Identifying specific molecular targets within EVs will allow 
clinicians to monitor patients non-invasively while also providing highly personalized treatment.  
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Finally, EVs are significantly more stable in blood compared to ctDNA, allowing for ease of 
study and fewer storage restrictions.82,83 
1.4.1      Cancer prognostics 
Using EVs for prognostics can be challenging, as there are currently no ways to isolate 
purely TDEVs. As such, researchers commonly look for molecular signatures found within the 
EVs to predict patient outcomes or treatment efficacy. miRNAs are the most commonly profiled 
EV marker for prognostic and treatment monitoring applications; specific miRNA signatures 
being predictive of worse survival in lung84, liver85,86, colorectal87, glioma88, and prostate89 
cancers. miRNA abundance and expression have also been found to be diagnostic compared to 
healthy controls; lung cancer patients had dramatically higher miRNA expression40 and unique 
signatures90 compared to a healthy populations. Prognostic signatures of EV-mRNA or other 
long RNA have been shown to be predictive of worse survival in several cancers including 
NSCLC,91 and HCC.72 EVs have also been suggested for diagnostic assays for specific tumor 
genotypes; Manda et al. developed a PCR assay to detect EGVR-VIII in high-grade gliomas in 
serum exosomes.92   
Similarly, EV proteins have been suggested for diagnostic and prognostic assays in many 
cancers including lung93,94, breast95, and pancreatic96 cancers. For example, one study used a 
sandwich-ELISA (enzyme-linked immunosorbent assay)-based assay and defined a 30 marker-
panel to distinguish late stage patients with NSCLC from a healthy population.97 Similarly, a 
pilot study analyzed EV protein surface markers to measure chemotherapeutic responses in 
women newly diagnosed with breast cancer.98 Sanfeld-Paulsen et al. used their previously 
developed Extracellular Vesicle Array to capture exosomes using antibodies printed in an array 
on epoxy-coated slides from 276 different patients with NSCLC. They then quantified the 
14 
 
number of exosomes captured by each antibody to cite surface protein expression in the given 
sample of exosomes. They found 100% of patients in their cohort expressed common exosome 
markers CD9 and 81, but more interestingly they found one surface marker that showed 
correlation with overall survival, CD171.93,97 Although potentially interesting, this outcome has 
not been validated. 
1.4.2      Treatment response and resistance monitoring 
In addition to prognostic studies, EV have been profiled to monitor specific therapies and 
resistance, such as chemotherapy, radiation, and immunotherapies. In a cohort of 203 NSCLC 
patients, miR425-3p was identified using HiSeq to differentiate between platinum chemotherapy 
resistant and sensitive patients.99 Similarly, profiling of EV cargoes has been shown to predict 
chemoresistance in CRC.100 Profiling mRNA in EVs is especially useful to monitor 
immunotherapy targets, such as PD-L1 or KRAS. In a cohort of melanoma and NSCLC patients, 
a high presence of PD-L1 in EV RNA correlated to a complete response for patients on anti-PD-
1 antibodies.101 This group used the exosome RNA extraction kit exoRNeasy (Qiagen), which 
first binds exosomes to exoEasy spin columns and then extracts RNA from the bound vesicles 
using Qiazol.101 This result is extremely promising, implying that using EVs from plasma as an 
early response marker is feasible.  However, one immediate problem with this method is that 
digital PCR is incredibly low throughput, only allowing for the measurement of eight samples at 
a time. 
Indeed, EV analysis is a potential tool for early cancer diagnosis, effective treatment 
decision making, and monitoring treatment responses, all of which will increase survival rates. 
The main challenge facing the clinical application of exosomes resides in understanding the 
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mechanisms that regulate their heterogeneity, as changes in TDEs contents can impact the 
reproducibility of diagnostic outcomes.    
1. 5         CTC isolation technologies 
1.5.1      Commercially available isolation methods  
Currently, the only FDA approved CTC isolation technology is CellSearch™, a system 
that uses a ferrofluid tagged with antibodies against the epithelial cell adhesion molecule 
(EpCAM) to magnetically sort EpCAM positive cells. Briefly, CellSearch™,  is a highly 
standardized technology that has been used to enumerate CTCs in large cohorts of breast102,103, 
metastatic colorectal103, prostate, and lung cancer patients. CellSearch™ enumerates CTCs based 
on several metrics, including size, morphology, and the expression of specific proteins. CTCs are 
classified as having a clear nucleus using DAPI staining, along with being cytokeratin (CK) 
positive and CD45 negative using immunofluorescence.  
Although CellSearch™ paved the way to use CTC in clinical settings, there are several 
downfalls to this technology, especially for use in lung cancers. It has been shown in several 
studies that CellSearch™ enumerates low numbers of CTCs from lung cancer patients, with 
several studies finding CTCs in only ~30% of patients. 104,105 One reason for this finding is that 
EpCAM is not expressed in 21.3% of primary lung tumors, indicating that there is a substantial 
population of CTCs that would be missed if isolating using EpCAM alone.106 Finally, the 
CellSearch™ equipment is expensive and requires immediate processing, creating a high barrier 
to entry for CTC studies. 
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1.5.2      Microfluidic isolation technologies 
 A second broad category of CTC isolation technologies are microfluidics, which take 
advantage of either physical properties of CTCs or protein expression on CTCs for isolation 
through immunoaffinity capture.107 The first group, technologies that use physical properties of 
CTCs, are frequently label-free technologies, which offer the benefit of returning an untouched 
pool of CTCs. These technologies rely commonly on the different size of CTCs (15-20µm) 
compared to white blood cells (WBCs, 8-12µm) to isolate pure CTCs. Examples of this type of 
technology include the Labyrinth108,109, the Vortex chip110, and filtration based microdevices.111 
While these technologies allow for a wide array of downstream applications, including 
functional studies, they tend to have low purity and have a high chance of clogging, both of 
which are detrimental to the use of CTCs in clinical settings.  
An alternative, and more commonly used, approach is immunoaffinity microfluidic 
devices that perform either positive or negative selection for antibodies found on cells of interest. 
The first immunoaffinity device, the CTC Chip, was developed in 2007 and used pillar structures 
etched in silicon and functionalized with anti-EpCAM to isolate CTCs from NSCLC patients.112 
This technology captured an average of 155 CTCs/mL compared to the average of 60 CTCs/mL 
isolated by CellSearch in a collective study of prostate, lung, breast, ovarian, and colorectal 
cancers.113 Following the advent of the CTC Chip came modifications to the original design 
including adding chaotic micromixers in the form of a Herringbone device that increases the 
number of collisions between cells and the antibody-coated device surfaces.114 These devices are 
ideal for CTC capture because the length scale afforded is similar to that of surface features on 
cells, allowing for highly specific probing of targeted cells. Other common immunoaffinity 
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microfluidic CTC isolation technologies include the Oncobean Chip115, MagSweeper116, and the 
CTC-iChip117. 
1.5.3      Graphene oxide (GO) chip 
The addition of nanomaterials into immunoaffinity microfluidic devices has increased 
their yield and specificity.  An excellent example of such a device is the graphene oxide (GO) 
chip that uses GO monolayers that have self-assembled onto a gold-patterned surface and are 
then functionalized to allow antibody presentation through Neutravidin-biotin interactions.118 
The capture efficiency of the device was originally reported to be 87% and the surface chemistry 
allows for the conjugation of any biotinylated antibody of interest, allowing the device to be used 
across many cancers. Additionally, due to the large number of active sites, cocktails of 
antibodies can be used on the same device, allowing for the capture of cell populations that 
would otherwise be missed by using only one capture antibodies. This was demonstrated with 
high efficacy in a cohort of stage I-III NSCLC patients, where CTCs were captured using anti-
EPCAM, anti-CD133, and anti-EGFR (epidermal growth factor receptor).119 In this study CTCs 
were detected in all 13 patients and at all 38 timepoints.  
The GO has been applied to numerous studies, demonstrating the efficacy of this device 
to isolate CTCs118–122. An additional benefit of the GO chip is the ability to perform downstream 
RNA characterization. On-chip RNA extraction followed by off-chip RNA purification and 
analysis was performed in studies of CTCs from lung119, prostate122, and breast123 cancer 
patients. In the first two GO Chip studies, the RNA analysis was performed using the highly 
multiplexed Biomark (Fluidigm), which performs RT-qPCR on 96 samples for 96 unique genes, 
while the third used an 18-gene PCR panel. Both Biomark studies were able to generate 
interesting RNA profiles, however this type of analysis would not be sufficient for exploratory 
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studies. Additionally, RNA from CTCs is found to be of a lower quality, making characterization 
even more challenging. There is a need to develop protocols and workflows for post-capture 
CTC-RNA characterization for discovery-based studies.  
1. 6         CTCs as biomarkers in NSCLC 
As previously stated, CTCs make an outstanding potential biomarker in NSCLC because they 
allow you to directly profile the tumor of origin. CTCs have been shown to be useful as both 
diagnostic and prognostic biomarkers in numerous cancers. 
1.6.1      Diagnostics 
Although CTCs are not currently used in clinical NSCLC diagnosis, many CTC metrics 
that have been measured in research settings have shown diagnostic potential. The most common 
of these are enumeration, mRNA, DNA mutations, miRNA, and protein expression. Several 
groups have reported that CTC counts were elevated in patients with NSCLC compared to 
healthy controls, and also that CTC counts decreased when the patients began radiation 
therapy.45,124,125 In addition to CTC enumeration, gene expression profiling could be a potential 
for lung cancer diagnostics. Hayes et al. looked at 51 tumors and 13 healthy controls to 
determine genetic markers for each of the types of lung cancer. For example, genes ASH1 and 
HMGB3 indicated adenocarcinoma with L587S, CLCA2 and HMGB3 determining squamous 
carcinomas.126 If these markers could be found in CTCs, that would represent the ability to 
diagnose specific subtypes of lung cancer.  
1.6.2      Prognostics and treatment monitoring 
In addition to disease diagnosis, CTC contents have been analyzed and several prognostic 
markers have been discovered. Chen et al. measured cytokeratin 19 (CK19) mRNA in CTCs 
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before and after radiation through reverse transcription PCR (RT-PCR). They found that patients 
with CK19 expression after radiation had overall poorer survival and progression-free survival 
compared to patients with negative CK19 mRNA expression.127 Another group performed a 
large-scale analysis using the National Cancer Institute-Cancer Genome Anatomy Project 
database to identify a panel of four genes that could be used together to predict prognosis and 
treatment efficacy. These genes are KRT19, ubiquitin thiolesterase, a gene highly similar to 
HSFIB1 for fibronectin, and TRIM 28.128 
CTCs have also been interrogated for their mutation status and compared to both cfDNA 
and original tumor. In 2008, CTCs isolated from NSCLC patients were tested using allele 
specific PCR for EGFR mutations. T790M mutations were found in 11 of 13 patients compared 
to only finding the mutation in 4 of 12 patients free plasma DNA, with a positive T790M 
mutation conferring drug resistance.129 In 2012, ALK rearrangement was found in both isolated 
CTCs and primary tumor from 5 ALK-positive NSCLC patients, offering a potential screening 
tool for crizotinib treatment.130 
In summary, CTCs offer the potential to be used in clinical settings, especially for 
determining or predicting prognosis or treatment outcomes. CTCs have not, however, crossed the 
necessary barriers to become used routinely in clinics. This is largely because of the isolation and 
characterization workflows used in these studies. As such, there is a need to thoroughly apply 
CTC assays to relevant clinical challenges and then validate these findings in larger cohorts.  
1. 7         Mission statement and hypothesis 
Liquid biopsies have the potential to dramatically alter the way in which we monitor 
cancer and inform treatment decisions. However, the adaptation of liquid biopsies routinely in 
the clinic is hindered by the isolation and characterization workflows for the biomarkers of 
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interest, along with thorough validation of clinical utility on both small and large scales. There is 
a clear need for the development of technologies to analyze EVs from patient plasma, along with 
studies to determine the clinical utility of both CTCs and EVs.  
 To this end, in my thesis I have developed workflows to isolate and analyze EVs, used 
these workflows to interrogate the clinical utility of EV cargoes in lung cancer, and investigated 
the clinical utility of CTCs using a microfluidic CTC isolation device in a population of lung 
cancer patients. These unique projects use techniques that are broadly applicable across the field 
of biomarkers, and the workflows developed are highly versatile and could be applied to a 





Chapter 2 Isolation and Characterization Workflows for Extracellular Vesicle (EV) 
Analysis 
2. 1         Abstract 
Extracellular vesicles (EVs), nanoscale vesicles 50-200nm in diameter, are lipid bound 
vesicles excreted from all cell types that are known to play important roles in the transfer of 
cellular information, drug resistance, and cancer metastasis. Additionally, EVs offer clinical uses 
including as biomarkers for cancer diagnostics or prognostics and drug delivery vehicles. While 
there are numerous reasons to study EVs from a biological and clinical perspective, their small 
size and low cargo concentrations makes them incredibly challenging to work with. As such, it is 
critical to develop highly sensitive isolation and characterization technologies to allow 
researchers and clinicians to harness the full potential of EVs for cancer diagnostics, prognostics, 
and therapeutics.  
Microfluidics offer the potential to isolate EVs with high purity, using smaller sample 
volumes than conventional methods, while still allowing for a wide array of downstream 
applications. Here, several microfluidic technologies are presented that isolate EVs using (1) 
phosphatidyl serine – annexin V binding, the newExoChip (2) On chip NK-EV biogenesis after 
NK cell capture and (3) direct EV biotinylation, DICE device. These methods are then validated 
using the necessary, and critical, characterization workflows, with an emphasis on protein 
characterization. These isolation technologies paired with sensitive characterization workflows 
are then applied to clinical cohorts.  
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2. 2         Resulting Publication Information  
The work within this chapter contains excerpts from the following publications and manuscripts 
as noted: 
1. Y.T. Kang, E. Purcell, C. Palacios-Rolston, T. Lo, N. Ramnath, S. Jolly, and S. Nagrath. 
“Isolation and Profiling of Circulating Tumor-Associated Exosomes Using Extracellular 
Vesicular Lipid–Protein Binding Affinity Based Microfluidic Device.” Small, 2019. 
https://doi.org/10.1002/smll.201903600  
2. Y.T. Kang*, Z. Niu*, T. Hadlock, E. Purcell, T. Lo, M. Zeinali, S. Owen, V. Keshamouni, R. 
Reddy, N. Ramnath, S. Nagrath. “On-Chip biogenesis of circulating NK cell-derived 
exosomes in non-small cell lung cancer exhibit anti-tumoral activity.” Advanced Science, 
2020 
3. Y.T. Kang*; E. Purcell*, T, Hadlock, T. Lo, A. Mutukuri, S. Jolly, and S. Nagrath. 
“Multiplex isolation and profiling of extracellular vesicles using a microfluidic DICE device.” 
Analyst, 2019. https://doi.org/10.1039/C9AN01235D  
Additional publications that have been generated because of the workflows developed in this 
section include:  
1. Y.T. Kang, T. Hadlock, T. Lo, E. Purcell, A. Mutukuri, S. Fouladdel, M. De Silva, H. 
Fairbairn, V. Murlidhar, S.A. Mclean, and S. Nagrath, "Dual-isolation and profiling of 
circulating tumor cells and cancer exosomes from blood samples with melanoma using 




2. T. Lo, Z. Zhu, E. Purcell, D. Watza, J. Wang, Y.T. Kang, S. Jolly, D. Nagrath, and S. 
Nagrath. “Microfluidic device for high-throughput affinity-based isolation of extracellular 
vesicles.” Lab on a Chip, 2020 https://doi.org/10.1039/C9LC01190K     
3. X. Tan, K. Day, X. Li, L. Broses, W. Xue, W. Wu, W. Wang, T.W. Lo, E. Purcell, S. Wang, 
Y.L. Sun, M. Oo, B. Baker, S. Nagrath, M. Day “Quantification and Immunoprofiling of 
Bladder Cancer Cell-Derived Extracellular Vesicles with Microfluidic Chemiluminescent 
ELISA.” In review 
4. Y.T. Kang, Y. J. Kim, B. Rupp, E. Purcell, T. Hadlock, N. Ramnath, S. Nagrath “Isolation 
of circulating markers for liquid biopsy using immunoaffinity-based stimuli-responsive 
hybrid hydrogel beads.” In submission 
2. 3         Introduction 
Although EV biology is a growing field due to their potential as cancer biomarkers, 
current EV isolation methods inhibit our ability to further characterize their diagnostic potential. 
The main challenge is the quantity of exosomes found in the blood. EVs are extremely dilute 
compared to blood cells, making it necessary to concentrate them before performing any 
downstream assays. Similarly, many applications of EVs rely on isolating specific 
subpopulations of EV, such as tumour cell or immune cell derived EVs. There is a need for 
technologies that isolate specific subpopulations of EVs with high purity, allowing for the 
determination of the potential clinical applications of EVs. 
Commercial exosome isolation kits are available and use a variety of techniques ranging 
from spin columns to immunoaffinity assays; however, their selectivity is poor, and these kits 
require many spinning and rinsing steps before running assays.131 Examples of commercial 
products for exosome isolation include ExoQuick (Systems Biosciences) and Total Exosome 
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Isolation Reagent (Thermo). These kits, however, have low purity compared to the gold standard 
method: ultracentrifugation (UC).131  
Ultracentrifugation is the most common EV isolation method; EVs are pelleted using a 
series of sequentially faster centrifugation steps. UC is very reliable and is compatible with a 
range of applications; it is, however, a long process, requires expensive equipment, and can 
damage EV membranes in the process. Despite these shortcomings, ultracentrifugation is 
considered the gold standard for exosome isolation and provides a consistent density-based 
isolation technique that is highly reproducible.132  Although largely effective at separating 
exosomes from other sample components, ultra-centrifugation requires many steps, is time 
intensive, and is not feasible for clinical applications. 
Microfluidics technologies offer many advantages and may become the optimal method 
for exosome isolation in the future. Owing to recent advances, numerous microfluidic devices for 
exosome isolation have been developed with better recovery and shorter processing times 
compared to UC.60,133,134 Among them, immunoaffinity-based microfluidic isolation using 
antibodies against exosomal surface proteins is advantageous as it allows for high specificity 
exosome isolation from heterogeneous samples, such as plasma, serum, or urine. Although very 
selective, antibody binding is strong, making it challenging to remove captured exosomes 
without damaging their membranes. Maintaining membrane integrity is of interest for many 
downstream applications including studying cell-interaction mechanisms.  
Microfluidics allow for on-chip profiling at significantly lower sample volumes than 
traditional assays while achieving higher sensitivity for applications including 
immunofluorescent staining, surface plasmon resonance (SPR), and surface enhanced Raman 
scattering (SERS).135–137 For example, Im et al. used 150 µL pre-processed exosomal samples to 
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evaluate ovarian exosome’s surface expression. While these on-chip profiling technologies are 
one potential path to clinical applicability of EVs, these methods largely require advanced 
knowledge of the target EVs to functionalize a device to capture the specific EVs within the 
sample.  
As an example, antibodies against the tetraspanin CD63 have been widely applied to 
exosome isolation from the plasma of patients with ovarian cancer, breast cancer, and 
glioblastoma.64,138–142 However, anti-CD63 is not a specific biomarker for any one cancer, and its 
expression is known to vary depending on the type of cancer.143 Recent studies using clinical 
samples showed that only 69.56% of lung cancer patients have CD63 positive exosomes with 
comparably low absolute expression level compared to other exosomal markers.94,144 To date, a 
few cancer specific exosomal proteins such as epidermal growth factor receptor (EGFR), 
prostate-specific antigen (PSA), and epidermal growth factor receptor 2 (HER2) have been 
incorporated into microfluidics for cancer-associated exosome isolation for lung, prostate, and 
breast cancers, respectively.145–147 However, none of these methods isolate purely tumour derived 
EVs (TDEs), and even fewer technologies isolate immune cell derived EVs or exosomes.  
Following the development of an isolation technology, it is critical to ensure that the 
isolated vesicles are pure and the vesicles of interest. Nomenclature and definitions around the 
types of EVs are currently being developed among researchers. A body of researchers, the 
International Society of Extracellular Vesicles, has set out a series of guidelines defining the 
characteristics and assays needed to definitely call a researcher’s isolated samples extracellular 
vesicles or exosomes.19 These include size (50-200nm), morphology, and the most challenging 
characteristic, protein expression. Proteins found in EVs differ based on the cell type of origin, 
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therefore protein assays need to be optimized and validated for each cell type and technology, 
and protein characterization technologies are in high demand.  
In summary, there is a need for microfluidic technologies that isolate specific EV 
populations using immunoaffinity-based chemistries. However, it is also beneficial to be able to 
release the EVs or use viable EVs after isolation. As such, the chemistries need to allow for a 
release mechanism that does not use highly basic solutions or high temperatures. Following 
isolation, it is critical to have accurate workflows for EV characterization to ensure that the 
samples are isolated with high purity and sensitivity. Finally, there is a need to develop 
technologies that couple isolation and characterization to decrease the amount of precious sample 
used.  
2. 4         Methods 
2.4.1      Ultracentrifugation 
 Plasma or cell culture media was centrifuged at 12,000xg for 20 minutes to remove 
cellular debris. The supernatant was then ultracentrifuged at 100,000xg for 90 min to pellet the 
EVs using 36 mL Polyethylene terephthalate (PET) tubes (Thermo Fisher).  Excess tube volume 
was filled with sterile PBS pH 7.4 (Gibco). The extracellular vesicle-pellet was washed with PBS 
and centrifuged at 100,000 x g for 90 min. Extracellular vesicles were suspended in 100 µL PBS 
pH 7.4 or RIPA with protease inhibitor cocktail (Fisher Scientific) and frozen at -20°C. EVs 
stored in PBS were then used for nanoparticle tracking analysis along with RNA extraction and 
characterization, while EVs in RIPA were used for western blot analysis.  
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2.4.2      Nanoparticle tracking analysis (NTA) 
Nanoparticle tracking analysis (NTA) was performed using Malvern’s Nanosight 
equipment. Two operation procedures were used depending on the volume of the sample. For 
larger volumes, quantification was performed using five 30-second runs at a flow rate of 20 
using the brightness setting of 15.  The camera detection was set to a level of 4 for all runs. Runs 
were then averaged with the average and standard deviation between the runs being reported. For 
smaller volumes, 30 µL of the prepared solution was applied to the jig of the system. The particle 
movement was monitored through a video sequence for 20 s in triplicate in stagnant mode. For 
either sample type, all data acquisition and processing were performed using NanoSight NS300 
control software, and concentration of particles in exosome size range was used for calculating 
capture and release efficiencies of the present platform. 
2.4.3      Protein extraction and Western Blot  
EVs were isolated from ultracentrifugation into 150 µL RIPA buffer (Thermo Scientific, 
cat #89900), protein concentration was measured by microBCA™ Protein Assay Kit (Thermo 
Scientific cat #23235). Western blot loading was normalized by using 5mL blood volume for 
extracellular vesicle isolation, loading the maximum protein (37.5 µL) in each lane, and using 
Bio-Rad’s Stain Free gels to allow normalization. Briefly, the protein was separated at 250V for 
30 minutes. Semi-dry transfer was then performed using Trans-Blot Turbo Transfer System 
(Bio-Rad) to a high fluorescence PVFD membrane (Bio-Rad, cat #1620261). The membrane was 
imaged using Bio-Rad’s ChemiDoc to quantify total protein per lane. The membrane was 
blocked and incubated overnight with primary antibody in 5mL of 5% bovine serum albumin 
(Sigma-Alrich) in Tris Buffered Saline (TBS) (Bio-Rad). with 1% Tween 20 (Sigma-Aldrich) 
(TBST). The membrane was then washed thoroughly before incubating with HRP-secondary 
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antibody in 3% nonfat milk in TBST for 90 minutes followed again by additional washes. 
Measurement was performed using SuperSignal™ West Pico PLUS Chemiluminescent Substrate 
(Bio-Rad, Cat#34579) and SuperSignal West Femto (Thermo, cat #34096) and imaged on the 
ChemiDoc. 
2.4.4      Wes Protein Processing 
The Wes system from Protein Simple was used according to manufacturer’s protocol. EV 
samples were isolated into RIPA buffer, same as for western blots. 3µL of protein lysate was 
used per sample, per lane. All antibodies used were from a rabbit host, and so the anti-rabbit 
detection kit was used (Protein Simple). The CD9 antibody (CellSignaling) was used at 1:50 
dilution, and the EGF Receptor antibody (CellSignaling) was used at 1:10 dilution.  
2.4.5      newExoChip fabrication and processing  
2.4.4.1  Device design and fabrication  
The newExoChip device has 30 ripple‐shaped channels, and each channel is composed of 
60 circular channels in a row. Each circle has a diameter of 500 µm and the distance between 
each circle is 900 µm. The newExoChip is fabricated by standard soft lithography including mold 
fabrication and PDMS molding. For the surface modification on the device, standard avidin–
biotin chemistry was used with optimization. In the final step, the devices were injected with 
Avidin (1 mL of filtered PBS + 100 µL of NeutrAvidin), placed in a Petri dish sealed with 
parafilm along with wet paper napkins, and incubated overnight in a standard refrigerator. After 
1–10 days, the devices were defrosted and washed out with filtered PBS. Before the biotinylated 
annexin V conjugation, the coverage of avidin in our device was checked and confirmed using 
biotinylated staining dye (Supporting Information S3). The devices were then injected with 110 
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µL of the biotinylated annexin V (10 µL annexin V + 100 µL of 1× binding buffer): 55 µL into 
the inlet, a 30‐min incubation period, 55 µL into the outlet, and another 30‐min incubation period 
before use. 
2.4.4.2 Sample Processing—Exosome Capture and Release  
The prepared model samples or patient plasma samples were processed using a Harvard 
syringe pump at the flow rate of 0.3–1.2 mL h−1. All samples were prepared in the 1× of binding 
buffer containing 2.5 mm of CaCl2 to be actively conjugated with annexin V. 300 µL of sample 
was withdrawn into a 1 mL syringe and connected to the device. After exosome capture, 200 µL 
of 1× binding buffer was processed at the flow rate of 1 mL h−1 to remove the excess unbound 
vesicles/proteins. For the release of the captured exosomes, 300 µL of 20 mm EDTA solution 
was flowed at the flow rate of 1 mL h−1 in two steps: the 1st 150 µL injection and 30 min 
incubation without flow. Another 150 µL was flowed and 200 µL of PBS buffer injection was 
followed at the flow rate of 1 mL h−1 to make sample 500 µL in total. 
2.4.4.3 On‐chip Protein Extraction and Western Blot Analysis  
Exosome lysis was performed using RIPA buffer with 1% protease inhibitor. The 
prepared buffer solution was flowed through the device at the flow rate of 50 µL min−1 right after 
exosome isolation. Initially, 40 µL of sample was injected to remove residual solution in the 
device and sample collection was started after 40 µL. This was immediately followed by an 
injection of 50 µL per device at the same rate. Devices were incubated for 5 min, and then 
injected with another 50 µL at 50 µL min−1. Finally, devices were manually injected with air to 
push out as much sample as possible from each device. The collected samples were then gently 
dispersed by vortex mixer and kept at −20 °C. Western blot analysis was performed as 
previously described (Chapter 2 Methods 2.4.3). Specifically, primary antibodies were 
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incubated overnight on a rocker at 4 °C at a concentration of 1:500 (Flotillin‐1, Santa Cruz), 
1:1000 (CD9, Cell Signaling; Calnexin, Cell Signaling), or 1:1500 (Beta‐Actin, Cell Signaling) 
in 3% non‐fat milk in TBST. Thorough rinsing was performed, and then secondary antibody was 
incubated for 2 h at room temperature (anti‐Mouse, Santa Cruz; anti‐Rabbit HRP, Cell 
Signaling) at 1:1500 in 3% non‐fat milk in TBST. 
2.4.6      NK-cell derived EV workflow to protein extraction 
2.4.5.1 Exosome biogenesis on graphene oxide (GO) chip 
NK cell capture was performed by flowing the sample containing NK cells through the 
prepared GO chip devices using a syringe pump at a flow rate of 1 mL h−1. PBS buffer was then 
applied to wash away nonbonded cells. 300 µL of MEM‐alpha serum‐free media with 20% 
exosome‐depleted fetal bovine serum (FBS) (Gibco, USA) and 200U/ml recombinant human 
interleukin 2 (rhIL‐2) (PeproTech, USA) was then pumped into the device with low flow rate (1 
mL h−1). Incubation for 12 h with the whole device was then performed at 37 °C, 5% 
CO2 incubator Galaxy 14S (Brunswick, USA) to generate the EV-rich supernatant.  
2.4.5.2 NK Cell‐Derived Exosomes Isolation/Release Using Magnetic Beads for Protein 
Extraction 
200 µL of supernatant from the device was directly applied to the prepared magnetic 
beads (ExoBead) conjugated with anti-CD63 for exosome capture. This mixture was incubated 
on a rotator for an hour, and magnetic beads were separated using a magnet, followed by PBS 
washing three times. The beads right after this step underwent SEM or western blot analysis. For 
the release of the captured exosomes on the beads, 1 mL of 0.5 × 10−3 M biotin solutions was 
added to the separated beads, consisting of 1 mL of filtered water and 10 µL of biotin solution 
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and incubated for 0.5–2 h. RIPA buffer with 1% protease inhibitor was prepared for lysis of 
captured exosomes. 30 µL of the prepared buffer solution was injected to postcapture ExoBeads 
and incubated for 20 min. After incubation, the protein lysate was aspirated and stored 
separately. Western blots were performed based on the protocols described above. Primary 
antibodies for this project were: Flotillin 1 (1:1000 dilution), HLA-C (1:2000 dilution), and 
CD56 (1:1000 dilution). Secondaries were anti-mouse HRP (1:1500 dilution, SantaCruz) and 
anti-rabbit HRP (1:1500 dilution, Cell Signaling).  
2.4.7      DICE Device fabrication and processing  
2.4.6.1 DICE Fabrication 
The DICE device has four quadrants, with each quadrant having 13 × 13 circular 
chambers connected by junction channels. Each circular chamber has a diameter of 100 μm and 
the pitch is 500 μm. The circular chamber design facilitates efficient EV isolation and easy 
analysis based on our previous simulation and experimental results.14 The height of the device is 
50 μm and to achieve this high-aspect ratio design, we fabricate the mold using deep reactive-ion 
etching (DRIE). Briefly, SPR220 was spin coated onto a four-inch silicon wafer at a thickness of 
3 μm before exposure and post-baking. DRIE was then performed to achieve a height of 56.1 ± 
0.79 μm. After mold fabrication, the DICE device was fabricated by combining PDMS and 
PDMS curing agent mix (1:10) before baking overnight at 70 °C. The prepared PDMS layer was 
bonded to an untreated glass slide by O2 plasma treatment. 
2.4.6.2 Device Functionalization 
For the surface modification of the device, we used standard avidin–biotin chemistry with 
optimization. Following initial device fabrication, ethanol with silane solution was injected into 
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each device and incubated for an hour. Each device was then injected with GMBS solution (5 
mL ethanol + 14 μL GMBS) and incubated for 30 minutes. Each device was once again washed 
out with ethanol before injection with a NeutrAvidin solution (1 mL filtered PBS + 100 μL 
NeutrAvidin). Each device was then stored in a parafilm sealed Petri dish containing wet paper 
and stored at 4 °C for future use. Devices used as no surface modification controls were not 
treated by the modification procedure. Control devices were injected with 3% BSA solution 
(0.03 g per 1 mL filtered PBS) to prevent nonspecific binding and incubated for at least 30 
minutes. This 3% BSA solution was washed out with PBS buffer before storage and use. 
2.4.6.3 Extracellular vesicle purification and sample preparation 
The sample collection and experiments were approved by University of Michigan 
Institutional Review Board (IRB). Informed consents were obtained from all participants of this 
clinical study and blood samples were obtained after approval of the institutional review board at 
the University of Michigan. All experiments were performed in accordance with the approved 
guidelines and regulations by the ethics committee at the University of Michigan. EV 
purification from the blood sample was followed by recent consents for general EV research. 
Whole blood samples were collected in EDTA tubes and were subsequently centrifuged at 2000g 
for 15 minutes to isolate plasma. The isolated plasma samples from cancer and healthy donors 
were kept at −80 °C before use and used within 6 months. From the separated plasma layer, 100 
μL aliquots were placed into ultracentrifugation tubes (Beckman Coulter, United State) along 
with 100 μL of 0.2 μm filtered PBS. The tubed samples then underwent Airfuge 
ultracentrifugation (Beckman Coulter, United States) using an A-100/30 angle rotor for 40 
minutes at 100 000g. After the 1st ultracentrifugation, 150 μL of supernatant was removed from 
each tube and replaced with 150 μL of filtered PBS, followed by an additional round of 
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ultracentrifugation at 100 000g for 40 minutes. Following ultracentrifugation, 150 μL of 
supernatant from each tube was discarded and the remaining contents containing the purified EV 
pellet were ready for biotinylation. For the performance verification of the DICE device, purified 
EVs from A549 lung adenocarcinoma were purchased and used as a model sample. This EV 
sample was directly biotinylated without any purification steps. 
2.4.6.4 Biotinylation of extracellular vesicles 
Purified EVs were biotinylated for non-biased immobilization following the EZ-Link 
protocol with optimization. EZ link biotin powder, EZ-Link Sulfo-NHS-LC-Biotin 
(ThermoScientific, United States) was utilized for EV biotinylation during these experiments. A 
10× concentration of 300 μM biotin solution was prepared by dissolving 1.6 mg of E–Z link 
biotin in 10 mL of filtered PBS. This 10× solution was then diluted to 1× by incorporating 100 
μL of the 10× solution with an additional 900 μL of filtered PBS. 100 μL of 1× 300 μM biotin 
solution was then added to 50 μL of purified EVs, followed by a 1-hour incubation. Refrigerated 
desalt spin columns were prepared using repeated PBS washing and centrifugation steps 
following the manufacturer stated procedure. After the hour-long EV incubation, 150 μL of the 
biotinylated EV sample was injected into the desalt spin column and centrifuged at 1500g for 2 
minutes. The sample was then passed through a 0.2 μm filter and stored in vials at −80 °C for 
future use. Biotinylation of purified A549 cell derived EVs for the EV immobilization on chip 
experiment followed the same procedure as that of clinical samples. To evaluate the effect of 
biotinylation on EV's surface marker binding sites, we prepared two different EV samples using 
a plasma sample from a healthy control: one before and one after biotinylation. EVs were 
isolated using an Airfuge ultracentrifugation using the previously described procedures. One 150 
μL sample was then biotinylated using the previously outline biotinylation procedure, while 
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another 150 μL sample did not undergo biotinylation. Both biotinylated and non-biotinylated 
samples were injected with 5 μL of CD9 anti-rabbit antibody in ultracentrifugation tubes and 
allowed to incubate for 1 hour. Each sample underwent a second Airfuge ultracentrifugation for 
20 minutes at 100 000g, followed by extraction of 100 μL of supernatant to remove excess 
antibody. 50 μL of filtered PBS was then added to the remaining sample in each UC tube, along 
with 3 μL of AlexaFluor 647 goat anti-rabbit (ThermoScientific, United States). This secondary 
antibody was incubated for 1 hour followed by 20-minute ultracentrifugation at 100 000g. After 
ultracentrifugation, 50 μl of sample was extracted from each UC vial and the pellet was 
discarded. The fluorescence intensities from these samples were compared by using a 
fluorescence microscope. 
2.4.6.5 Device operation and performance verification 
The prepared model samples or patient biotinylated EV samples were processed using a 
Harvard syringe pump. Filtered PBS was first injected through the inlet of each device to remove 
leftover NeutrAvidin. A total of 100 μL of pre-enriched EV sample was then pumped through 
the inlet of each device, followed by another PBS wash step to clear any non-bonded sample 
from the PDMS chamber. Multiplexed immunofluorescence staining was performed by using 
each of four different outlets to inject either specific antibodies or lipophilic dyes. 
2.4.6.4 Field emission scanning electron microscopy (FE-SEM) analysis 
EVs captured within the device were fixed in 2.5% glutaraldehyde for one hour to retain 
their morphology. After rinsing with PBS, the samples were dehydrated in a graded 
concentration of ethanol (50%, 70%, 90%, 95%, and 100%) for 10 min at each step (two times 
for 100%). The samples were dried using hexamethyldisilane, followed by overnight air drying 
in the hood. The dehydrated samples were then mounted on aluminum stubs and sputter coated 
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with gold to create a conductive layer. The samples were observed by FEI Nova 200 Nanolab 
Dualbeam FIB scanning electron microscope at The Michigan Center for Materials 
Characterization (MC2) at University of Michigan. 
2.4.6.5 On-chip immunostaining analysis 
For immunofluorescence staining, each device was first blocked with 5% BSA solution. 
Next, inlet tubing was removed from each device and 3′′ tubing was attached to each of the four 
outlets. Through each of these outlets, 50 μL of either PD-L1, Vimentin, CD9, or EGFR (1 : 20 
dilution in 1% BSA solution) were applied and incubated overnight at 4 °C. After overnight 
incubation, a PBS wash was run through each outlet to remove excess primaries. The outlet 
tubing was then removed, and a single tube was attached to the inlet. A secondary solution of 2.5 
μL anti-mouse IgG2b 488 and 2.5 μL anti-rabbit IgG 647 in 100 μL of 1%BSA was pumped 
through the device inlet and incubated for 35 minutes. A final PBS wash was applied through the 
inlet to clear unbound secondaries. Each device was then imaged at 4×, 10×, 20×, and 40× 
magnification (Eclipse TI2, Nikon, Japan.) Devices were scanned in FITC for PD-L1 
confirmation and CY5 for confirmation of Vimentin, CD9, and EGFR. Analysis was performed 
by measuring the fluorescent intensity of each circular chamber in each quadrant. The average 
intensity across all chambers per quadrant was taken by dividing total intensity by the area of the 
chambers summed. The standard deviation is then representative of the variations in fluorescence 
intensity across all the chambers in one quadrant. 
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2. 5         Results 
2.5.1      Optimized workflows for EV quantification and characterization 
The backbone for EV research is the isolation and validation workflows that come before 
the downstream clinical or biological application. First, several isolation methods are available, 
ultracentrifugation131,148, commercial kits (commonly polymer precipitation) 47,51,52, and 
immunoaffinity (commonly microfluidics)63,141,149–152, Figure 2-1. Following isolation, the 
International Society for Extracellular Vesicles has created a checklist for the necessary 
workflows to validate pure EV isolation.19 The backbone for these workflows is shown in Figure 
2-1. These guidelines require protein expression69, size and concentration measurement69, and 
then morphology validation using electron microscopy67,68. From there, the EVs can be used for 
clinical applications such as RNA profiling40,65,68,92,153,154, protein expression78–80, functional 
analysis155–157, or drug delivery26,29,30,33,34. To perform NTA, electron microscopy, or applications 
Figure 2-1 Outline of EV isolation, characterization, and profiling methods.  
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where intact EVs are needed, the EVs are isolated straight into PBS. If protein characterization is 
the goal, then the EVs are isolated into RIPA with PIC.  
Each study involving EVs must go through the required assays as shown in “Necessary 
Characterizations” in Figure 2-1. before researchers can proceed with their application (i.e. 
biomarker, drug delivery, etc). An example of the data collected from these workflows are 
shown in Figure 2-2. For these experiments, EVs were isolated from either cell culture media or 
plasma using ultracentrifugation and isolated into two buffers, the first into PBS and the second 
into RIPA buffer. From the PBS samples, NTA and transmission electron microscope were 
performed to validate the size and shape of the EVs, along with quantifying the concentration of 
the EVs, Figure 2-2A. The NTA results indicate a clean sample with most vesicles within the 
expected size range, 50-200nm, Figure 2-2A. The TEM image indicates a nice round, spherical 
morphology, demonstrating an intact EV at the correct size, 85nm, Figure 2-2B.  From the RIPA 
sample, western blots were performed to show the presence of the EV-specific proteins CD9 and 




 NTA and EM workflows remain the same for all samples, however, different EV 
populations will express unique EV-specific proteins. For example, it is known that EVs from 
lung cancer plasma have elevated CD9 and CD81, but low CD63, while EVs from NK cells do 
not express CD9 or the other tetraspanins.19,94 These restrictions mean that optimization needs to 
be performed for every unique EV application. In the next several sections, I describe unique EV 




Figure 2-2 Examples of EV characterization assays 
A. Nanoparticle tracking analysis (NTA) of a cell-line derived EV sample indicates the 
concentration and size of isolated EVs. B. Transmission electron microscopy (TEM) of a 
single EV isolated from a plasma sample. Scale bar is 1µm. C. Western blot analysis of EVs 
isolation from 1-5mL of plasma using UC. The EVs were analyzed for both CD9 and CD81, 





2.5.2      newExoChip isolation technology using PS-Annexin V binding chemistry to isolate 
tumor-specific exosomes 
As discussed above, the first step in the EV or exosome workflow is reliable isolation. 
However, one of the main challenges of using EVs for clinical and biological applications in 
cancer is isolating purely tumor derived EVs. Immunoaffinity‐based microfluidic EV isolation 
using anti‐CD63 is widely used; however, anti‐CD63 is not specific to cancer‐EVs, and some 
cancers secrete EVs with low expression of CD63.143 For example, recent studies using clinical 
samples showed that only 69.56% of lung cancer patients have CD63 positive exosomes with 
comparably low absolute expression level compared to other exosomal markers.144 To date, a 
few cancer specific exosomal proteins such as epidermal growth factor receptor (EGFR), 
prostate-specific antigen (PSA), and epidermal growth factor receptor 2 (HER2) have been 
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incorporated into microfluidics for cancer-associated exosome isolation for lung, prostate, and 
breast cancers, respectively.145,146 
Alternatively, phosphatidylserine (PS), usually expressed in the inner leaflet of the lipid 
bilayer of the cells, is shown to be expressed on the outer surface of cancer associated EVs. A 
new exosome isolation microfluidic device (newExoChip), conjugated with a PS‐specific protein, 
to isolate cancer‐associated exosomes from plasma, is presented, Figure 2-3. Briefly, the device 
achieves 90% capture efficiency for cancer cell exosomes compared to 38% for healthy 
exosomes and isolates 35% more A549‐derived exosomes than an anti‐CD63‐conjugated device. 
Immobilized exosomes are then easily released using Ca2+ chelation. The recovered exosomes 
Figure 2-3 Design of the newExoChip with schematic of capture mechanism. 
A. Picture of the newExoChip with dimensions, indicating the many chambers for exosome 
capture. B. Illustration of the capture and release schematic for the PS-Annexin V isolation 
and release chemistry. 
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from clinical samples are characterized by electron microscopy and western‐blot analysis, 
revealing exosomal shapes and exosomal protein expressions. The newExoChip facilitates the 
isolation of a specific subset of exosomes, allowing the exploration of the undiscovered roles of 
exosomes in cancer progression and metastasis.  
 The annexin V immobilized microfluidic device is designed with alternating narrow and 
wide ripple‐like designs, inspired by the ExoChip, that enhances the binding interaction between 
specific exosomes and PS‐targeting molecules, thus resulting in higher capture efficiency and 
purity at conditions of high flow rates (Figure 2-3). Compared to our previous ExoChip60, 
the newExoChip has 225 times more micro‐sized circular chambers, enabling faster sample 
processing with higher selectivity (Figure 2-3A). COMSOL models indicate that there are lower 
velocities along the edges of the circular chambers than the rectangular chambers, Figure 2-4. 
This lower velocity allows the EVs to better bind to the device, slower velocities mean increased 
binding time and hence higher binding potential. This higher binding potential allows us to 
capture higher concentrations of EVs compared to previous device designs.  
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Following validation experiments with control devices and cell line models, we then 
applied this technology to study clinical blood samples from patients with non‐small cell lung 
cancer (NSCLC) and melanoma to verify the translational potential of our devices. This was the 
first device that we developed and there were concerns about whether the newExoChip would 
isolate enough EV material to fully characterize, especially when using our protein workflows.  
We extended our study to 12 clinical plasma samples from lung (n = 4), melanoma (n = 
3) and healthy donors (n = 5). In all cases, we used 30–100 µL of plasma samples for exosome 
isolation using our newExoChip. The concentration, size distribution, shapes, and proteins 
A B 
C D 
Velocity - Streamlines Velocity - Surface 
Velocity - Streamlines Velocity - Surface 
Figure 2-4. Comparative COMSOL models of the newExoChip.  
A-B. Velocity profiles for newExoChip and C-D. a standard rectangular chamber demonstrates the 
decrease in velocity along the edge of the chambers. This decrease in velocity allows for increase 
binding in the newExoChip. 
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expression levels of exosomes released from the device were evaluated using NTA, SEM, and 
western blot analysis. Figure 2-5A shows the various exosome concentrations for each patient 
and by cancer type. Although the five healthy donors show similar exosomal concentrations, the 
cancer patients showed a wide range of exosome concentrations. The Ma showed the highest 
(2.79 × 109 per mL) and Ld showed the lowest concentration (2.89 × 108). Statistical analysis of 
particle size confirmed specificity of most samples, both cancerous and healthy (Figure 2-5B). 
While there is a wide range of particulate sizes captured, the mean size of every sample falls 
below 150 nm in diameter, and the mode of each sample (excluding Ld) falls lower than the 
corresponding mean. Interestingly, the average size of exosomes from lung cancer was bigger 
than those of melanoma and healthy control. Similar size differences were shown in our cell line 
experiments. This could imply that lung cancer exosomes isolated by PS‐annexin V affinity 
might be larger than usual or that another majority of extracellular vesicles in lung cancer might 
affect this size distribution. However, this information, along with the median values, showed 
that a considerable portion of samples collected from all sample types fall within the exosomal 




To confirm that the captured vesicles from our device are exosomes, we used western 
blot analysis to verify the expression of exosomal markers. Instead of using CD63, which is 
known to have lower expression on lung cancer exosomes, we used CD9 and Flotillin‐1 as 
exosomal markers. From the western blot analysis using three lung plasma samples and two 
melanoma samples, we see positive bands for both exosomal markers (Figure 2-5D). 
Additionally, the samples were probed for Beta‐Actin as a standard loading control and calnexin 
to verify that there was no cellular contamination within the samples.  
Figure 2-5. Isolation of exosomes from clinical samples from cancer patients and healthy 
donors.  
A. Vesicle size distribution regarding mean, mode, and D‐values (D10, D50, and D90) after 
release. B. Exosome concentration after newExoChip‐based exosome recovery. C. SEM 
image of isolated exosome and the magnified view of the exosome from a melanoma patient. 
D. A representative western blot analysis of the protein isolated from newExoChip and 
characterized for exosomal markers and intracellular protein marker in five different cancer 
patients' plasma samples. 
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In summary, the PS-Annexin V binding chemistry of the newExoChip allows us to capture 
highly pure cancer-associated EVs from clinical plasma samples. This offers the potential for 
clinical applications of EVs for diagnostics and prognostics. However, this chemistry is only 
effective for tumor derived EVs. Other EVs of interest, including those from immune cells, 
would not be captured using this method. As such, other isolation chemistries are needed.  
 
The results and excerpts in this section are found in the following publication:  
Y.T. Kang, E. Purcell, C. Palacios-Rolston, T. Lo, N. Ramnath, S. Jolly, and S. Nagrath. 
“Isolation and Profiling of Circulating Tumor-Associated Exosomes Using Extracellular 




2.5.3      On‐Chip Biogenesis of Circulating NK Cell‐Derived Exosomes in Non‐Small Cell 
Lung Cancer Exhibits Antitumoral Activity 
 As the recognition between natural killer (NK) cells and cancer cells does not require 
antigen presentation, NK cells are being actively studied for use in adoptive cell therapies in the 
rapidly evolving armamentarium of cancer immunotherapy. In addition to utilizing NK cells, 
recent studies have shown that exosomes derived from NK cells also exhibit antitumor 
properties. Furthermore, these NK cell‐derived exosomes exhibit higher stability, greater 
modification potentials and less immunogenicity compared to NK cells. Therefore, technologies 
that allow highly sensitive and specific isolation of NK cells and NK cell‐derived exosomes can 
enable personalized NK‐mediated cancer therapeutics in the future.  
Figure 2-6. Schematic for the workflow to isolate NK-exosomes after on-chip biogenesis 
from captured NK cells. 
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Here, a novel microfluidic system to collect patient‐specific NK cells and on‐chip 
biogenesis of NK‐exosomes is proposed, the schematic of the workflow is show in Figure 2-6. 
In a small cohort of non‐small cell lung cancer (NSCLC) patients, both NK cells and circulating 
tumor cells (CTCs) were isolated, and it is found NSCLC patients have high numbers of NK and 
NK‐exosomes compared with healthy donors, and these concentrations show a trend of positive 
and negative correlations with bloodborne CTC numbers, respectively. It is further demonstrated 
that the NK‐exosomes harvested from NK‐graphene oxide chip exhibit cytotoxic effect on CTCs. 
This versatile system is expected to be used for patient‐specific NK‐based immunotherapies 
along with CTCs for potential prognostic/diagnostic applications.  
 However, for this application to become clinical feasible, thorough characterization of the 
isolated exosomes is critical. The isolation of exosomes after isolation of the parent cells on the 
GO chip is a novel technique, and we again needed to establish whether there would be enough 
product for characterization. Because the cells, and not the EVs, were captured, we needed to 
validate whether the quantity of EV-protein was sufficient for western blot analysis. A further 
challenge of this technology is that we isolated NK cell derived EVs, which are notorious for not 
expressing CD9, our best EV-marker.19 As such, we tested and optimized new markers, flotillin 
1 (FLOT1) and HLA-C, both of which fall within MISEV’s guidelines for EV purity. 
  In our clinical cohort of 5 lung cancer patients and 2 healthy controls, we first 
demonstrated the isolation of NK cells on the NK-GO chip Figure 2-7A. The highly pure NK 
cell isolation allows us to ensure that the collected EVs are definitively NK-EVs. The purity of 
those EVs was qualified using FLOT-1 and HLA-C, Figure 2-7B.  Although both healthy donors 
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and lung cancer patients had varying levels of both, the strong presence of both markers indicates 
the definite isolation of EVs. This result also demonstrates that despite only using a very low 
number of EVs, we were able to get reliable western blot results. This is emphasized by the 
finding that patients’ samples from which we captured only 1,000 NK cells excreted only 2x108 
EVs, which is notably lower than other devices we have developed, Figure 2-7C. The western 
blot purity finding is further complemented by the finding that our EV isolation from NK-cells 
on GO chip led to EV purities that were above 60% by size, and above 80% for 4 out of 5 lung 
cancer patients. Finally, we were able to calculate the excretion rate of NK cell-derived EVs on 
chip per NK-cell, which has been rarely studied, Figure 2-7D. The excretion rate finding is the 
driving force for the final chapter of this thesis, Chapter 5.  
Figure 2-7 Analysis of clinical samples from NSCLC patients using NK‐GO microfluidic 
platform. 
 A. Immunofluorescence image examples of CD56/NCR1 + NK cells captured on NK‐GO 
chip (Scale bar = 20 µm); B. western blot analysis for showing the positive expression of 
FLOT1 and HLA‐C in exosomes from clinical samples; C. profiling in quantity of NK cells 
and NK cell‐derived exosomes among different patients and healthy individuals observed after 
12 h on‐chip incubation; D. total extracellular vesicle concentration and percentage of 
exosomes among patient samples and healthy control samples; E. biogenesis of exosomes 




The results and excerpts in this section are found in the following publication:  
Y.T. Kang*, Z. Niu*, T. Hadlock, E. Purcell, T. Lo, M. Zeinali, S. Owen, V. Keshamouni, R. 
Reddy, N. Ramnath, S. Nagrath. “On-Chip biogenesis of circulating NK cell-derived exosomes 
in non-small cell lung cancer exhibit anti-tumoral activity.” Advanced Science, 2020 
 
2.5.4      Multiplex isolation and profiling of extracellular vesicles using a microfluidic 
DICE device. 
In addition to their use as isolation technologies, microfluidics offer the opportunity to 
perform on-chip characterization of isolated molecules, including EVs. In this work, we present a 
simple strategy to immobilize and analyze EVs for multiple markers on a single microfluidic 
device and perform differentiated immunostaining-based characterization of extracellular 
vesicles (DICE). This device, composed of four quadrants with a single inlet, captures 
biotinylated EVs efficiently and facilitates multiplexed immuno- staining to profile their 
extracellular proteins, allowing for a multiplexed approach for non-invasive cancer diagnostics in 
the future, Figure 2-8. From controlled sample experiments using cancer cell line derived EVs 
and specific fluorescence staining with lipophilic dyes, we identified that the DICE device is 
capable of isolating biotinylated EVs with 84.4% immobilization efficiency. We extended our 
study to profile EVs of 9 clinical samples from non-small cell lung cancer (NSCLC) patients and 
healthy donors and found that the DICE device successfully facilitates immunofluorescent 
staining for both the NSCLC patients and the healthy control. This versatile and simple method 
to profile EVs could be extended to EVs of any biological origin, promoting discoveries of the 
role of EVs in disease diagnostics and monitoring.  
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2.5.4.1 Device optimization and on-chip EV immobilization  
To isolate and analyze EVs in a non-biased way, we designed an EV isolation device that 
was antigen independent. For that, we pre-conjugated biotin onto the surface of EVs for 
immobilization on our microfluidic device, Figure 2-8A. This streamlined procedure uses only 
20 µL of sample and is sufficient to analyze using immunostaining. After the biotinylation of 
EVs, we evaluated their size profiles by using NTA, the average vesicle size within tested 
samples falls within the standard 50–200 nm size distinction of EVs, which agrees with 
previously reported values.147,158 The ability of the DICE device to utilize avidin/biotin affinity 
for EV capture was examined by NTA, fluorescence imaging and scanning electron microscope 
analysis. First, we prepared two different DICE devices with and without NeutrAvidin 
conjugation and processed an identical amount of biotin conjugated A549 EVs to evaluate the 
EV immobilization efficiency of our device. The concentration of initial and resulting (after EV 
Figure 2-8. Differentiated immunostaining characterization of extracellular vesicle (DICE) 
chip for extracellular vesicle profiling 
 A. Procedure of the DICE; B. Fabricated DICE device (left) and immobilized extracellular 
vesicles in DICE device (right), scale bar is 500nm; C. Design of the DICE device. 
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capture) samples were compared using the NanoSight NS300 (Marven Instruments, UK) EV 
concentration within biotinylated samples measured both pre- and post-capture using NTA. 
As seen in Figure 2-9A, NeutrAvidin conjugated DICE devices are nearly four times 
more effective than control devices at immobilizing biotinylated EVs. To confirm this 
immobilization qualitatively, we used immunofluorescent staining and SEM analysis. Non-
conjugated and NeutrAvidin conjugated devices were injected with biotinylated EVs, followed 
by an incubation periods and PBS wash. Green PKH dye was then applied to each device, 
staining the lipid bilayer of EVs still present within the device. Figure 2-9B shows the 
significant presence of EVs within NeutrAvidin conjugated devices, demonstrating the 
effectiveness of the avidin/biotin-based EV capture within the small chambers of the DICE 
device. To further confirm the presence of EVs in the device, SEM images were taken showing 
the capture of EVs both in the chambers and along the channels of the device, Figure 2-9C. The 
25,000× image confirms the previously reported spherical morphology of EVs, further 
confirming the pure isolation of EVs from our samples. 
Figure 2-9 Biotinylation and isolation of extracellular vesicles 
A. Immobilization efficiency of A549 derived exosomes compared to a control device without 
streptavidin conjugation; B. The immobilized extracellular vesicles stained with lipophilic 
dye, PKH-green; C. Scanning electron micro- scope (SEM) analysis of the on-chip 
immobilized extracellular vesicles from the lung cancer cell line, A549. Scale bars are 100 





2.5.4.2 Multiplexed profiling of the EVs from clinical samples 
We analyzed our small clinical cohort (n = 5 NSCLC patients, n = 4 healthy control) in 
terms of nanoparticle tracking analysis and immunostaining results. Multiplexed profiling of EVs 
from patient samples was carried out using the DICE device. Lung cancer patient and healthy 
donor blood samples were processed to isolate and then biotinylate EVs for experimental use. 
EV sample concentrations were measured using NTA analysis before being applied to the DICE 
device. EV concentration and size results, given in Figure 2-10A, demonstrate a 186% greater 
EV concentration within samples derived from lung cancer patients than in healthy patient 
samples. While the greater number of EVs in cancer has been previously reported159,160, this 
result also indicates the utility of this EV isolation method for lung cancer samples. Recent 
studies with larger sample size reported no significant difference in total EV concentration in 
plasma between cancer patients and healthy donors.161,162 Mean value of particles within both 
lung cancer patients and healthy donors were reasonably equivalent (116.92 vs. 117.25). Healthy 
donor and lung cancer patient samples were applied to NeutrAvidin conjugated DICE devices for 
EV immobilization.  
Multiplex profiling was then performed utilizing simultaneous application of PD-L1, 
Vimentin, CD9, and EGFR antibodies followed by secondary fluorescent antibodies. Fluorescent 
imaging showed considerable presence of all four antibodies on the surface of the captured EV. 
As demonstrated in Figure 2-10B, which depicts the significant capture of EGFR-expressing 
EVs, three of the four quadrants of each device were positive in their specified secondary 
fluorescent channel (FITC anti- mouse IgG2b 488 for PD-L1 and CY5 anti-rabbit IgG 647 for 
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Vimentin, CD9, and EGFR). Fluorescent intensity was determined by measuring the intensity of 
the entire area of each quadrant of the device and subtracting away the background intensity. 
This normalized the intensity normalizes for fluctuations in background light and small device 
defects. Additionally, the same volume of plasma was run through each device, to normalize for 
volume.  
The three quadrants that were positive (Vimentin, CD9 and EGFR) were all stained with 
the same secondary antibody (anti-rabbit IgG 647) while the secondary antibody for PD-L1 was 
different because of the differing host of the PD-L1 antibody (rabbit vs. mouse), Figure 2-10C. 
Figure 2-10. DICE-based multiplexing results of 5 different clinical samples 
 A. EV concentration and size distribution analysis; B. Evaluation of EGFR expression on EVs 
from a lung cancer patient. (Scale bar = 50 μm); C. Immunofluorescence intensity analysis of 
clinical samples using three different protein markers including Vimentin, CD9 and EGFR. 
Expression in arbitrary units. 
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It is possible that the reason there was no positive signal for PD-L1 was because of the differing 
imaging wavelength as well as the different secondary antibodies. Further testing would be 
needed to verify that this was a true negative PD-L1 staining. Other than HC1, EGFR intensities 
of lung cancer patients were found to be higher than that of healthy controls. Vimentin, which 
was found to be expressed on lung cancer EVs, is also notably expressed in EVs from healthy 
donors. Because vimentin is one of the most dominant cytoskeletal elements in leukocytes163, 
one might want to interpret a high expression of vimentin on healthy EVs with care.  
We have found similar results of person-dependent differential protein expression using 
the quantitative western blot system, the Wes (Protein Simple). The Wes uses capillary action to 
quantify protein expression from only 3µL of protein lysate. The Wes creates an output of a 
protein peak, in a.u., with marked molecular weights as quantified based on loaded standards. 
Using healthy plasma in a titration from 1mL to 4mL, EVs were isolated using 
ultracentrifugation. The protein was then processed using the Wes for the EV protein CD9, 
allowing for quantified protein expression. This method is beneficial because of the ability to 
directly compare protein expression between samples. In Table 2-1 we see that as plasma 
volume increases, so does CD9 expression, which makes logical sense. This is corroborated by 
the result from Figure 2-2, where protein concentration appears to increase with increased 
volume. However, the Wes allows us to see that the CD9 concentration does not increase 







Table 2-1 CD9 protein quantification using Wes System 
Patient ID: Plasma volume Total CD9 quantity (a.u.) CD9 per mL (a.u./mL) 
HC5 1 mL 0 0 
HC5 2 mL 4,514 2,257 
HC5 3 mL 12,023 4,007 
HC5 4 mL 63,256 15,814 
HC6 1 mL 12,132 12,132 
HC6 2 mL 32,147 16,073 
HC6 3 mL 55,478 18,492 
 
We then moved to use the Wes system to profile patient samples for CD9 and found that 
there is a wide array of concentrations between patients, even when normalized for starting 
volume of plasma. Interestingly, like from the DICE device, we find that the amount of CD9 on 
the isolated EVs varies most dramatically by person, and is cancer independent. It is interesting 
to note that Lung Cancer 1-4 all have metastatic lung cancer, and have dramatically higher CD9, 
while Liver Cancer 1 has stage II hepatocellular carcinoma and DCIS 1 has ductal carcinoma in 
situ, or the earliest stage of breast cancer, and they have lower CD9 expression. This could be 
because the samples have more EVs or higher CD9 expression, further analysis would be 
needed. Finally, we used two samples to demonstrate the presence of EGFR, a protein of interest 
in many cancers, in EVs from cell lines (H3255) and Lung Cancer Patient 5.  
Table 2-2 CD9 expression in cancer patient derived EVs 
Patient ID: CD9 per mL (a.u./mL) 
Lung Cancer 1 38,071 
Lung Cancer 2 85,095 
Lung Cancer 3 6,308  
Lung Cancer 4 10,681 
Liver Cancer 1 1,095 





Table 2-3 CD9 and EGFR expression using Wes 
Sample Type: Protein: Protein expression (a.u.) 
H3255 CD9 959,580 
H3255 EGFR 36,789 
Lung Cancer 5 CD9 681,603 
Lung Cancer 5 EGFR 704,345 
 
The results and excerpts in this section are found in the following publication:  
Y. T. Kang*, E. Purcell*, T. Hadlock* et al. Multiplex isolation and profiling of extracellular 
vesicles using a microfluidic DICE device. Analyst 144, 5785–5793 (2019). 
2. 6         Discussion 
 The study of EVs will allow researchers to develop diagnostic and prognostic tests, 
understand cancer biology, and develop cancer therapeutics. Microfluidic technologies are 
highlighted when used to isolate EVs from the plasma of cancer patients, allowing researchers to 
study these nanosized particles more effectively. First, it is critical to validate all novel 
technologies for their ability to isolate pure EVs or exosomes. This is done to the MISEV 
standards to ensure consistency within the field, allowing EVs to become clinically relevant 
biomarkers. The most challenging aspect of validating the purity of isolated vesicles is protein 
characterization. Western blots are the standard method for probing a sample for proteins of 
interest. However, this method traditionally uses large volumes or high concentrations of protein 
to ensure success. It was necessary to first develop western blot workflows and then validate 
them using microfluidic technologies developed in our lab. Here I presented several novel 
microfluidic EV, or exosome, isolation and profiling technologies along with the western blot 
analyses that ensured the purity of the isolated samples.  
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 Using the first device presented, the newExoChip, we showed that our PS targeting 
microfluidic device is capable of capturing tumor-associated exosomes more efficiently than the 
previous ultracentrifugation method and well-known exosomal protein marker method. Although 
most previous studies have focused on exosomal proteins, monitoring the exosomal lipids for 
alteration depending on the disease status might be more suited for clinical use. Exosomes from 
tumor cells have been shown to have the potential to induce antitumor activity, so their PS 
expression might help its activation. Thus, the exosomes isolated using this PS-based method 
might be more effective to induce immune response, suggesting that this subset might be useful 
for further clinical use. Several prospective studies have shown that PS is expressed on cancer 
derived exosomes in ovarian cancer and prostate cancer. In addition to these, our studies making 
use of PS expression on exosomes from lung cancer and melanoma is consistent with previous 
results. These results empower the theory that cancer exosomes express PS abundantly and may 
induce some immune response. The present newExoChip facilitates the isolation of cancer-
associated exosomes, thus allowing us to explore the undiscovered roles of exosomes in cancer 
progression and metastasis. 
 The second workflow presented uses the graphene oxide (GO) microfluidic chip to 
isolate NK cells.  As a proof of concept, here we have demonstrated the possibility of a 
streamlined microfluidic approach to on‐chip biogenesis and harvest of natural killer cell‐derived 
exosomes through comprehensive studies using NK cell lines and clinical samples from lung 
cancer patients. In the future, NK cell‐derived exosomes may find a complementary use as both 
diagnosis and therapeutic tools for patients with cancer. Given the burgeoning interest in this 
field, it is important to fill the technical gaps pertaining to exosome isolation, harvest, and 
expansion. We hereby present a highly sensitive method to isolate NK exosomes derived from 
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viable NK cells using our NK‐GO chip. Using the NK‐GO chip, we showed that patients with 
non‐small cell lung cancer presented with high numbers of NK and NK cell‐derived exosomes 
compared with healthy donors.  
 Finally, the potential of the microfluidic DICE device was presented as a multiplexed 
isolation and protein profiling tool through simultaneous studies using cancer cell derived EVs 
and plasma samples from cancer and healthy donors. These results demonstrate the ability of the 
DICE device to successfully capture and multiplex concentrated EV samples. As biotinylation of 
concentrated EV samples allows for the capture of EVs of unknown origin, the ability to derive 
the protein profile of EVs on the DICE device enables a rapid and thorough investigation into the 
vesicles source. The ability to separate and differentiate multiple primary and secondary 
antibodies within the four channels of the device demonstrates the DICE device’s potential as a 
platform for multiplex profiling involving antibodies other than the four tested here. Although 
we found that the expression of EV proteins is largely patient dependent, we were able to 
corroborate this finding using the Wes system, where we found that CD9 expression is highly 
person dependent.  
 In conclusion, microfluidic technologies offer the potential to isolate EVs with high 
purity and at enough for the necessary characterization assays. EV isolation technologies come in 
many forms depending on the objective of the device, and it is critical that characterization 
assays are developed and validated for all those technologies. Here I have presented three unique 
methods for EV isolation and the western blot characterizations that validated their isolation 




Chapter 3 Mutation Monitoring of EV-RNA and EV-Protein in Metastatic NSCLC 
Patients to Predict Patient Outcomes. 
 
3. 1         Abstract 
Extracellular vesicles (EVs) are a stable, abundant biomarker in the blood commonly 
used to serially profile molecular characteristics of patient tumors through a non-invasive liquid 
biopsy. In non-small cell lung cancer (NSCLC), identifying the presence of sensitizing and 
resistance epidermal growth factor receptor (EGFR) mutations dictates treatment plans. Here, 
EVs isolated from stage IV NSCLC patients were longitudinally monitored for the presence of 
sensitizing and resistant mutations. EGFR mutations were detected in both EV-derived RNA 
(EV-RNA) and EV-derived protein (EV-protein), demonstrating the benefits of using EVs for 
multiplexed cargo analysis that is not possible with other common biomarkers. Using EV-RNA, 
tumor biopsy matched sensitizing mutations (exon 19 del and L858R) were detected in 90% of 
patients and resistance (T790M) mutations in 100% of patients. For exon 19 deletion positive 
patients with 2+ serial timepoints, mutant EV-RNA burden mirrored disease trajectory in 100% 
of patients.  
3. 2         Resulting Publication Information  
E. Purcell*; S. Owen*, E. Prantzalos, A. Radomski, N. Carman, T. Lo, C. Subramanian, N. 
Ramnath, and S. Nagrath. “Detection of EGFR mutations in exosomal RNA and protein mirrors 
disease status in metastatic non-small cell lung cancer patients.” In submission 
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3. 3         Introduction 
The widespread adoption of targeted therapies using small molecule tyrosine kinase 
inhibitors (TKIs) has greatly benefited the 10-30% of advanced non-small cell lung cancer 
(NSCLC) patients who  have sensitizing epidermal growth factor receptor (EGFR) mutations in 
an otherwise challenging to treat cancer.164,165 This subset of NSCLC patients harboring 
sensitizing (L858R and exon 19 deletion (exon 19 del)) EGFR mutations have seen significantly 
improved survival due to TKIs; yet resistance often occurs in as few as nine months, commonly 
through the secondary EGFR T790M mutation.7–9 While it has been documented that additional 
mutations arise during treatment, traditional tumor monitoring technologies are not commonly 
used to monitor for these changes. To improve patient care, it is critical to have real-time 
knowledge of a patient’s mutation status, thereby allowing clinicians to alter treatment strategies 
accordingly. As such, the development of a method for non-invasive longitudinal monitoring 
offers the potential to drastically improve real-time treatment personalization.  
Due the invasiveness and localized sampling of the tumor biopsy, the gold standard in 
patient care is not frequently used for repeated monitoring, may not result in enough material for 
testing2, and may miss mutations carried in other tumor regions. To address these challenges, 
advancements in liquid biopsies have led to the clinical use of blood-based biomarkers, mostly 
commonly circulating tumor DNA (ctDNA), to monitor changes in the tumor non-invasively and 
longitudinally.166 Yet, ctDNA assays are limited by several notable technical challenges; ctDNA 
is shed only during cell death167 and suffers from low abundance17 and rapid clearance from 
circulation.168,169 Hence, ctDNA has the potential to miss the most current molecular changes in a 
tumor cells that are the most evasive leading to treatment resistant. 
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Extracellular vesicles (EVs), lipid bilayer bound nanovesicles approximately 30-150 nm 
in diameter, are a promising alternative blood-based biomarker offering increased abundance and 
stability compared to ctDNA.82,83 They are functional vesicles secreted from live cells as a 
mechanism of cell-cell communication and contain cargo from their originating cells, including 
DNA, RNA, and protein, which is protected by the lipid bilayer from exogenous degradation 
while in circulation.18  The stability of these vesicles in circulation is the key distinguishing 
factor compared to ctDNA.  
Given the tiny amount of cargo carried by these nano-sized vesicles, the development of 
techniques that can analyze these important carriers is an active area of research in recent times. 
To date, groups have largely been limited to microRNA or protein to glean information about a 
patient’s disease, and to develop diagnostic and prognostic signatures.40,170 A final key benefit of 
using EVs for a liquid biopsy compared to ctDNA is the ability to performed multiplexed 
analysis of EV-derived RNA (EV-RNA) and EV-derived protein (EV-protein). However, thus 
far, the detection of mutations carried in EVs in either analyte has been reported by few groups 
and has been biased towards nucleic acid analysis, with few groups reporting the detection of 
mutant proteins in extracellular vesicles. 
 Significantly, mutation profiling in extracellular vesicles is an emerging field, with the 
first studies focusing on the detection of cancer-specific mutations.171–174 Mutations carried in 
EVs have been shown in glioblastoma, pancreatic cancer, and NSCLC. The clinical application 
has centered on improving detection rates compared to ctDNA alone, commonly by combining 
ctDNA with  DNA and RNA derived from exosomes (a subset of small EVs).174,175 Most 
recently, Castellanos-Rizaldos et al. co-isolated exosomal RNA and cell-free RNA for mutation 
detection from a panel of 30 EGFR mutations. Similar to other studies, this work was limited 
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based on the use of pre-amplification steps prior to qPCR, which can introduce signal strength 
bias, for mutation detection and was constrained to a single time point for evaluation. While 
increasing the detection rate of these rare mutations was achieved, these studies have not 
demonstrated their utility in a clinical setting and remain single-analyte analyses.  
Although there have been no studies using mutations carried in EVs to monitor a cohort 
of patients, initial evidence suggests this tracking may enable enhanced patient monitoring.176  
Therefore, to provide clinical benefit, the use of mutational profiling in EVs needs to advance 
beyond single timepoint detection for longitudinal mutation burden monitoring.  This approach 
necessitates a more robust and unbiased analytical techniques to provide molecular information 
not attainable through radiographic imaging, the current gold standard.  
This study followed a cohort of metastatic NSCLC patients to quantify the EGFR 
mutation burden carried in EV cargo. Sensitive approaches were optimized to profile the 
mutations carried in EVs at the RNA and protein levels. Specifically, digital droplet-based PCR 
(ddPCR) was used to analyze the EV-RNA without pre-amplification while mutated protein 
content of EVs was profiled using western blot. Patients carried at least one sensitizing EGFR 
mutation (exon 19 del, L858R) based on tumor biopsy and were receiving TKI therapy at the 
time of enrollment. Moreover, a subset of patients in this study already carried the resistance 
T790M mutation at the beginning of longitudinal monitoring. Resistance mutations would 
potentially decrease the efficacy of TKIs, although novel TKIs are being developed to target 
these mutations as well. Despite the predicted TKI sensitivity, patients had differing therapeutic 
responses, which is a well-known challenge of TKI therapies. As such, there is a need to develop 
an enhanced approach to predict who will have favorable outcomes, or who should receive an 
alternative therapy.  
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To this end, in this study the cohort was longitudinally monitored for EGFR mutation 
burden carried by EV-RNA and EV-protein. To date, to the best of our knowledge, there have be 
no previous studies tracking exclusively EV mutations in a cohort of cancer patients using EV-
RNA or EV-protein cargo. This study highlights the potential benefits of dual-monitoring both 
EV-RNA and EV-protein; distinct roles for EV-RNA and EV-protein were revealed.  
3. 4         Methods 
3.4.1      Patient Enrollment 
All blood was collected following IRB (HUM00119934) approval, and all patients gave their 
informed consent to participate in the study. All patients had metastatic lung adenocarcinoma. 
The cohort of patients in this study had known EGFR mutations.  




3.4.2      EV Isolation from cell culture and patient plasma 
EVs were first isolated and characterized from cells in culture to validate our assays. H1975, 
H3255 and H1650 cells were grown in RPMI-1640 (Gibco) supplemented with 10% fetal bovine 
serum (FBS) (Sigma-Alrich) and 1% Antibiotic-antimycotic (Gibco). Cells were grown to 80% 
confluence before subculturing using 0.05% Trypsin-EDTA (Gibco).  To prepare extracellular 
vesicles, cells were seeded at 3,000,000 cells/100 mm dish (Sarstedt) in complete media. 24 
hours after seeding, cells were washed three times with phosphate-buffered saline (PBS) pH 7.4 
(Gibco) and incubated for 72 hours in serum-free RPMI-1640 media (Gibco). Cell culture media 
(CCM) was centrifuged at 2,000 x g for 15 min and frozen at -20°C. This media was processed 
according to the  
Plasma was prepared for EV isolation using one of the following three methods and was stored 
in the -80C freezer until use.  
Plasma prep 1 (Ficoll): Whole blood was collected in EDTA tubes. Samples were 
prepared using Ficoll-PaqueTM PLUS (GE Healthcare) following the manufacturer’s 
protocol. The plasma and leukocyte layers were collected for CTC isolation and effluents 
were centrifuged following the plasma prep 3 protocol.  
Plasma prep 2 (Dextran): Whole blood was collected in EDTA tubes. 1 mL of 6% 
dextran solution (w/v) was mixed into 5 mL whole blood. The sample sat 1-1.5 hours at 
room temperature to allow the red blood cells sedimentation. The supernatant was 




Plasma prep 3: Whole blood was collected in EDTA tubes was centrifuged at 2,000xg 
for 15 minutes at room temperature. The plasma supernatant was collected and frozen at -
20°C for up to 30 days. 
EVs were isolated from either plasma, plasma preps, or cell culture media using 
ultracentrifugation, see Chapter 2 Methods 2.4.1 Ultracentrifugation.   
3.4.3      EV quantification and RNA extraction 
After isolation using UC, the EVs that had been suspended in PBS were split for quantification 
and RNA extraction. EVs were first quantified for size and concentration using NTA using 
Malvern’s Nanosight. Quantification was performed using five 30-second runs at a flow rate of 
20 using the brightness setting of 15.  The camera detection was set to a level of 4 for all runs. 
Runs were then averaged with the average and standard deviation between the runs being 
reported.  
The remaining EVs in PBS were lysed using TrizolTM Reagent (Trizol) (Invitrogen) at a 1:10 
ratio of extracellular vesicle suspension to Trizol and incubated at room temperature for 5 
minutes. A 1:5 ratio of chloroform (Sigma-Aldrich) to Trizol was added and briefly vortexed to 
mix, then incubated for 2-3 minutes at room temperature. The sample was centrifuged at 
12,000xg for 15 minutes. The aqueous phase was collected and mixed in a 1:1 ratio with 70% 
ethanol (Sigma-Aldrich). Total RNA was purified using the Norgen Single Cell RNA isolation 
kit (Norgen Biotek Corp.). cDNA was prepared using SuperScript IV VILO Master Mix with 
ezDNase Enzyme (Invitrogen) following the manufacturer’s protocol. All purified RNA and 
cDNA products were handled in a PCR workstation to prevent contamination. 
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3.4.4      EV-RNA processing validation using RT-qPCR  
Reverse transcription quantitative PCR (RT-qPCR) was used to validate the EV processing 
conditions to ensure the EVs were not degraded. 20µL TaqManTM gene expression PCR 
reactions were prepared using TaqManTM Fast Advanced Master Mix (Applied Biosystems) in 
96-well MicroAmp Fast Optical Plates (Applied Biosystems) and processed on a QuantStudio 3 
(Applied Biosystems) using fast cycling conditions. Each mRNA:sample pair was analyzed in 
technical triplicates. 
Table 3-1 TaqManTM gene expression assay IDs 
TaqManTM gene expression assay IDs 
Gene Assay ID 
ACTB Hs01060665_g1 
GAPDH Hs03929097_g1 
3.4.5      Cell-free DNA extraction and mutation profiling 
Cell-free DNA (cfDNA) was isolated from the plasma using the QIAamp Circulating Nucleic 
Acid Kit (Qiagen) following the manufacturer’s processing protocol. cfDNA was eluted into 15 
μL for ddPCR mutation detection, see below section. 
3.4.6      Mutation detection by droplet digital PCR 
EGFR mutations were identified by using RainDropTM ddPCR (RainDance Technologies). In 
brief 25 μL reactions were prepared using TaqManTM SNP Assay (Life Technologies), 2x 
TaqMan Genotyping Master Mix (Applied Biosystems), and droplet stabilizer (RainDance 
Technologies). Maximum cDNA was loaded into each dPCR reaction. The PCR reaction was 
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loaded onto the Source Chip (RainDance Technologies) to for droplet generation and collected 
into an 8-tube PCR strip (Axygen). The PCR tubes were transferred to the thermocycler for 45 
rounds of PCR amplification (Bio-Rad). The PCR tubes, containing the samples, were then 
transferred onto the Sense Machine (RainDance Technologies) where the fluorescence intensity 
of each droplet was measured.  
For the point mutations, L858R and T790M, mutations were considered present based on the 
detection of one or more positive droplets within the pre-established gates based on positive EV-
RNA controls. For exon 19 del, deletions were considered present based on the detection of one 
or more positive droplets above the threshold. A threshold for detection was determined based on 
the number of false positive droplets detected using EV-RNA negative controls. The maximum 
number of false positive droplets detected in any negative control (16 droplets) was used as the 
threshold for detection. All presented data is represented as the threshold subtracted from the 
total number of mutant positive droplets counted and any further normalization specified in the 
respective figure.  
Table 3-2 TaqManTM EGFR mutation detection assay IDs 
Gene Assay ID 
L858R AHRSRSV 
T790M AHRSROS 
Exon 19 deletion Hs00000228_mu 
68 
 
3.4.7      EV-protein extraction, quantification, normalization 
EV-protein was extracted and western blots were performed according to the methods outlined in 
Chapter 2 Method 2.4.3 Protein Extraction and Western Blot. The primary antibodies used 
in this work are listed in Table 3-3.  
Table 3-3 Antibodies for EV-protein analysis using western blot 
Target protein Dilution Catalog number 
(Cell Signaling) 
CD9 1:1000 #13174 
ACTB  1:1000 #4970 
GAPDH  1:1000 #5174S 
Calnexin 1:1000 #2679 
EGF Receptor L858R Mutant 
Specific 
1:1000 #3197 
EGF Receptor exon 19 E746-
A750del specific 
1:1000 #2085 
Anti-rabbit IgG, HRP-linked 
Antibody 
1:1500 #7074S 
Western blots normalization was performed following Bio-Rad’s Stain Free Gel analysis 
protocols. Briefly, following protein separation and transfer, the blot is imaged using Bio-Rad’s 
Stain Free Blot imaging setting to capture the total protein per lane. Using Bio-Rad’s Image Lab 
6.0.1 software, the total protein in each lane is compared and a normalization coefficient 
determined. After blotting for specific proteins, each band is compared to the total protein of the 
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lane, adjusted using the normalization coefficient, and quantified as a Normalized Protein 
Intensity.  
3. 5         Results  
3.5.1      EV Cargo Carries Mutations from Cells of Origin 
To first establish experimental protocols and demonstrate the presence of EGFR 
mutations in EVs, EVs secreted from lung cancer cell lines with known EGFR mutations were 
tested for EGFR mutations. EV-RNA and EV-protein were tested using ddPCR and western blot, 
respectively. ddPCR offers a highly sensitive platform to directly quantify the number of mutant 
transcripts from bulk RNA without risk of pre-amplification bias177, allowing for direct 
comparison between samples and patients. Briefly, the EVs were lysed using TrizolTM Reagent. 
The Norgen Single Cell RNA kit (Norgen Biotek) was used to purify and isolate the EV-RNA, 
due to the miniscule amount of RNA contained in these samples. RNA was reverse transcribed 
and directly loaded onto the RainDropTM (RainDance Technologies) ddPCR system for analysis.  
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Matching the cells of origin, EV-RNA derived from H3255 carried a heterozygous 
L858R mutation (Figure 3-2A, Figure 3-3), EVs from H1975 carried heterozygous L858R and 
T790M mutations (Figure 3-2A), and EVs from H1650 carried exon 19 del (Figure 3-2B). As 
expected, the assay showed that the EVs were negative for EGFR mutations that were not 
present originally in their cell line of origin. Additionally, in healthy donor EV-RNA (HC1-3), 
no mutant droplets were detected in these samples using either the L858R or T790M ddPCR 
assays (Figure 3-2A, B and Figure 3-3). However, the exon 19 del ddPCR assay showed an 
average background of 14.5 ± 2.12 (n=2) droplets in healthy donor EV-RNA, like the 
background signal from negative control cell line EV-RNA, Figure 3-4. This assay 
Figure 3-2 EGFR mutations carried in RNA and protein from cell line derived EVs 
H1975 (L858R/T790M), H3255 (L858R), H1650 (exon 19 del). 
A-B. EV-RNA ddPCR droplet counts of lung cancer cell line-derived and healthy plasma prep 
1 for A. L858R and T790M point mutations and B. exon 19 del C. Normalized protein 
intensity for L858R and exon 19 del EGFR mutations from cell line derived extracellular 
vesicles using western blots. 
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simultaneously screens for 19 different deletion variants using pooled primers, resulting in 
increased background signal. A threshold for positive detection was determined based on the 
highest background signal observed among all negative control samples. This threshold for 
detection was used for all subsequent analysis for NSCLC patient EV-RNA and can be seen on 
in the images of Figure 3-4.  
Cell line derived EVs also carried mutant EGFR protein, as demonstrated using western 
blot. Specific identification of the two activating mutant proteins was achieved. L858R was 
Figure 3-3 EGFR point mutations, L858R and T790M, detected in lung cancer cell 
line derived EV-RNA. 
A. Representative ddPCR plots for EGFR L858R (top) and T790M (bottom) from EV-
RNA generated using control lung cancer cell line derived EVs and healthy control EVs 
from plasma prep 1. The mutation signal is detected in the FAM channel (x-axis), wildtype 
signal is detected in the VIC channel (y-axis) and empty droplets are shown in the bottom 
left of each plot. B. Table of EGFR L858R and T790M point mutation status in lung cancer 




detected exclusively in H3255 and H1975 derived EVs (Figure 3-2C, D), and exon 19 del only 
in H1650 derived EVs (Figure 3-2D). A validated T790M antibody is not yet commercially 
available, and therefore the samples were not tested for this mutation. Each EV-protein sample 
was additionally profiled for the EV marker CD9, and was shown to be free of cellular 
contamination based on calnexin, Figure 3-2C, D.  
Protein intensity for each marker was normalized to the total protein loaded into each 
lane using BioRad’s StainFree Gel technology. Each band was normalized to the total protein per 
lane, eliminating the need for housekeeping genes which are not equally present in all EVs due 
to their loading mechanisms and cells of origin.178 StainFree Gels have been found to be more 
consistent than housekeeping proteins or Ponceau staining as a loading control and provide the 
added benefit of controlling for differential loading.179,180  
Figure 3-4 Exon 19 deletion mutation quantification and gating for positive detection.  
H1650 cells, H1650 EVs, and H1975 EVs were analyzed for the presence of the 19 
exon19del variants in the assay.  
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3.5.2      Metastatic NSCLC Patient Cohort and Study Design for EGFR Mutational 
Profiling in EVs 
The above established dual EV-RNA and EV-protein mutational profiling was applied to 
analyze EVs from blood plasma in a cohort of ten metastatic NSCLC patients with at least one 
kno  wn sensitizing EGFR mutation based on primary tumor biopsy. Patients were enrolled after 
consent and blood was collected under IRB approval. The cohort’s median age was 64 years 
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(range, 45-82 years) and was well distributed between male and female. Full patient 
demographics can be found in Table 3-5.   
 
 
Table 3-4 Patient EGFR mutation ddPCR and extracellular vesicle characterization 
75 
 
Seven of the ten patients had samples collected at multiple time points, termed visits. The 
time between each visit varied depending on patient care, however, the time ranged from 26 to 
231 days (mean = 89 ± 40 days) across all patients. The visit notation is used throughout this 
study to highlight general trends on the utility of patient monitoring using EVs to be compared 
across patients, however patient specific details and timelines are shown in Figure 3-9 and 
Table 3-4. 
While a plethora of EV isolation methods have been widely developed, including 
ultracentrifugation148, microfluidic devices for EV capture60,181,182, and commercially available 
kits such as ExoQuick (System Biosciences), EVs in this study were isolated using 
ultracentrifugation, which offers the widest array of downstream applications and high purity 
Table 3-5 Patient demographics for metastatic EGFR NSCLC cohort 
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compared to the above methods131,183 and is compatible with a range of sample input volumes. 
After isolation, EV concentration and size was determined using nanoparticle tracking analysis 
(NTA), Table 3-4. Each EV sample was tested for EGFR mutations matching the tumor biopsy 
result. Additionally, matching ctDNA samples, nine samples across five patients, were tested for 
the corresponding EGFR mutations to compare detection rates.  
3.5.3      EV Isolation Validation 
The blood samples were preprocessed to isolate plasma using red blood cell depletion 
methods, validation experiments demonstrating this material can be utilized for EV analysis are 
shown in Figure 3-5.  EVs were isolated from the effluent material generated in a tangential 
circulating tumor cell (CTC) characterization study.109  To ensure that the EV cargo was not 
damaged by RBC depletion prior plasma extraction, standard EV characterization assays for the 
three plasma isolation methods were performed and compared. 15mL of blood from a healthy 
donor was divided and processed using 5mL of blood using each of the three plasma generation 
methods: Ficoll RBC removal followed by centrifugation (prep 1), dextran RBC removal 
followed by centrifugation (prep 2) or centrifugation alone (prep 3).  For all reported values, 
error bars are indicative of the average and standard deviation of 3 technical replicates. 
EV size and concentration of the three plasma prep methods was measured using NTA 
and the size of the EVs did not vary with isolation method; yielded vesicles were within the 
standard range for EVs (50-160 nm), Figure 3-5A. The concentration has been normalized to 
starting blood volume, reported values are per mL of original blood volume. The measured 
concentration of the EVs isolated using plasma prep 2 was dramatically higher than the 
concentration from plasma prep methods 1 or 3. The higher concentration could be a result of 
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residual dextran macromolecules being measured.184 Another possibility is that dextran allows 
for more efficient recovery of EVs during ultracentrifugation. Further experiments would be 
needed to verify the cause of this increase. 
The relative abundance of house-keeping genes, ACTB and GAPDH, was measured 
using RT-qPCR. Using plasma prep 3 EVs as the baseline for comparison, plasma prep 1 EVs 
had similar levels of the two genes, whereas plasma prep 2 EVs had less than 10% 
comparatively, Figure 3-5B. One explanation for the result is that the differences in EV-RNA 
Figure 3-5 Validation of EV isolation techniques 




yield is from inefficiencies in EV lysis in the presence of remaining dextran molecules.  Another 
is that the EV-RNA was damaged during the dextran processing, leading to lower abundance. 
Further testing would be needed to verify the reason. Because the detected levels of 
housekeeping genes were similar for plasma preps 1 and 3, plasma prep 1 samples were used for 
EV-RNA characterization. 
EV-protein characterization was performed using microBCA and western blot. There was 
slightly higher protein yield from plasma prep 2 than plasma prep 1, and both were higher than 
plasma prep 3, Figure 3-5C.  Western blot analysis of the three plasma prep methods showed 
similar expression of the following proteins: exosomal marker CD9, housekeeping gene 
GAPDH, and contamination marker calnexin, Figure 3-5D.  The cellular contamination marker, 
calnexin, was validated to be negative using a titration of plasma-derived EVs ranging from 1-
3mL of plasma used. To do so, the samples were processed without performing the 12,000xg 
spin in the ultracentrifugation protocol. The presence of the calnexin band indicates the success 
of this antibody along with the necessity of the semi-final centrifuge step to remove cellular 
contamination. 
Scanning electron microscopy images of EVs isolated from a healthy control prep 3 and a 
patient prep 1 to demonstrate successful EV isolation, Figure 3-5E, F. Scale bar indicates 1 µm. 
For additional verification, NSCLC patient plasma preps were processed either (1) 
directly into PBS for NTA quantification or (2) into RIPA lysis buffer for protein analysis. Three 
plasma prep 1 samples were measured using NTA and were found to have similar size, 130 ± 
17nm, and concentration, 3x1010 ± 2x1010, Figure 3-5E. From the same patients and time points, 
the plasma prep 2 samples were measured for EV-protein quantity using microBCA with an 
average of, 73 ± 18 µg/mL blood in 150 µL of protein lysate from 5mL of blood, Figure 3-5F.  
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In summary, it was found that the plasma prep 1 would be best used for RNA studies, while 
plasma prep 2 was best used for protein studies.  
3.5.4      Longitudinal Detection of EGFR Mutations in EV-protein 
 
EV-protein was isolated from the plasma of four patients over 3-4 visits. EV-protein was 
tested for sensitizing mutations exon 19 del or L858R based on initial biopsy. EGFR mutations 
Figure 3-6 Detection of EGFR mutations in EV-protein. 
A-D. EV-protein with detected mutant EGFR from patients across multiple visits from A. L3 with exon 
19 del B. L5 with exon 19 del C. L9 with L858R, and D. L10 with L858R. Samples were additionally 
screened for CD9, GAPDH, and calnexin. Normalized mutant EV-protein is quantified above each 
western blot using BioRad’s StainFree Gel technology to normalize to the total protein as quantified by 
imaging the Stain Free Gel after transfer to a PVDF membrane. ND = not detected. 
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in the EV-protein were detected using western blot in samples from 4/4 (100%) patients, two 
patients with exon 19 del mutations and two with L858R mutations. Patients L3 and L5 have 
moderately identifiable bands for exon 19 del, while having various levels of CD9 and similar 
GAPDH bands, Figure 3-6A, B. The two patients demonstrated similar detection rates, with one 
patient having exon 19 del EV-protein detected in 3/4 of samples (L3) and the second in 2/3 of 
samples (L5). Interestingly, one patient has a trending increase in their mutated EGFR EV-
protein, while the other has a steady decrease, despite both being clinically stable through all 
timepoints.  
 Conversely, the L858R band is present in samples from patients L9 and L10, but less 
distinct compared to exon 19 del in L3 and L5, Figure 3-6C, D. While the bands are less 
distinct, there is L858R EV-protein at all the timepoints tested. The second patient, L10, shows a 
net increase in L858R EV-protein over time compared to visit one, although the amount does not 
increase at all visits. The less optimal bands could be the result of EV packaging, the protein 
itself, or several other challenges. However, the CD9 and GAPDH proteins are highly variable 
between samples for the patients with L858R and are less clean than would be expected from 
either cells or healthy EVs.  
EGFR mutations found in EV-protein demonstrate the potential to use EVs as multiple 
cargo biomarkers. This finding marks the first demonstration of EGFR mutations detected in 




3.5.5      EGFR Mutations in EV-RNA Detected in Metastatic NSCLC Patients 
In compliment, EV-RNA was isolated from 10 patients with multiple samples (n=33 total 
samples) collected from each of these patients at different time points (up to six visits) through 
their course of treatment. The mutation burden was evaluated in each sample, defined as the 
number of mutant EGFR droplets detected using ddPCR normalized to 5 mL of starting blood 
Figure 3-7 Full western blot images for patient EV protein samples 
A, C. Stain Free Blot images showing the total protein per sample, used to perform quantification 
of specific bands.  
B, D. Bands for 4 proteins of interest. The top image in each part demonstrates an EGFR 
mutation, either exon 19 del (Figure 3-7B) or L858R (Figure 3-7D).  All samples were 
additionally tested for calnexin (MW ~90-100kDA), GAPDH (~50-70kDA), and CD9 (~25-
35kDA). Calnexin, a cellular contamination marker, is negative or under expressed in all samples. 
GAPDH has varying expression levels, indicating the need for total protein quantification. CD9 is 




volume. Exon 19 del was detected in 7/8 patients, Figure 3-8A.  Patients varied as to the number 
of timepoints with exon 19 del positive EV-RNA, with some patients having mutant EV-RNA at 
100% of timepoints (L3, L4, L7), and one having no detected exon 19 del, L8, Figure 3-8B. It is 
important to note that the patients had varying number of visits, ranging from 1-5 (average = 
Figure 3-8 Detection of EGFR mutations in EV-RNA samples from metastatic NSCLC 
patients. 
A. EGFR exon 19 deletion transcript concentration per timepoint for the eight patients pre-identified as 
being exon 19 del positive. B. Percent of time points that tested positive for EGFR exon 19 del mutations 
per patient. C. Mutant EV-RNA concentration for both L858R and T790M mutations across time points for 
two patients. D. Percent of time points that tested positive for L858R and T790M mutations by patient. E-
F. Comparative concentration of EGFR mutations found in ctDNA and EV-RNA along with Venn diagrams 
displaying the overlap in samples with detected mutations in EV-RNA and ctDNA for E. four samples with 
known exon 19 del mutations and F. five samples with known L858R and T790M mutations.  
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2.88, n=8). Taken together, the positivity rate across all samples for exon 19 del was 78% 
(n=18/23).  
The remaining two patients L9 & L10 co-harbored L858R and T790M mutations. 
Although the data is collected from only two patients, there was a larger range in the number of 
mutant transcripts detected for the two point mutations than were observed for exon 19 del. 
Patient L9 had a range of 0-80 T790M transcripts detected, compared to L10 with a range from 
0-0.5 transcripts per 5mL blood, Figure 3-8C. Additionally, the point mutations were detected 
less frequently per patient compared to the patients with exon 19 del. L858R was detected in 
75% of timepoints in L9 and in 50% of time points in L10. Even more modest was the detection 
of T790M, found in 50% of visits in L9 and only 17% of visits in L10, Figure 3-8D.  
For nine samples, matched ctDNA was tested alongside EV-RNA for the EGFR 
mutations using the same ddPCR technique. For patients with exon 19 del, ctDNA was found in 
only 1/4 samples tested, compared to 4/4 EV-RNA samples, Figure 3-8E. Similarly, five 
L858R/T790M samples had dual testing and results show that 3/5 samples tested positive for 
L858R in both ctDNA and EV-RNA, while the remaining 2/5 were positive for L858R in only 
EV-RNA. The T790M was detected less frequently in both ctDNA and EV-RNA, with only 2/5 
samples having mutations in both ctDNA and EV-RNA, one having only ctDNA mutations, and 
two having no detected T790M mutations, Figure 3-8F. 
3.5.6      Longitudinal Monitoring of EGFR Mutations in EV-RNA Mirrors with Disease 
Trajectory 
To explore the utility of EV-RNA in patient care, transient mutant EGFR burden was 
compared to the clinical outcomes of seven patients across up to six visits, Figure 3-9. At each 
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timepoint, response to therapy is classified as either a stable (n=17 samples) or progressing 
(n=22 samples) based on available clinical data corresponding to each blood draw visit following 
the guidelines established in RECIST (Response Evaluation Criteria in Solid Tumors) 34. EV-
RNA was determined to mirror disease status when an increase in mutation burden occurred at 
the same timepoint as progression, or conversely if a decrease or no change in mutation burden 
occurred at a timepoint when a patient was determined to have stable disease, Figure 3-10A. 
Figure 3-9 Clinical data timeline mapped to the mutant EV-RNA at each visit. 
A-G. Normalized droplet counts for EGFR mutations in EV-RNA using ddPCR. A timeline 
with each patient’s clinical data is displayed in days from start of treatment. Clinical data 





 Each patient’s progression was classified based on overall disease trajectory into one of 
three categories based on trend in EV-RNA burden over time: consistently progressing (n=2 
patients) Figure 3-10B, consistently stable (n=3 patients), Figure 3-10B, and divergent (n=2 
patients), Figure 3-10C. The two patients with consistent progression, L1 and L2, both carried 
Figure 3-10 Changes in EGFR mutation burden in EV-RNA mirror disease status. 
A. Schematic demonstrating EV-RNA mirroring disease status. An increase in mutant EV-RNA mirrors 
progressive disease, while a decrease or no change in EV-RNA would mirror stable disease.  B. Mutant EV-
RNA concentration for exon 19 del patients across multiple visits for patients with consistently progressive 
(top) or consistently stable (bottom) disease C. Mutant EV-RNA concentration for L858R/T790M in 
divergent patients, L9 (top) and L10 (bottom) across multiple visits. D. Percent of EV-RNA samples drawn 
at a timepoint when EV-RNA mutation burden mirrors disease status for patients with exon 19 del. E. Change 
(Δ) exon 19 deletion mutation burden in EV-RNA between timepoints for patients who are clinically stable 
compared to progressing, p-val = 0.0059 using an unpaired t-test. F. Percent of EV-RNA samples drawn at a 




exon 19 del and had increasing EV-RNA mutation burden that mirrored disease progression, 
Figure 3-10B. Both patients had no detectable EV-RNA mutations in their first visits, however 
as their disease progressed, the mutation burden increased with each visit. L1 had increased size 
of lung nodules between visits 2 and 3, which correlated with the onset of detectable exon 19 del 
in their EV-RNA. Between visits 3 and 4, the size and number of lung nodules both increased, 
corresponding with a mutation burden increase of 223%. Similarly, patient L2 had progressing 
disease between visit 1 and 2, which was reflected by the onset of EV-RNA mutation detection. 
While the patient was clinically stable between visit 2 and 3, only a modest 40% increase in 
mutation burden was observed. L2’s disease further progressed after visit 3. Ultimately, both 
patients were placed in hospice shortly before their final time point in this study and are now 
both deceased.  
The second category, comprised of patients L3-L5 who were consistently stable, all 
carried exon 19 del. They had sustained, clinically stable disease and showed a downward trend 
in their EV-RNA burden at nearly every time point, Figure 3-10B. L5 initially had brain 
metastases and high levels of EV-RNA, however each subsequent time point demonstrated 
radiologically monitored resolution of brain metastases. This observation of sustained decreased 
EV-RNA burden is notably different than what was observed in L2, which showed a sustained 
increase in mutant EGFR burden, despite temporarily being classified as having clinically stable 
disease. All three patients with sustained clinical stability, L3-5, have been stable for 191, 182, 
and 204 days, respectively, since the final EV-RNA time point (Figure 3-9). 
In the last category, patients L9 and L10 each carried L858R and T790M and showed 
divergent clinical trajectories. L9 had undetectable levels of L858R and T790M EV-RNA at the 
initial visit and was clinically stable. However, as the patient progressed, EV-RNA burden of 
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L858R and T790M increased between visits 3 and 4, 83% and 2460% respectively (Figure 3-
10C). At 87 days after the final blood draw, L9 has continued to show progression, and has brain 
metastasis. Conversely, L10 was progressing while on TKI therapy but did not have any 
detectable L858R or T790M EGFR burden. However, when the patient’s therapy was switched 
to chemotherapy (pemetrexed) and the disease stabilized, the L858R mutation became detectable 
and increased by 672% between visits 5 and 6 in EV-RNA, Figure 3-10C. This patient has 
continued to be clinically stable for 133 days since the final blood draw (Figure 3-9). 
EV-RNA exon 19 del burden mirrored clinical trajectories at 12/14 timepoints across all 
five patients with 2+ timepoints, with the definition of mirroring being shown in Figure 3-10A. 
Patients ranged from having 67% to 100% of timepoints where EV-RNA mutation burden 
mirrored disease trajectory, Figure 3-10D. When quantitatively compared, the change in exon 19 
del EV-RNA transcripts (ΔEV-RNA) between timepoints is significantly lower, quantified using 
an unpaired t-test with a p-val <0.05, for patients who are stable compared to progressing (p-val 
= 0.0059, two-tailed t-test), Figure 3-10E. Conversely, the two patients with L858R/T790M 
mutations saw 33% and 40% mirrored timepoints for L858R EV-RNA and 67% and 60% 
mirroring for T790M EV-RNA, Figure 3-10F. It is important to note that for both point 
mutations, especially for T790M, the detection rate was low, therefore conclusions cannot be 
accurately drawn about the relationship between ΔEV-RNA burden and disease progression. 
3. 6         Discussion  
Using ddPCR and western blots, EVs isolated from lung cancer patient plasma were 
analyzed for EGFR mutations. In this pilot study, the utility of EV-RNA and EV-protein is 
demonstrated to not only screen for the presence of mutations, but to dynamically monitor 
88 
 
patient disease status. Mutant EV-RNA was detected in 9/10 patients, and for 6/7 patients who 
were longitudinally monitored, mutant EV-RNA burden mirrored clinical trajectory. Within 
patients who had exon 19 del, ΔEV-RNA mutation burden strongly indicated disease trajectory, 
demonstrating that a single time point may be insufficient to assess patient status. The power of 
liquid biopsies enabled multiple time points from each patient to be collected.  
While evidence from this pilot study suggests the rate of increase in EV-RNA mutation 
burden may be linked with progression severity, larger studies are needed to investigate this. For 
the patients with exon 19 deletion, both patients who had consistent progressive disease 
succumbed to their disease and are now deceased. These patients had similarly consistent 
increase in EV-RNA mutation burden. Conversely, the three patients with decreasing EV-RNA 
exon 19 del burden have remained clinically stable for an average of 192 ± 9 days after the final 
blood draw. These patients saw consistently decreasing EV-RNA mutation burden that mirrored 
their stable disease status. This was further highlighted by the finding that there is a significant 
difference in the exon 19 del ΔEV-RNA burden between timepoints between stable and 
progressing patients. These results indicate that changes in EV-RNA mutant burden may be an 
early indicator of clinical stability and perhaps even indicate disease progression before clinical 
monitoring methods. 
Of the two patients with L858R/T790M mutations, one patient’s EV-RNA burden 
mirrored disease trajectory, while the other did not. L9 has had sustained progressive disease 87 
days after the final blood draw. Conversely, L10, after switching from a TKI to chemotherapy 
between visits 4 and 5, has remained clinically stable for 133 days after the final blood draw, 
despite an increase in L858R EV-RNA. The change from TKI therapy to chemotherapy during 
this study could impact the utility of targetable mutations carried in EV-RNA for patient 
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monitoring. Without the use of TKIs specifically targeting mutant EGFR, an increase mutant 
burden may not indicate treatment resistance in the tumor. Therefore, while EV-RNA may 
mirror disease trajectory for patients receiving targeted therapy, this may not extend to patients 
receiving other treatment types, such as chemotherapy and further studies are needed to 
investigate this. 
Additional studies with larger cohorts are needed to validate these findings, however, this 
study presents initial evidence that increase in EV-RNA indicates progression for patients 
receiving targeted therapy. Future studies are needed to determine if EV-RNA can be used to 
detect progression prior to current techniques. Of interest, L6, only had two time points collected 
but saw an upward trend in their burden despite being clinically stable thus far. The preliminary 
findings presented here warrant a recommendation that the clinical trajectory of this patient 
should closely be monitored for indicators of disease progression. 
While EV-protein was detected in samples from four patients, there was not an observed 
correlation between EV-protein burden and EV-RNA burden and there were too few patients to 
make assessments of correlation to disease. Previous studies in cell lines have shown that when 
exposed to TKIs, EGFR mutations result in differential protein stability compared to wildtype 35; 
Treatment with the TKI erlotinib led to protein degradation in a mutant dependent manner, 
without significantly changing the transcriptomic expression. Additionally, osimertinib, the 
primary TKI the patients in this study were receiving, has been suggested to reduce protein 
stability in both wildtype and T790M mutant EGFR. The decreased stability of EGFR protein 
due to TKI treatment can lead to increased cellular protein turnover thereby either (1) reducing 
the amount of protein packaged into EVs or (2) leading to increased degradation of either 
cellular protein or EV-protein, both of which would reduce the quality of the proteins found in 
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EVs, as seen in this study.185 Further studies will need to be performed to elucidate information 
about the mutated protein found in EVs.     
Liquid biopsies hold the potential to address spatial heterogeneity and longitudinal 
monitoring limitations. However, the only FDA-approved liquid biopsy test, the Cobas v2, for 
mutation detection, relies on ctDNA. While capable at detecting the presence of new mutations, 
this test is still currently considered a “rule in” test, with the recommendation of a tissue biopsy 
to confirm a mutant negative result.186 Compared to ctDNA, EVs demonstrated a more robust 
detection of exon 19 del, and similar detection rates for point mutations L858R and T790M, 
Figure 3-8E, F. To avoid splitting the sample or using pre-amplification steps, this study 
screened solely for EGFR mutations detected by tumor biopsy, therefore future studies are 
needed to expand further to screening for mutations in EV-RNA not originally detected by tumor 
biopsy. By instead using EVs, liquid biopsy mutation screening has the potential to advance 
beyond the current “rule in” test.   
This work lays the groundwork for future studies to establish the utility of mutations 
found in EV cargo for patient care. In this novel proof of concept study, EVs were screened for 
previously identified EGFR mutations carried by each patient. Changes in EV-RNA correlated 
with disease trajectory; however, the clinical implications of EV-protein remain unclear. The 
utility of EV mutation monitoring warrants further investigations across additional mutations and 
cancer types. Further, the dual analysis of EV-derived cargo has the potential to go beyond 
monitoring and be used in lieu of a tumor biopsy for non-invasive screening for both sensitizing 
and resistance mutations in EGFR across a patient’s treatment course. This minimally invasive 
approach could be integrated into the standard of care enable more rapid identification of 




Chapter 4 Circulating Tumor Cells Isolated from Stage III NSCLC Patients Using 
Microfluidic Graphene Oxide (GO) Chip Predicts Progression Free Survival 
 
4. 1         Abstract 
Stage III non-small cell lung cancer (NSCLC) patients commonly undergo radiation 
treatment (RT), with imaging scans being the standard of care for determining disease 
progression both during and after RT. However, imaging technologies only detect progression 
after it has occurred, which may be well after tumor growth or disease progression has begun. In 
this work, we determined whether CTC metrics, including the number of CTCs, change in the 
number of CTCs during treatment, and PD-L1 expression on CTCs, can be used as a blood-based 
biomarker to predict patient outcomes in stage III NSCLC. At six timepoints through treatment, 
blood from 26 stage III NSLC patients was processed for CTC isolation and analysis using the 
immunoaffinity graphene oxide (GO) microfluidic chip. The primary endpoint was disease 
progression, either locoregional, distant, or death. CTCs were present in 100% of patients 
(n=26/26), and at 93% of timepoints (n=102/110). The number of CTCs decreased significantly 
from pre-treatment (Pre-TX) to mid-radiation (p=0.02, paired two-tailed t-test), after radiation 
(p=0.04, paired two-tailed t-test), and mid-immunotherapy (p=0.02, paired two-tailed t-test) 
timepoints. By calculating the percent decrease in CTCs from Pre-TX to mid-radiation therapy, it 
was found that patients who had a large decrease in CTCs had sustained stability. Conversely, 
patients who had an increase in CTCs during radiation therapy were likely to have progression.  
Patients were split in two even groups, defined by a 75% change in CTCs between Pre-TX and 
mid-radiation. A decrease in CTCs of less than 75% precluded a significantly shorter PFS time, 7 
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months vs 21 months average monitoring time with no progression (p = 0.005, log-rank test).  
Secondarily, it was found that the three patients who had progression while receiving anti-PD-L1 
immunotherapy had a quantity of PD-L1+ CTCs greater than the median at all time points. 
Survival analysis shows that having >50% PD-L1+ CTCs at Pre-TX potentially predicts a shorter 
PFS. In conclusion, CTCs isolated using the GO chip are a potential blood-based biomarker to 
predict patient outcomes in stage III NSCLC patients undergoing RT.  
4. 2         Resulting Publication Information  
E. Purcell, Z. Niu, S. Owen, M. Grzesik, A. Radomski, H. Fairbairn, S. Jolly*, S. Nagrath*. 
“Circulating tumor cells (CTCs) isolated from stage III NSCLC patients using microfluidic 
graphene oxide (GO) Chip predicts progression free survival.” In preparation. 
4. 3         Introduction 
 Approximately 190,000 people were diagnosed with non-small cell lung cancer 
(NSCLC) in 2020. While localized, NSCLC has a survival rate of  63% and while regional, the 
survival rate is 35%, however when the cancer becomes metastatic the survival rate drops to 
7%.1 The current treatment for stage III, NSCLC, the final stage before metastatic cancer, is 
combination chemotherapy and radiation (RT) followed by anti-PD-L1 (programmed death 
ligand 1) immunotherapy for one year.2,5 Being able to predict which patients will metastasize as 
early as the first few weeks of the RT would allow those patients to receive highly personalized, 
precise clinical intervention. To achieve this level of precision medicine, it is critical to 
repeatedly profile a patient’s tumor to have accurate, up-to-date information about the patient’s 
ever-changing tumor. However, current clinical practices rely on imaging scans and needle 
biopsies, which are expensive, time consuming, invasive, and minimally repeatable. As such, 
93 
 
there is a need for inexpensive, quick, minimally invasive, and easily repeatable technologies to 
characterize a patient’s tumor, allowing for maximally personalized, precise treatment decisions.  
Researchers have proposed the liquid biopsy to fill this need. The liquid biopsy is an 
assay that characterizes a biomarker found in a simple blood draw with the goal of informing 
treatment decisions or predicting patient outcomes. Liquid biopsies can be done many times 
throughout a patient’s treatment, allowing for longitudinal monitoring of that patient. Common 
biomarkers include circulating tumor DNA or RNA (ctDNA/RNA), extracellular vesicles (EVs), 
and circulating tumor cells (CTCs).107,187 ctDNA is the most common clinically used biomarker 
and is used mainly in cancer diagnostics or when looking for minimal residual disease188,189. 
However, ctDNA suffers from fast clearance and degradation in the blood stream as a result of 
the other circulating blood components.168,169  A second promising marker, EVs, are 
nanovesicles excreted from all cell types that contain molecular information from their cells of 
origin, including tumor cells.19,21,65,190 EVs contain DNA, RNA, proteins, and other analytes 
allowing for multi-analyte tumor profiling, however tumor-derived EVs are found in a backdrop 
of non-specific EVs in the blood.39,40,173,187,191,192 Since there are no technologies to reliably 
isolate specifically tumor derived EVs, their clinical use is still largely undetermined. Although 
these two biomarkers are promising, the challenges associated with their isolation and 
characterization make them less suitable for serial tumor profiling compared to CTCs.   
CTCs, conversely, are tumor cells shed from a solid tumor that circulate in the blood and 
give researchers direct information about the tumor. In many cancers, including NSCLC, the 
quantity as well as contents of CTCs, such as protein expression, RNA and DNA profiles, can be 
correlated to progression-free survival, overall survival, and disease stage.42–45,127  Although 
CTCs are powerful biomarkers, their low concentration in the blood, 10-100 CTCs/mL, 
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compared to a backdrop of 106 white blood cells are challenging. For CTCs to become clinically 
useful biomarkers, highly accurate isolation and characterization techniques are critical, with 
many technologies being developed each year.  
CTCs express unique surface proteins compared to white blood cells, making 
immunoaffinity-based technologies promising for isolating CTCs. The most common of which is 
the FDA-approved CellSearch®, which uses antibodies against epithelial cell adhesion molecule 
(EPCAM) to capture CTCs with magnetic beads.113,193  Lung cancer CTCs, however, have been 
shown to lack EPCAM expression109,194, making CellSearch® an ineffective technology for 
isolating CTCs from NSCLC. To overcome this challenge, novel immunoaffinity-based methods 
have been developed to isolate CTCs using multi-antibody cocktails, allowing CTCs to be 
isolated based on several surface proteins instead of solely EPCAM.122 One example is the 
graphene oxide microfluidic chip (GO Chip) that we developed to isolate CTCs with high purity 
and specificity.195 The GO Chip is a microfluidic technology that uses antibodies against CTC 
surface proteins to immobilize them on functionalized gold nanoposts. The GO chip was 
optimized to isolate CTCs specifically from NSCLC patients using anti-EPCAM, anti-epidermal 
growth factor receptor (EGFR), and anti-CD133 to increase the capture of lung cancer CTCs.118–
120,122,196  
Previous studies have correlated CTCs and CTC metrics to timepoints during treatment, 
or loosely to clinical outcomes, however none have demonstrated the clinical utility of 
monitoring CTCs in stage III NSCLC patients.177,193,197,198 In a cohort of stage I-III NSCLC 
patients, we used the GO chip to demonstrate that the percent of PD-L1+ CTCs increased after 
RT, raising from 0.7% of CTCs to 24% of CTCs in 1mL of blood.199 Additionally, we used RT-
qPCR to further profile the isolated CTCs and found that PD-L1 and LGALS3BP were 
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significantly upregulated in the CTCs of patients with worse progression. Dorsey et al. 
developed an adenoviral probe that monitors telomerase activity to detect CTCs from the blood 
both before and after RT. They tracked 10 stage III NSCLC patients and found that patients had 
a substantial decrease in CTCs from before RT to after RT, with an average dropping from 62.7 
to 0.6 CTCs/mL.200  This group followed up their initial study with a larger cohort including 48 
patients and found that 75% of the 20 patients who had recurrence saw an increase in the CTC 
counts post-RT. While these studies demonstrate the potential utility of using CTCs to monitor 
NSCLC patients through treatment, they did not correlate CTC metrics to clinical outcomes such 
as progression free survival (PFS) time.  
In the current study, we use the GO chip to profile CTCs from locally advanced (stage 
III) NSCLC patients across both RT and immunotherapy. We isolated the CTCs and performed 
molecular characterization to develop CTC signatures that predict which patients will have 
shorter PFS time. By identifying which patients will have poor response to radiation therapy, 
clinicians can adapt treatment regimens using alternative lines of therapy for these patients. The 
cohort for this study all received combination chemotherapy and RT for six weeks, with most of 
the patients then receiving durvalumab for 1 year following their RT. Blood was drawn at six 
timepoints across both treatments and profiled for CTCs, making this the first study that 
monitored patients across both RT and durvalumab.  
For each blood sample, two GO chips were processed in parallel to isolate and 
characterize CTCs to develop these CTC signatures. Using the first GO chip, we determined the 
quantity of CTCs using immunofluorescent staining. The second GO chip was used for on-chip 
RNA extraction followed by transcriptome profiling using Affymetrix microarrays for gene 
expression analysis. The CTC metrics were then analyzed and correlated to clinical data such as 
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gross tumor volume (GTV) and PFS. We then determined CTC signatures that are predictive of 
shorter PFS time for stage III NSCLC patients. Here we identified a CTC signature that is 
present early in a patient’s RT that is predictive of shorter PFS, thereby allowing enough time for 
clinical intervention. 
4. 4         Methods 
4.4.1      Patient Enrollment  
Patients provided written consent and all blood was collected under IRB approval from 
the University of Michigan. All patients had either stage IIIA or stage IIIB non-small cell lung 
cancer and had no previous therapies.  
4.4.2      Sample Collection 
Blood was collected from patients into 5 mL EDTA tubes.  Blood was stored on a rocker 
until use to ensure the blood did not separate. 2mL of the blood was processed on the GO chips, 
1 mL per chip. 
4.4.3      Graphene Oxide Chip Fabrication 
The GO chip was fabricated following procedures described previously118. Briefly, the 
PDMS chamber and silicon substrate were prepared separately and bonded using corona 
discharge. The gold patterned silicon substrate was prepared in the University of Michigan’s 
Lurie Nanofabrication Facility using standard photolithography to pattern the silicon wafer with 
50,000 gold flowers. Specifically, the silicon wafers are first deposited with one layer of chrome 
and one layer of gold.  
GO chip functionalization is then performed in a wet lab. GO suspension is premade with 
graphene oxide, N, N-dimethylformamide (DMF), Tetrabutylammonium (TBA) hydroxide, and 
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phospholipid-polyethylene–glycol-amine (PL-PEG-NH2). Silicon substrates are immersed in the 
GO suspension for 10 minutes, followed by the addition of cross-linker compound N-(gamma-
maleimidobutyryloxy) succinimide (GMBS) and Neutravidin. The GO chip was stored at 4°C 
until use. 
4.4.4      CTC isolation using GO Chips 
Two GO chips per sample were removed from the 4C fridge, and a 1mL PBS wash was 
flowed at 100 µL/min to rinse off the Neutravidin. Antibody cocktails were prepared during the 
PBS wash: 1% bovine serum albumin (BSA) in PBS filtered through a 0.5 µm filter, anti-
EPCAM, anti-CD133 (Miltneyi), and anti-EGFR (RayBiotech). Following PBS wash, antibody 
cocktail was flowed through the inlet of each device at 20 µL/min, the devices were then 
incubated for 30 minutes.  The devices were turned, and antibody cocktail was flowed through 
the outlet of each device at 20 µL/min and incubated for another 30 minutes. Following the 
incubation, another PBS wash was performed, 1 mL PBS at 100 µL/min.  3% BSA in PBS 
filtered through 0.5 µm filter was then flowed, 1mL at 100 µL/min, to decrease non-specific 
binding.  Before applying blood to the devices, the blood was pipetted several times to ensure 
complete mixing.  1mL of blood was flowed at 1mL/hr through the inlet of the device to isolate 
CTCs and the effluent from each device was collected. To remove red blood cells (RBC) and 
other blood components, 6mL of PBS was flowed at 100 µL/min. 
4.4.5      On-chip CTC fixation  
After CTC isolation, one of the devices had PFA flowed, 1mL at 100 µL/min with a 40 
min incubation, to fix the CTCs for future enumeration.  Following PFA, 1mL PBS was flowed 
at 100 µL/min to wash extra PFA.  The inlet and outlet of the chip was then parafilmed and the 
device was stored in a parafilmed dish with a wet kimwipe in a 4C fridge to avoid drying.  
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4.4.6      Immunofluorescent Staining of GO Chips 
Immunofluorescent staining was performed on the GO chips that were fixed with PFA 
and stored at 4℃. The GO chips were removed from the fridge and allowed to heat to room 
temperature on the bench. To permeabilize the cells, we flowed 1mL of 0.02% TritonX at 
100µL/min and incubated for 30 minutes.  PBS was then washed through the device, 1 mL at 
100µL/min.  The devices were blocked at 100µL/min and incubated for 40 minutes using a 
cocktail of blocking solutions: 200µL goat serum, 300µL 6% BSA in PBS, and 500µL PBS per 
device.  Primary antibody cocktail was applied immediately after blocking and flowed at 
50µL/min. The devices were incubated overnight at 4℃.  The following day, primary antibodies 
were washed off using 2mL of PBS flowed at 100µL/min.  Secondary antibody cocktail was then 
applied at 50µL/min and incubated for 1 hr at room temperature. The unbound secondary 
antibody cocktail was then washed off with 2mL PBS at 100µL/min.  DAPI was then applied to 
the devices at a concentration of 1µL in 1 mL. A final PBS wash was performed to remove 
excess DAPI, 2 mL PBS at 100µL/min.  The inlets and outlets of the device were covered with 
parafilm and stored before imaging.   
 
Table 4-1 Antibodies used for Immunofluorescent Staining 
 Primary Antibodies Secondary Antibodies 
Channel Name Company Name Company 





Thermo Fisher  
Cat# A21131 





Thermo Fisher  
Cat# A21123 










4.4.7      GO Chip Imaging and CTC enumeration using Fluorescent Microscopy 
The GO chips were scanned on an inverted Ti2 Eclipse fluorescent microscope with an 
LED light source.  Each chip was scanned at 30x, using a 20x objective and an added 1.5x on the 
microscope. The chips were scanned in 4 channels with the following exposures and intensity 
percentages: DAPI (100ms, 15%), FITC (200ms, 30%), CY3 (200ms, 30%), and CY5 (200ms, 
30%). After scanning, the images are opened in the Nikon NIS Analysis software to count for 
CTCs.  CTCs are counted as being DAPI+/PanCK+/CD45- cells.  A subset of PD-L1+CTCs is 
counted as being DAPI+/PanCK+/CD45-/PD-L1+ cells.  
4.4.8      On-chip RNA extraction  
The second GO chip was used for RNA extraction.  Following CTC isolation, 100 µL of 
PicoPure RNA Extraction Buffer was flowed into the chip. The chip was then incubated at 42C 
for 30 minutes.  Following incubation, 100 µL of UltraPure DEPC-treated water was flowed 
through the device and was collected in a sterile Eppendorf. This second RNA sample contains 
the RNA extracted from the CTCs.  Each sample was frozen at -80C until purification. 
4.4.9      CTC RNA Purification off-chip  
After on-chip RNA extraction, the RNA was frozen at -80℃. To purify, the samples were 
thawed on ice before purification using the Arcturus® PicoPure® RNA Isolation Kit (Thermo 
Fisher, Cat# KIT0204). Purified RNA was stored in the -80℃ freezer until processing.  
4.4.10      Affymetrix Clariom S PICO microarray processing  
After thawing gently on ice, 11µL of the RNA samples were plated into a sterile 
barcoded PCR plate supplied by Thermo Fisher. The samples were then shipped to Fisher 
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scientific for microarray services by their lab. Briefly, RNA was quantified using PCR before 
running on Clariom S PICO human microarrays. Data was then returned to our lab for analysis.  
4.4.11      Analysis of RNA microarray data 
Standard microarray data processing procedures were followed in R programming 
environment (4.0.2). Briefly, raw intensities were imported as CEL files using the oligo package. 
The intensities were then normalized and summarized into gene-wise expression values using a 
robust multichip average (RMA) method.201 Quality control plots, including normalized unscaled 
standard error (NUSE), relative log expression (RLE) as well as principle component analysis 
(PCA) were generated to discover outliers in the dataset. The probesets were then annotated 
using clariomshumanhttranscriptcluster.db package. If multiple probes were mapped to the same 
gene, the one with highest average expression across all samples was selected. Differentially 
expressed genes were then calculated between different conditions using the limma package. A 
paired-sample design was used for the comparisons between different time points and treatment 
outcomes.  
4.4.12      Statistical Analyses of Clinical Data 
Comparisons between two groups, such as “Stable” and “Future Progression” were 
performed using unpaired Student’s t-tests, two-tailed. Comparisons between timepoints were 
performed using a paired Student’s t-test, two-tailed. Correlation was performed by making a 
Pearson’s correlation matrix, and reported values are Pearson’s r. Survival analysis was 
performed using Kaplan-Meier survival curves using the Logrank method (Mantel-Cox test). 
Receiver operator characteristic (ROC) curves were generated using a 95% confidence interval 
using the Wilson/Brown method. All analysis was conducted in GraphPad Prism V9.   
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4. 5         Results  
4.5.1      CTC isolation using graphene oxide (GO) Chip in stage III NSCLC patients  
From whole blood, we isolated CTCs using the previously developed graphene oxide 
based microfluidic GO chip for CTC enumeration and mRNA characterization, Figure 4-1. In 
brief, the GO chip consists of a silicon wafer patterned with 50,000 gold flowers, graphene oxide 
nanosheets are adsorbed onto the surface, and a PDMS chamber is covalently bonded form a 
single chamber.121 The device is then functionalized to tether the following capture antibodies on 
the surface: anti-EpCAM, anti-EGFR, and anti-CD133.119 EpCAM is an epithelial marker 
commonly expressed on CTCs, EGFR is a protein expressed in lung cancer, and CD133 is a 
stem-cell like marker that has been shown to cause high propensity for tumorigenic phenotypes 
in lung cancer.202  Two GO chips were run in parallel for each patient blood sample, one for CTC 
enumeration and one for RNA extraction of captured CTCs, Figure 4-1. These data were then 
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compared to clinical metrics to generate CTC profiles that were assessed for their ability to 
predict poor patient outcomes. 
CTCs were enumerated on the first GO chip using on-chip immunofluorescent staining. 
Staining was performed using a previously published protocol.119 We stained the devices for four 
markers of interest: DAPI, a nuclear dye; pan-cytokeratin (panCK), a CTC marker; CD45, a 
leucocyte marker; and programmed death ligand-1 (PD-L1). Following immunofluorescent 
staining, the GO chips were imaged using an inverted fluorescent microscope, and CTCs were 
counted based on the presence of these stained proteins.  A CTC was counted as a CK+/CD45-
Figure 4-1 Overview of CTC isolation and characterization summary.  
A. Schematic of CTC isolation using microfluidic GO Chip. Each sample is processed on 
two devices, one for enumeration via immunofluorescent staining and the second for mRNA 
microarray analysis. The CTC characteristics are then used generate profiles that are 
predictive of progression free survival. B. The timeline of patient sample draws shown, the 
black timepoints indicate no treatment, the blue time points are during radiation therapy, and 
green time points are during durvalumab for the majority of patients. Some patients received 
no future therapy after radiation, and some received a different immunotherapy.    
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/DAPI+ cell, with a subpopulation of CTCs being PD-L1+ CTC counted as panCK+/CD45-
/DAPI+/PD-L1+ cells, Fig 4-1A.  
In this cohort, patients were profiled through both radiation therapy (RT) and 
immunotherapy at a total of six timepoints, Figure 4-1B. Patients undergo six weeks of 
concurrent chemotherapy and RT; for the first four weeks, patients receive the same radiation 
dose, however, the dose for the final two weeks is determined based on the patient’s imaging 
scans at week 4 of RT. Following radiation, most patients (16/26) had 1 month of no treatment 
before starting an anti-PD-L1 immunotherapy, durvalumab. Some patients, however, were 
enrolled before durvalumab became standard of care. Of these, 2 patients received a different 
immunotherapy, 8 patients received no immunotherapy, and 1 died during radiation. Full clinical 
information and demographics is found in Table 4-2.   
CTCs were monitored at six strategic timepoints through both RT and immunotherapy. 
The first timepoint, Pre-TX, occurred before patients received any treatment and serves as a 
baseline. The Week 1 (W1) time point is during the first week of RT, and potentially a timepoint 
that could offer a very early indication of patients’ disease. Week 4 (W4) is the fourth week of 
RT and the timepoint when the clinical team altered patients’ radiation dosing. This timepoint 
offers an optimal time to adjust patient treatment. The Week 10 (W10) timepoint is one month 
after patients finish chemotherapy and RT but before they receive durvalumab. This timepoint is 
used as the end point for radiation efficacy. The Week 18 (W18) timepoint is approximately 1 
month into the patients’ immunotherapy, while the Week 30 (W30) timepoint is approximately 4 
months into immunotherapy. The timeline of blood draws with a treatment timeline is in Figure 




4.5.2      Absolute CTC number decreases through treatment but does not correlate to 
patient outcome 
The number of CTCs in 1 mL of blood was enumerated for each patient, revealing unique 
trends in CTC counts. As seen in Figure 2A, the patients have different trajectories, however, 
Table 4-2 Patient demographic data 
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several overall trends became apparent. For reference, each horizontal line indicates the 
trajectory of one patient, with each mountain peak height representing the CTC concentration per 
mL of blood. Any blank spaces or discontinuous lines indicates that the patient missed the blood 
draw at that timepoint. As the patients were plotted based on their CTC counts at Pre-TX, the 
mountain plot indicates that most patients have a substantial decrease in CTCs from Pre-TX to 
Week 1 of radiation. While many patients sustain the low number of CTCs through the end of 
RT, several patients had comparatively high numbers of CTCs at W10 after RT, Figure 4-2A. 
Instead looking at the CTC counts averaged by timepoint, we see that there was a significant 
decrease in CTCs from Pre-TX to Week 1 (p = 0.02, paired t-test), and from Pre-TX to both 
Week 10 and Week 30 (p = 0.04 and 0.02 respectively, paired t-test), Figure 4-2B. This result 
further solidifies that CTCs decrease at the start of RT; however, this additionally elucidates that 
CTCs are lower after RT and several months into immunotherapy at Week 30.  
After demonstrating a significant change in CTCs based on timepoint, we investigated 
whether CTC concentration at the timepoints around RT correlated to gross tumor volumes 
(GTVs) measured before and during RT. The number of CTCs were correlated to GTV using 
Pearson’s correlation matrix, and values reported are Pearson’s r, with significant correlations 
having p<0.05 Figure 4-2C. This analysis reveals whether two values are correlated by 
comparing the values’ rank within all the values, i.e. if variable 1 is consistently high when 
variable 2 is high amongst their populations, the two variables are correlated. As expected, the 
Pre-TX and W4 GTVs were strongly correlated (p = 0.0076, Pearson’s correlation t-test). 
Interestingly, the number of CTCs does not correlate to GTV at any of the time points, with 
some timepoints being even slightly negatively correlated with GTV, such as W4 and W10.   
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This analysis also revealed that the number of CTCs is loosely correlated between some of the 
Figure 4-2 CTC isolation and enumeration using graphene oxide (GO) chip 
 
A. Ridge plot demonstrating the CTCs per mL of blood at each time point for each patient. 
Horizontal lines denote one patient, with each mountain peak representing the number of CTCs 
at that timepoint per mL. Patients are arranged from highest Pre-tx CTCs to lowest. Scale bar 
reads the height of a 500 CTC/mL peak. B. Bar plot of CTCs per mL at each time point for all 
patients grouped. Statistics performed using two-tailed, paired t-test (* denotes p-val < 0.05). C. 
Correlation matrix with Pearson’s r shown in each square demonstrating the correlation 
between the GTV (gross tumor volume) at two time points, Pre-tx (pre-treatment) and at week 4 
of radiation, along with the CTC numbers at four timepoints (* denotes p-val < 0.05, ** p-val < 
0.005, *** p-val < 0.0005). D. CTCs per mL of blood plotted based on whether the patient has 
stable disease or ultimately progressed. E-F. Trajectories of the number of CTCs/mL through 
all six timepoints as split into E. stable and F. patients with future progression.   
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time points, but not all, Figure 4-2C. For instance, the number of CTCs at Pre-TX is correlated 
to the number at W1 and W10 but not W4. However, the number of CTCs at W4 does correlate 
to the number at W10. Numerous studies have found that CTC number and GTV do not correlate 
in various cancers, including squamous cell carcinoma of the head and neck region, 
hepatocellular carcinoma, and small cell lung cancer.203–205 This could be for multiple reasons, 
including the variation in vasculature around and within a tumor which could change the rate of 
dissemination of CTCs found into the blood.206  
The absolute number of CTCs at each timepoint was then compared to disease 
progression; patients were grouped into either “Stable” and “Future progression” based off their 
clinical outcomes. The number of CTCs at each timepoint where then plotted for the two groups, 
Figure 4-2D, and was found to not differ significantly between the stable and progressing 
patients. The individual CTC trajectories of the stable, Figure 4-2E, and progressing, Figure 4-
2F, patients were plotted and further demonstrate that there is no difference in the number of 
CTCs between the stable and progressing patients.  
4.5.3      Large decrease in CTCs during RT predicts longer progression free survival time 
When doing an interpatient comparison, the heterogeneity between patients and tumors is 
likely the most important factor in CTC dissemination.206 Instead, a comparison within each 
patient is a more reasonable strategy, comparing the number of CTCs longitudinally within one 
patient to determine how their individual disease in changing, Figure 4-3A. We quantified this 
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as the percent change in CTCs, giving us a standardized change in CTCs that can then be 
compared between patients.  
Figure 4-3 Change in CTCs during radiation treatment predicts progression free survival. 
A. Schematic demonstrating the hypothesis of change in CTCs within one patient. B. Percent change in 
GTV and CTCs between Pre-TX and Week 4 for 16 patients plotted by patient. C. Percent change in 
CTCs plotted against percent change in GTV. Color and symbol shape denote whether the patient has 
stable disease, locoregional progression, or distant progression or death. Lines indicate a quadrant where 
patients found within the quadrant almost all have progression, 5/6 patients. D-F. Percent change in CTCs 
by patient with each patient labeled by disease status for D. Pre-TX to Week 1, E. Pre-TX to Week 4, and 
F. Pre-TX to Week 10 timepoints. G-H. Kaplan Meier curves demonstrating the difference in progression 
free survival (PFS) between patient groups determined by the percent change in CTCs between Pre-TX 
and Week 4 for two different cutoffs G. increasing or decreasing CTCs and H. CTCs decreasing by more 
or less than 75%. I. Receiver operator curve for both the percent change in CTCs and GTV between Pre-
TX and Week 4. All p-val are two-tailed.  
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% 𝑐𝑐ℎ𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 =  
(𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝑎𝑎𝑎𝑎 𝑎𝑎𝑡𝑡𝑡𝑡𝑎𝑎 1 − 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝑎𝑎𝑎𝑎 𝑎𝑎𝑡𝑡𝑡𝑡𝑎𝑎 2)
𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝑎𝑎𝑎𝑎 𝑎𝑎𝑡𝑡𝑡𝑡𝑎𝑎 1
 
 First, percent change was calculated for GTV and CTCs between Pre-TX and W4, the 
two timepoints when patients had both tumor imaging scans and CTC enumeration. We found 
that all the patients had the expected decrease in GTV, while not all patients had a decrease in 
CTCs, Figure 4-3B. One patient had no change in CTCs while 4 patients had an increase in 
CTCs. The quantity of change does not correlate, however, with some patients having a large 
decrease in GTV with a minimal decrease in CTCs and the opposite. This analysis does reveal 
that there are three groups of patients as defined by their percent change in CTCs from Pre-TX to 
W4: high % decrease, moderate % decrease, and increase.  
Percent change in CTCs was correlated to percent change in GTV and each patient was 
labelled by their clinical status, either (1) stable, (2) locoregional progression, or (3) distant 
progression, Figure 4-3C. All 5 patients who had future progression had an increase in CTCs 
between timepoints. Interestingly, the percent change in GTV for the progressing patients is 
widely spread, ranging from 40-80%. This indicates that it is the percent change in CTCs and not 
GTV that corresponds to the future progression of these patients.  
The percent change in CTCs between Pre-TX and W1, Figure 4-3D, Pre-TX and W4, 
Figure 4-3E, and Pre-TX and W10, Figure 4-3F, were plotted. The percent change in CTCs was 
plotted for each patient, and each patient was labelled according to the same metrics of 
progression: stable, locoregional, and distant progression. As shown in Figure 4-3D, F, the 
patients who have future progression were indistinguishable from stable patients at Pre-TX and 
W10 timepoints. Alternatively, patients who have future progression have a higher percent 
change in CTCs between Pre-TV and W4, Figure 4-3C, indicating that a higher percent change 
in CTCs between Pre-TV and W4 may be a predictor of future progression. 
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To perform survival analysis, the patients were first divided based on increasing (n=4) or 
decreasing (n=16) CTCs between Pre-TX and W4, Figure 4-3G. There was a significant 
difference between the two populations, with the patients who had an increase in CTCs having a 
PFS time of only 5 months (p=0.0125, log-rank (Mantel-Cox) test). Conversely, among the 
patients who had a decrease in CTCs, only two of the patients had future progression, most of the 
data points were censored. The monitoring time was an average of 17 months for the patients 
with a decrease in CTCs.  
A second cutoff, a decrease in CTCs of more (n=8) or less (n=8) than 75%, divided the 
patients into two even groups. This cutoff shows that patients who had less than a 75% decrease 
in CTCs had a significantly shorter PFS time of 7 months (p=0.0056, log-rank (Mantel-Cox) 
test). Among the patients who had a decrease of more than 75%, none of the patients had future 
progression, so all the data points were censored. The average monitoring time was 21 months. 
This data strongly indicates that having more CTCs at W4 compared to Pre-TX is an early 
indicator of future progression.  
Finally, receiver operator characteristic curves (ROC) were used to determine which of 
the two potential predictors of future progression is more accurate between percent change in 
GTV and CTCs between Pre-TX and W4. ROC curves are used to illustrate the diagnostic or 
prognostic potential based on a binary outcome. This analysis assesses with what accuracy a new 
patient who is added to the cohort would be correctly predicted to be stable or progressing based 
on the specified criteria. Using percent change in GTV to predict future progression led to an 
area under the curve (AUC) of 0.55, meaning a patient would be correctly predicted to be stable 
or progressing 55% of the time. Conversely, using percent change in CTCs led to an AUC of 
0.88 (p=0.02, AUC), or an 88% chance of correctly classifying a patient.  
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4.5.4      High percentage of CTCs with programmed death ligand 1 (PD-L1) expression 
indicates higher chance of future progression 
Following RT, many of the patients received the immunotherapy durvalumab, an anti-
PD-L1 antibody. We investigated whether the presence of PD-L1 on CTCs was predictive of 
patient outcome for patients receiving durvalumab. Because durvalumab targets PD-L1 
expressed on cancer cells, we hypothesize that having a higher number of PD-L1+ CTCs would 
be predictive of increased durvalumab efficacy. First, we investigated the presence of PD-L1+ 
CTCs at each time point, Figure 4-4A. Among all the patients, there was a significant decrease 
in PD-L1+ CTCs from Pre-TX to W1 of RT (p=0.02, paired two-tailed t-test), something that has 
been previously reported.199 The number of PD-L1+ CTCs was on average dramatically lower at 
the later timepoints (W18, W30). However, many of the patients who had these final two blood 
draws coincidentally had very low CTCs at most timepoints, so this finding should be interpreted 
with caution.  
To remove the bias of having varying numbers of total CTCs, the percent of PD-L1+ 
CTCs was plotted for all patients, Figure 4-4B, demonstrating that the percent of PD-L1+ CTCs 
had a large spread among all patients at all timepoints. To assess the relationship between PD-L1 
expression on CTCs and patient outcomes on durvalumab, the analysis was further restricted to 
only the patients who received durvalumab (n=16), Figure 4-4C. As before, the percent of PD-
L1+ CTCs at each timepoint was plotted, and the range was still widespread. However, by 
adding a second variable to the analysis, the three patients who had progression while on 
durvalumab were labelled in red. It is apparent that these three patients always appear in the 
upper half of patients at all timepoints for percent of PD-L1+ CTCs. This finding corroborates a 
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previous finding that an increase in PD-L1+ CTCs has the potential to act as a marker of 
resistance to PD-1/PD-L1 inhibitors.207 
To round out this analysis, survival analysis was performed based on the percent of PD-
L1+ CTCs at each time point for patients who had durvalumab, and the most predictive 
timepoint was Pre-TX. The patients were split by > or < than 50% of CTCs being PD-L1+, and 
the group that had >50% PD-L1+ CTCs had a shorter PFS time, 14 months compared to 21 
months censored (p=0.069, log-rank (Mantel-Cox) test, survival analysis) Figure 4-4D. As such, 
Figure 4-4 PD-L1 expression on CTCs indicates metastatic potential. 
A. Number of PD-L1+ CTCs per mL at each timepoint. B. Percent of CTCs that are PD-L1+ 
at each timepoint. C. Percent of CTCs that are PD-L1+ for only the patients who received 
durvalumab immunotherapy. D. Survival analysis for patients who received durvalumab with 
a cut off of 50% PD-L1+ CTCs. 
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our finding conflicts with our previous hypothesis, and now see that a higher expression of PD-
L1 may be an indicator of poor outcomes on durvalumab.  
4.5.5      Differential gene expression analysis using Affymetrix microarrays shows 
aggressive CTC phenotype 
Common methods for high-throughput RNA analysis include PCR panels, RNA-seq, and 
single-cell sequencing. However, when analyzing CTCs, it is incredibly challenging to achieve 
adequately high RNA concentration and quality to use these methods. Microarrays, conversely, 
were originally designed for FFPE samples, which are notoriously challenging to characterize 
because of their low RNA quality. Additionally, recent advancements have decreased the 
necessary microarray input to 100pg of RNA, or as few as 10 cells. As such, microarrays offer 
the optimal combination of needing a low RNA input while still quantifying gene-level 
expression from >20,000 genes, making them an ideal method for CTC characterization. 
Here, we isolated RNA on-chip using the Arcturus PicoPure kit, followed by off-chip 
purification, and microarray analysis using Affymetrix’s Clariom S PICO chips processed by 
Fisher Scientific. We then developed and used an analysis workflow in R based off common 
microarray analysis methods using the packages oligo and limma.208 For the microarray analysis, 
we used the Pre-TX, W4, and W10 timepoints based on the previous CTC and PD-L1 analyses, 
and a total of 59 patient CTC samples were processed. This microarray analysis represents a 
much more thorough RNA profiling than that used in previous GO Chip studies, RT-qPCR using 
the Fluidigm Biomark.122,199 
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Two main quality control analyses were performed, the normalized unscaled standard 
error (NUSE) and relative log expression (RLE) before normalization using rma. The NUSE is 
used to identify samples that have an error outside the range of the rest of the samples and should 
be centered around 1.0 for all samples. Here, we see that the NUSE has a decent amount of 
variability, with four samples having a higher NUSE than other samples, Figure 4-5A. 
Typically, we want to remove samples with high errors, however in this type of longitudinal 
analysis, removing one sample would require us to remove an entire patient from the analysis. 
As such, we will leave all samples after this analysis. The second analysis, RLE, instead assess 
how far from 0 the differences in expression level are across each microarray. The RLE shows 
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Figure 4-5. Quality control data for Affymetrix microarray samples.  
Top. Normalized Unscaled Standard Error (NUSE) plot for the 83 samples included in this 




outliers. Additionally, principal component analysis (PCA) was performed, although there were 
no obvious groupings based on timepoint, patient, or progression.  
Following QC, the data was normalized, and differentially expressed gene analysis 
(DEG) was performed. Two types of DEG analyses were used: non-paired and paired. Non- 
paired analyses group the samples by timepoint, regardless of whether the patient had multiple 
samples in the progression. The paired analyses consider the patient ID and performs moderated 
paired t-tests. The number of samples included in each of the two analyses can be found in Table 
4-3. 
 Using the two analysis methods, it was found that there were no differentially expressed 
genes (DEGs) between either Pre-TX or W4 and W10. There were, however, many DEGs 
between Pre-TX using the eBayes function, empirical Bayesian function, which uses either an 
input of a paired or unpaired t-test to determine significant genes. Genes were considered 
differentially expressed if they had a p < 0.05 and a false discovery rate (FDR) < 0.05 using the 
eBayes method. All p-values are reported as adjusted p-val, adjusted using an FDR cutoff of < 
0.05.  It was found that there are 304 significantly upregulated DEGs, shown in Table 4-4. While 
continued and deeper analysis is still needed, several genes on the list are of particular interest 
based on their previously shown implications in cancer.  
 





Multiple timepoints Number of patients included 
in paired analysis 
Pre-TX & W4 14 
Pre-TX & W10 20  





Upregulated Genes: 304, adj P-val < 0.05 
F5 DSC2 C19orf38 SNX3 OSTF1 TRIM24 
IL4R METTL9 CACYBP NLRP12 TMBIM4 SHOC2 
ORM1 BASP1 WDR41 DNTTIP1 AGTPBP1 MTF1 
APMAP AGO4 FOLR3 RAB10 NAGK TIMP1 
RGL4 RBP7 HSDL2 CHCHD7 CSF2RA MYL12A 
FAM200B SMAD4 UBE2J1 SSR2 RBPJ CDK19 
NQO2 FAM157A FAM157B CERT1 RAB8B TMEM167A 
S100A12 PGLYRP1 GPCPD1 AQP9 CDC42 DDAH2 
CDA FPR2 CD14 GMFG SIRPA E2F3 
ALPL ZFP36L1 CR1 ATP5MPL H3-3B TBL1XR1 
GDE1 S100A4 CTSH IL1RN NFE2 MCTP1 
MMP9 CA4 UBLCP1 CEACAM1 FCGR2A PJA2 
CDC42EP3 MICU1 FCGR3A APBB1IP KCNE3 SPCS2 
RAB27A WASHC3 ITGB2 LRRC25 PPT1 IFNAR2 
EIF4E3 ACSL1 RSL1D1 MMP8 SNAP23 RPS27L 
MCEMP1 ZDHHC20 OSBPL8 MYD88 TTC17 SH3KBP1 
S100A6 MAPK14 EPB41L3 TALDO1 HSD17B11 STEAP4 
HMGB2 PADI4 IL17RA EFHD2 PYCARD RAB5IF 
QPCT ZNF438 SHKBP1 RNF24 ZYX KREMEN1 
GBA DNMT3A FPR1 PCNX1 GSR H3C10 
TSPO TXNL1 JPT1 LILRB3 PHF21A ST20 
LAMTOR5 CREB5 STK38 RNF130 UBXN2B AGTRAP 
PLBD1 GABARAPL2 NCOA6 STX10 UHRF1BP1L RBM22 
PGK1 PGAM1 HK3 TBC1D1 HSD11B2 HCK 
GAPDH BLOC1S1 KMT2B MON1B RTF1 LMAN2 
PXK TLR1 PLSCR1 TXNDC17 SULT1B1 NDUFB6 
S100A9 GCA RNF123 VCAN MANSC1 VASP 
TXN NMI DNAJC25-GNG10 FCGR1A DDX59 LPXN 
DYSF TES DHRS7 PSMD9 CIDEB ACP1 
ANXA3 CTSD SAMSN1 SRGN PFKFB3 ADGRE2 
PYGL VAPA RNF141 SCPEP1 PHF12 IFITM1 
CYB5R4 MS4A6A PFN1 BST1 NGLY1 GRB2 
CST7 S100P VNN1 MYL6 MGAM TRIM8 
MTARC1 CYBA CDKN1B POMP LITAF SRP14 
PLP2 VEZF1 TYROBP ZSWIM6 LRP10 CHTOP 
RAC2 ARPC5 FCGR3B ARHGDIB RAD23B ORMDL2 
PROK2 PRAMEF10 MARK2 C1D HTATIP2 ROCK1 
ANPEP NDUFA2 JAML ABHD12B ARHGAP15 H2AZ1 
ANKRD13D GNAI2 ALOX5 CKLF MDH1 CD53 
ETS2 RNF10 ADM TNFAIP6 GNG5 UBL5 
KCNJ15 CD58 PLAC8 SLC2A3 ENO1 VPS18 
H3C11 NCF4 CLEC4D LGALS1 CEACAM5 NUAK2 
CNIH4 STAT5B NOP10 SDCBP CR1L GTPBP1 
CAMP DEGS1 STXBP5 DR1 IL18RAP SF3B1 
EIF4B ARPC2 RARA ARPC1B S100A10 LYST 
VNN2 COPE DYNLT1 FCER1G ZFP91-CNTF ASB7 
IFNGR2 RTN3 LTB SELL CMTM2 RAB32 
ZBTB7B MSRA ERO1A CCDC28A UBQLN2 LTA4H 
PRR13 CFL1 EMB IFITM2 PPP1CA NFIL3 
NAIP MIEN1 HEBP2 PELATON RASGRP4  
S100A11 ATG3 INSIG2 GLT1D1 OTUB1  
Table 4-4 Upregulated genes between Pre-TX and W4 CTCs 
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Table 4-5 Select DEGs between Pre-TX and W4 with function 
Gene Cancer type Finding Refs 
STAT5B Prostate, pancreatic, breast 
• Proliferation, differentiation survival, 
migration, metastasis  
• Function and development of Tregs 
• Activated STAT5 is associated with 
suppression in antitumor immunity and 
proliferation, invasion, and survival of 
tumor cells 
209–212 
ANXA3 Lung adenocarcinoma 
• Overexpression found to be 
significantly associated with metastasis, 
decreased overall survival, advanced 
clinical stage 
213 
S100A6 Gastric, colorectal, pancreatic, HCC 
• Promotes cell proliferation and invasion  214–216 
S100A12 Papillary thyroid cancer, gastric cancers  
• Silencing inhibited cell proliferation, 
migration, invasion 
217,218 
RAB27A NSCLC, renal cell carcinoma 
• Regulates tumor microenvironment and 
promote tumor growth, poor survival 
• Resistance to chemotherapies 
219–221 
RAB10 HCC 
• Promotes cell survival, proliferation, 
poor prognosis 
• Dysregulated RAB mediated vesicle 




 Select genes were chosen because of their functions in cell proliferation, migration, 
metastasis, and survival of tumor cells, Table 4-5. The selected genes were found to be 
upregulated in CTCs at W4 and represent a CTC phenotype that is more invasive or aggressive 
compared to those of the Pre-TX. As shown in Figure 4-6, the above listed genes, STAT5B, 
S100A6, S100A12, ANAXA3, RAB27A, and RAB10 are all significantly upregulated in CTCs 




4. 6         Discussion 
There is a critical need for technologies to monitor lung cancer in a non-invasive, 
repeatable manor that can predict which patients will have favorable outcomes on radiation 
therapy. Circulating tumor cells (CTCs) offer the exciting potential to directly profile tumor cells 
while only needing a peripheral blood draw. The GO Chip is a microfluidic device that uses 
immunoaffinity to capture CTCs on the surface of the device with high purity and sensitivity. In 
this work, we present the use of the GO Chip to isolate CTCs in treatment naïve, stage III 
NSCLC patients through radiation treatment.  
 We found that CTCs were present in 100% (n=26/26) of patients and in 92.7% 
(n=102/110) of blood samples, an average of 51.0 ± 94.4 CTCs/mL (range 0-504) across all 
timepoints. This is dramatically higher than the number of CTCs as determined by the FDA 
Figure 4-6 Upregulated genes in CTCs from Pre-TX to W4 
Expression of upregulated genes: A. STAT5B, B. S100A6, C. S100A12, D. ANAXA3, E. 




approved CellSearch45,224, demonstrating the necessity of using the GO Chip antibody cocktail of 
EPCAM, CD133, and EGFR, as opposed to just EPCAM like CellSearch.  
 CTCs were enumerated at six timepoints across radiation therapy and immunotherapy, 
however the most predictive timepoints were the Pre-TX and W4 of RT timepoints. While we 
found that the number of CTCs decreased during RT like several previous studies200, this does 
not have an clinical implication as the absolute number of CTCs did not correlate with PFS at 
any timepoint. Instead, we did find that the change in CTCs between Pre-TX and W4 of RT was 
a promising marker of shorter PFS. Patients with an increase in CTCs only had 5 months of PFS 
(n=4) compared to 15 months average monitoring time (n=12) for patients with a decrease in 
CTCs (p=0.011, log-rank (Mantel-Cox) test, survival analysis). Similarly, patients with less than 
a 75% decrease in CTCs had 7 months of PFS (n=8) compared to 21 mo. average monitoring 
time (n=8) for patients with a large decrease in CTCs (p=0.0053, log-rank (Mantel-Cox) test, 
survival analysis). This is a dramatically shorter PFS and indicates the potential to use CTCs as 
an early predictor of progression. Additionally, because this finding uses the W4 timepoint, there 
is substantial time to alter patient treatment before progression, approximately 4-6 months.  
 A second interesting finding is that the patients who will have progression on 
durvalumab, an anti-PD-L1 immunotherapy, all had higher than average PD-L1+ CTCs at all 
measured timepoints. Although not statistically significant, we did find that having >50% PD-
L1+ CTCs at Pre-TX was indicative of shorter PFS for patients receiving durvalumab, 14 mo. 
PFS (n=6) compared to 18.8 mo. censored monitoring time (n=10, p=0.069, log-rank (Mantel-
Cox) test, survival analysis). Although we were unable to acquire matched tissue samples for this 
analysis, previous studies have shown high concordance between PD-L1 expression on CTCs 
and matched tumor samples.225 The presence of PD-L1+ CTCs could have serious implications 
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for the efficacy of anti-PD-L1 immunotherapies. As CTCs have been shown to lead to 
metastasis226, having high PD-L1 expression, an immune evasion protein227, on the surface of 
CTCs may allow them to escape immune surveillance and continue to seed metastasis. One study 
even found that it was not sufficient to block simply PD-L1 on the surface of CTCs to stop 
metastasis, but instead it was necessary to block CD47 as well.228  
 Finally, differential gene analysis was performed using Affymetrix Clariom S PICO 
microarrays. Analysis code was written in R using the oligo and limma packages. There were 
significantly upregulated genes between Pre-TX and W4 that corresponded to a CTC phenotype 
that was invasive, proliferative, and potentially immune invasive. These CTCs may represent the 
cells that are escaping chemotherapy or radiative cell death. By having these highly tumorigenic 
cells circulating in the bloodstream, this may indicate a potential therapeutic target. This mRNA 
expression finding may also help explain how PD-L1+ CTCs in the blood stream may lead to 
future progression, as the CTCs express additional invasive markers. Final steps need to be 
completed for the RNA analysis of this work. First, DEGs need to be fully profiled and 
categorized to understand the phenotype of these CTCs, using methods such as gene ontology 
and gene enrichment analysis. We additionally still need to further subgroup the patients into 
stable vs progressing, to determine whether any genes are predictive of future progression.  
 In summary, this work demonstrates the potential to use CTCs to predict patient 
outcomes in stage III NSCLC using the highly sensitive GO Chip. To continue moving this work 
forward, a larger validation cohort will be needed to verify the finding of this pilot cohort of 26 
patients. Additionally, further work is needed to understand the role of PD-L1 expression on 





Chapter 5 Single Cell Droplet Microfluidic CellMag-CARWash to Study NK Cell EV 
Biogenesis 
5. 1         Abstract 
Single-cell characterization is becoming increasingly necessary as researchers continue to 
elucidate the role of cellular heterogeneity in biological processes and diseases, such as cancer. 
The study of single cells, however, is non-trivial; single-cell isolation and analysis devices need 
to be incredibly precise and face many challenges. While there are many methods proposed to 
perform single-cell isolation and analysis, microfluidics are optimal technologies because of their 
small scale and ability to manipulate fluids on the pico- and micro- scale. Droplet microfluidics 
offer the opportunity to isolate target cells in aqueous droplets suspended in oil, allowing for 
single-cell analysis. Combining droplet microfluidics with well-known immunoaffinity magnetic 
isolation techniques, here we present the adapted CellMag-CARWash droplet microfluidic 
system and optimized the workflow to isolate single NK92-MI cells into single cell droplets. The 
isolated NK cells are then used to investigate the heterogeneity in extracellular vesicle excretion 
in the presence of known NK cell activators. 
5. 2         Resulting Publication Information 
E. Purcell*, C. Cook*, B. Rupp*, N. Mesyngier, A. Radomski, A. Kaehr, R. Bailey, S. Nagrath. 
“Droplet microfluidic MagCell-CARWash elucidates single-cell EV heterogeneity in activated 
NK cells.” In preparation 
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5. 3         Introduction 
 Cellular heterogeneity in diseases such as cancer has become increasingly well studied 
as researchers begin to understand how cellular differences can affect everything from immune 
function229 to drug resistance.230 As such, a myriad of single cell analysis techniques are being 
developed, ranging from single cell isolation technologies231 to single cell functional assays.232 
Technologies that combine both isolation and biological assays allow for shorter processing 
times, minimal hands-on time, and decreased sample loss compared to needing to isolate and 
then perform an assay. The most common single cell isolation techniques are fluorescence 
activated cell sorting (FACS)233,234, magnetic activated cell sorting (MACS)235,236, manual cell 
picking, and microfluidics.237,238 FACS, MACS, and manual cell picking offer the ability to 
isolate single cells but require large sample volumes or tissue samples and require post-
processing for analysis beyond protein expression. Additionally, after separation using FACS or 
MACS, downstream applications need to be performed by hand, with reagents added to each 
well. Microfluidic technologies, however, can alleviate these many of these challenges, allowing 
for isolation and characterization to be performed in an automated fashion.  
Microfluidic technologies for single cell isolation are becoming increasingly promising; 
the small scale of microfluidic devices allows researchers to manipulate fluids on a pico- and 
micro- scale, thereby minimizing assay volumes.  Commercial single-cell microfluidic 
technologies are available, the most notable of which is the DEPArray from Menarini 
Biosystems. This system uses dielectrophoresis to route cells through a microfluidic chamber; 
cells are selected by the user based on fluorescent antibody attachment, similar to FACS.239 This 
technology, however, takes lengthy processing time and has been primarily used for fixed or 
FFPE samples up until this point.240 The DEPArray is also not a combined 
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isolation/characterization system, requiring users to optimize downstream applications 
separately, such as PCR DNA anlalysis.241  
A second commercially available microfluidic cell sorter, integrated fluidic circuits 
(IFCs), were developed by the Quake group and commercialized by Fluidigm.242 IFCs facilitate 
isolation of single cells in nanoliter-sized chambers by a system of pressure controlled 
microfluidic valves that can cut off fluid flow in selected channels. While these circuits have 
been applied to obtain single-cell level genetic analyses243–245, they are limited in the total 
number of cells interrogated based on the size of the device.246 Additionally, their fabrication and 
operation require more complex techniques and training, which limits their widespread 
application. 
A popular research-scale example, deterministic lateral displacement (DLD), is a 
microfluidic cell sorting technique that employs an array of pillars to separate cells into different 
streamlines as a function of their hydrodynamic diameter.247 DLD can discriminate between cells 
based on size, shape, and deformability, and can separate multiple cell types at a time.237 
However, it is subject to low throughput from high fluidic resistances on device as well as issues 
with clogging that can be difficult to eliminate.248 Most challengingly, DLD strategies do not yet 
yield single-cell solutions, despite their label-free and high purity advantages. 
A sub-type of microfluidic devices, droplet microfluidic devices are technologies that 
isolate single cells into aqueous droplets surrounded by an oil phase.249 Single cell droplet 
microfluidics allows researchers to isolate single cells in droplets, before manipulating the 
droplets to isolate cells of interest and perform assays.250 Cells are either introduced to droplet 
systems as a pure population and diluted to achieve single-cell concentrations 251,252, or sorted 
into distinct populations either through passive or active methods.  
124 
 
One successful commercially available single cell droplet microfluidic technology, 10X 
Genomics, uses serial dilution to achieve single-cell concentrations, meaning target cells need to 
be a high proportion of the sample to ensure sufficient detection. This technology does offer a 
wide array of single-cell assay options, ranging from genomics253 to transcriptomics.254 On a 
research scale, DeKosky et al. developed a droplet microfluidic system that uses pure cell 
populations to sequence antibody repertoires from B-cells.252 Non-sorting technologies, however, 
require pure cell populations, which can be challenging to achieve from blood or other complex 
fluids, and frequently require a large cell volume. 
 Active sorting methods within single-cell droplet microfluidics frequently use 
fluorescence-based systems that isolate cells based on the presence of fluorescent signal either 
directly on cells or using a reporter antibody.246,255 Active sorting methods, however, are 
complicated systems, requiring the use of actuatable external fields. The triggering of these fields 
must be spatially engineered and closely timed with the detection of an appropriate signal, which 
necessitates droplet ordering and limits the window for observation.256 Depending on the field 
used, active droplet sorting may also require expensive equipment to monitor droplets and 
generate sorting pulses.257 While active sorting does have many advantages, including being able 
to isolate cells based on several characteristics, however, it can be challenging to introduce 
fluorescent molecules or probes into droplets.258 Active droplet sorting depends on a successful 
chain of events, including detection of cells/droplets of interest and synchronized timing of 
external field actuation. This can be challenging to achieve in concert, leading to cell loss. 
Passive sorting methods, however, allows for the precise and reliable isolation of specific 
cell populations, with comparatively simple mechanics. Magnetic sorting is an incredibly 
common passive sorting mechanism and offers optimal integration into droplet microfluidic 
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devices. Magnetic-based cell isolation microfluidic devices are common, with groups frequently 
develop these technologies to isolate rare circulating tumor cells.259,260 Magnetic-based single-
cell droplet microfluidic systems would allow for the isolation of specific cell populations 
without the need to add fluorescent probes or dyes, thereby expanding the potential downstream 
assays. Several droplet systems have been developed to isolate magnetic particles, including the 
CAR-Wash device, created by Doonan et al. The CAR-Wash system accepts an input of particles 
in droplets, coalesces droplets into a wash buffer, isolates specifically magnetic targets, and then 
reforms droplets in the product stream.261 Off-target cells escape through a waste outlet, allowing 
for the pure isolation of magnetic particles in a clean aqueous medium, like cell culture media. 
While this device has been used for only magnetic beads up until now, it offers the incredible 
potential of isolating single cells with high purity.  
One of the principal benefits of single-cell droplet microfluidic systems is the ability to 
combine single-cell isolation and analysis into one stream-lined workflow to study unique 
aspects of cellular heterogeneity. Natural killer (NK) cells are a type of lymphocyte that works as 
the body’s early defense system to fight against foreign invaders via the innate immune system. 
As part of this innate immune system, NK cells are known to secrete a variety of signaling 
molecules including cytokines, chemokines, and extracellular vesicles (EVs).262,263 EVs are 
nanoparticles that are secreted from most cell types and contain protein, mRNA, and lipids from 
the parent cell.264 After secretion, EVs can circulate through the body and be uptaken by other 
cells, allowing for intercellular signaling. The signaling pathways of NK cells via cytokines and 
chemokines has been well explored in previous studies,262,265 however the study of EVs is a 
developing area of research.  
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While initial studies have demonstrated the cytotoxic effects of NK-EVs156,157,266, there 
remain many challenges when aiming to use NK-EVs as a therepeutic. One critical question is 
whether activated NK cells generated more or fewer NK-EVs. Federici et al. showed that NK-
EVs further activate additional CD56+ NK cells267, which would be critical to enhance the 
efficacy of an NK-EV therapy. It has already been shown that T-cells and B-cells require 
activation before EV generation.268–271 As such, we are particularly interested in further 
expanding the previous knowledge to understand the heterogeneity of NK-EV excretion in the 
presence of various NK stimulatory molecules, such as IL-12.272 
 Here, we describe the adaptation and use of the droplet microfluidic CARWash system, 
here called the CellMag-CARWash to isolate single NK cells tagged with anti-CD56 
Dynabeads™. This technology is then applied to understand the heterogeneity of EV biogenesis 
from single NK cells, in droplets, under the presence of NK activating molecules. The CAR-
Wash system was originally developed to isolate green fluorescent protein–histone H2B fusion 
protein bound to magnetic beads, where beads are pulled to the edge of the device using a 
magnet before being collected into a product stream, allowing off-target protein to be washed 
away. In this study, NK-92MI cells were isolated from both pure and mixed cell populations 
using the CellMag-CARWash system. The efficiency and purity of this system was quantified, 
initial studies were conducted to assess the viability of cells after processing through the 
CellMag-CARWash system. To further characterize the single cell EV secretion, we performed 
preliminary analysis demonstrating the potential of using GFP cells to generate GFP-EVs. The 
CellMag-CARWash system allows for specific isolation of viable target cells, thorough washing 
of the isolated target cells, re-encapsulation of single cells into single droplets, and has a rapid 
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processing time, making it an optimal technology for analyzing fragile immune cells, such as NK 
cells.  
5. 4         Methods 
5.4.1      Cell culture  
NK-92MI cells were cultured in a T75 flask with 10 mL of minimum essential medium (MEM, 
Thermo Fisher) alpha supplemented with fetal bovine serum, horse serum, and antibiotic-
antimycotic. Jurkat cells (T-cells) were cultured in a T75 flask with 10 mL of Roswell Park 
Memorial Institute (RPMI, Thermo Fisher) supplemented with fetal bovine serum and antibiotic-
antimycotic. To better visualize cells and improve the analysis, NK cells and T-cells were 
fluorescently labelled CellTracker dye (Thermo Fisher). Cells were removed from culture, 
washed with PBS to ensure no serum remained and resuspended in 5mls of serum free media and 
5µL of CellTracker. The cells incubated for 30 minutes at 37℃ before being washed twice with 
PBS to remove the remaining CellTracker. K562 GFP cells were cultured in a T75 flask with 10 
mL of Dulbecco’s Modified Eagle medium (DMEM, Thermo Fisher) supplemented with fetal 
bovine serum and antibiotic-antimycotic. 
5.4.2      EV harvesting 
To harvest EVs, cells were counted, and 1.5 million cells were added to a dish with 8mLs of the 
appropriate serum full media, as above. Cells were allowed to recover in media for 24 hours 
before being washed with PBS to remove EVs from serum and were reseeded in EV free media. 
Cells were then incubated for 24-72 hours to allow for the secretion of EVs. After incubation, 
EVs were removed and the isolated using the Ultracentrifuge protocol, Chapter 3.  
128 
 
5.4.3      Magnetic Bead Attachment to NK cells 
To isolate NK cells using magnetic beads, NK-specific antibodies were first conjugated on to 
magnetic beads before attaching the magnetic beads to the NK cells, Figure 5-1. To isolate NK 
cells using magnetic beads, NK-specific antibodies were first conjugated on to magnetic beads 
before attaching the magnetic beads to the NK cells. First, the streptavidin coated M280, 2.8µm 
Dynabeads™ (ThermoFisher) were removed from the sterile bottle and rinsed 5x with 0.2µm 
filtered PBS by pressing the magnet to the side of the tube, allowing the liquid to be removed 
and the beads left behind. The clean beads are then resuspended in their original volume of 0.1% 
BSA in PBS. Biotinylated anti-CD56 antibodies (R&D Systems, cat# BAF2408) are then 
incubated with the beads at room temperature for 30 minutes on a rocker, allowing the 
biotinylated antibodies to bind with the streptavidin coated Dynabeads™. Following antibody 
binding, excess antibody was rinsed off by diluting the bead-antibody solution with 1mL of 0.1% 
BSA in PBS. The beads are then again trapped using the magnet, allowing the solution to be 
removed. The anti-CD56 conjugated beads are rinsed 4 times. After conjugation, the anti-CD56 
conjugated beads are incubated with the cells of interest for 30 minutes at room temperature on 
the rocker.  Before further experimentation, bead-tagged cells are imaged to ensure effective 






CD56 from beads 
using magnet
Incubate CD-56 
dynabeads with cell 
population to bind 
to NK cells
Figure 5-1 Workflow for CD-56 Dynabead conjugation and attachment to NK cells 
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5.4.4      Droplet generator and CellMag-CARWash device fabrication  
Device fabrication has been described previously.261 Masters are fabricated using standard 
photolithography techniques. SU-8 2025 negative epoxy photoresist is spin coated to a thickness 
of ~40 µm on a silicon wafer and baked. It is exposed to UV light through a design mask 
transparency obtained from CAD/Art Services, Inc. Device designs are constructed using 
AutoCAD software. Unpolymerized photoresist is removed via development in propylene glycol 
monomethyl ether acetate. After baking, wafers are treated with tridecafluoro-1,1,2,2-
tetrahydrooctyl trichlorosilane using chemical vapor deposition. To fabricate devices, 
polydimethylsiloxane (PDMS) is mixed at a 10:1 ratio of base to curing agent, degassed, and 
poured onto the master. Once cured, the PDMS stamp is cut out and ports are punched out using 
a 30-gauge needle. The stamp is bonded to a glass coverslip via oxygen plasma activation. 
5.4.5      Droplet generator and CellMag-CARWash set-up 
All devices are treated prior to the experiment with aquapel (Pittsburg Glass Works, cat#47100); 
this incubates for one minute before being flushed and replaced with FC-40 oil (Sigma Aldrich, 
cat#F9755). Pieces of tubing are inserted into the device ports then their respective pressure vial. 
The output tubing of each device leads to a 0.6-mL Eppendorf tube for collection. 1% 
Fluorosurfactant-008 (RAN Biotechnologies, Inc, 008-FluoroSurfactant-1G) in Novec 7500 oil 
(The 3M Company; Novec 7500) comprises the oil samples flowed on device. 
Reagents are delivered on device using a custom-built pressure controller. Nitrogen gas is 
directed into two splitting manifolds that connect to several two-stage regulators. These 
regulators allow for pressure selection. The gas then passes through an array of LHDA0531115H 
solenoid valves that actuate in response to LabView signals from an NI PCIE-6251 multifunction 
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data acquisition device. The headspace of reagent vials is pressurized via steel pins, and reagent 
is driven onto the devices via 20-centimeter long pieces of #30 PTFE tubing. Both the droplet 
generation and CellMag-CARWash devices are imaged on a Leica DMi8 light microscope, and 
videos are captured using a VEO 640L high-speed camera from Vision Research Inc. Image 
processing occurs using ImageJ software from the NIH. 
5.4.6      Single cell droplet generation 
We have previously described the droplet generation process, Steve et al, thus here we described 
the specifications for this system.  The cell solution is pipetted to mix the contents before 30-50 
µL is aspirated to load into the “sample hopper”. The hopper consists of a cut 200 µL pipette tip 
placed inside a pressure vial and connected to the device via 5 cm length of #30 PTFE tubing and 
5 mm length of connector tubing. This vial is positioned upside down so the sample remains 
inside the pipette tip. The pressures are set according to the following table and applied on 
device via a custom pressure controller. 
Table 5-1 Droplet generation specifications 
Pressure Vial Port Pressure (kPa) 
1-2 Oil 75 
1-3 Cell Sample 60 
 
Device operation takes between 5 and 15 minutes, depending on sample size. At the end of 
operation, air enters the device, at which point the sample pressure (1-3) is turned off to allow 
the oil to rinse the sample hopper. At this point, sample loading and device operation can be 
repeated. The device can be re-used several times for samples of the same identity. Device 
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usability is determined through brightfield imaging of the device to check for blockages or 
contamination. 
5.4.7      CellMag-CARWash processing 
After connecting the tubing of each port to the device, electrode syringes containing 3M sodium 
chloride are connected to the electrode ports. Eight Neodymium magnets are installed on the 
device, approximately 400 µm away from the washing channel, with four above and four below 
the coverslip. At this point, each piece of tubing from the device is inserted into its respective 
pressure vial: 
Table 5-2 CellMag-CARWash specifications 
Pressure Vial Port Pressure (kPa) 
1-1 PBS or cell media 45 
1-2 Oil coflow 40 
1-3 Droplets 35 
1-4 Oil spacer 45 
2-5 Oil resegmenter 30 
2-6 Waste 15 
 
A platinum wire is placed into the low salt buffer vial and connected to the working electrode. 
The ground electrode is attached to the needle of one of the electrode syringes.  
Droplet samples are rinsed by drawing up the oil phase in a syringe and injecting it onto the top 
of the droplets. Much of the oil phase is removed before using a razor blade to cut off the neck of 
the tube. The cut tube is then set inside the sample pressure vial (1-3). Pressures are applied and 
adjusted as necessary to achieve smooth flow within the device. Once all droplets have traveled 
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through the device, the sample and waste pressures are turned off, so the wash buffer and oil can 
rinse the sample input tubing and carry all resegmented droplets into collection. Operation time 
typically takes between 15 and 45 minutes, depending on sample size. Similar to the droplet 
generator, the CellMag-CARWash can be reused for replicate samples, but a new device is set up 
for different sample types. 
5.4.8      Post CellMag-CARWash droplet processing 
Following droplet generation and CellMag-CARWash processing, cells in droplets (referred to as 
simply droplets) are stored on ice during transport, ~30 minutes. The droplets are either kept 
intact to investigate droplet stability and cell viability in live cell experiments, or coalesced using 
1H, 1H, 2H, 2H-perfluoro-1-octanol (Sigma Aldrich, cat# 370533) to gather the cells into the 
aqueous phase for ease of counting. 
Droplet coalescing 
Droplets that have been coalesced separate into an aqueous or oil phase. The cells are removed 
from the aqueous phase and put into a well plate for imaging. 
Intact droplet imaging 
To study droplet stability, or cells in droplets, droplets are then either incubated in a 1.5mL tube 
or loaded into a microfluidic incubation chamber. The incubation chamber is the same PDMS 
top that is used in the GO Chips from Chapter 4, but briefly is a 50µm tall single chamber that is 
approximately the dimensions of a 1”x3” glass slide. The difference here is that the PDMS 
chamber is bonded using an O2 plasma etcher directly to a glass slide, creating one large 
chamber. Incubation chambers are first primed with oil before loading the droplets using a 
Harvard syringe pump at 10µL/min.  Droplets in either tubes or incubation chambers are stored 
at 37℃ until imaging. 
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5.4.9      Live/Dead analysis 
Live/Dead Viability Kit (Invitrogen Kit #L3224) was used to determine the viability of cells 
within the droplets. However, it was not possible to easily introduce the assay to the droplets. 
Instead, a portion of the droplets were placed in a well plate and excess PBS was added. By 
mixing the droplets with the excess PBS this caused the droplets to break and cells to gather in 
the PBS solution. The PBS solution was then removed from the oil, placed in a new well and 
0.5ul of calcein-AM and 0.25ul of ethidium homodimer-1 was added to the cell suspension. The 
solution incubated for 30 minutes in the dark before being imaged using fluorescent microscopy. 
Cells were counted as either live or dead based on the presence of green (calcein/live stain), red 
(ethidium homodimer-1/dead stain), or both.   
5.4.10      Fluorescent imaging and analysis 
Droplets with cells are imaged using a Nikon Ti2 Eclipse inverted microscope. Droplets are 
imaged at 6x magnification to assess overall droplet stability and at 60x magnification when 
looking at cell stability and viability, or EVs in droplets. Images are taken in brightfield to look 





5. 5         Results  
The CellMag-CARWash system presented an optimal solution for isolating clean, pure 
target cell populations using immunoaffinity magnetic beads. In this study, we present the 
adaptation of the CAR-Wash droplet microfluidic system to isolate single NK cells in droplet. 
We then aim to use these single, live NK cells to study EV excretion rate between individual 
cells, Figure 5-2. As a brief overview, magnetic beads are first attached to cells before being 
processed through the droplet generator device. This device isolates each cell into an individual 
aqueous droplet separated by oil using a common T-junction, one of the hallmark droplet 
generation techniques. The droplets are then processed through the CellMag-CARWash device 
where the magnetic bead tagged cells are reintroduced in droplets after positive selection 
isolation. These single-cell droplets are then incubated to generate EVs for quantification.  
Figure 5-2 Overview of the droplet CellMag-CARWash system.  
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5.5.1      Magnetic Bead Attachment Optimization 
 In this study, we attached antibody-conjugated magnetic Dynabeads™ to cells to mimic 
the magnetic particles used in the original CAR-Wash study. These magnetic beads need to be 
attached to the cells of interest with high specificity, ensuring we only isolate the target cells—
NK92-MI cells—while letting non-specific cells pass through. Additionally, we need to ensure 
adequate bead attachment to capture cells using the CellMag-CARWash, while not having 
excess unbound beads in the solution.  
Several parameters were optimized to ensure the effective bead attachment, including 
antibody concentration, bead concentration, and incubation concentration and duration. Briefly, 
M-280 streptavidin conjugated Dynabeads™ were incubated with anti-CD56 antibodies for 30 
minutes at room temperature. Following incubation, excess antibodies were rinsed from the 
beads using a magnet. The anti-CD56 Dynabeads were then incubated with the cells for 30 
minutes on a rocker at room temperature. Optimization experiments were performed using the 
NK-92mi cell line.  It was found that the optimal concentration of antibodies:beads is 1:2 by 
volume, and a 30 minute incubation was sufficient for the anti-CD56 conjugated Dynabeads to 
A 
Figure 5-3 Anti-CD56 Dynabead™ attachment to NK92-MI cells 
A. Representative image of bead attachment on NK cells B. Quantification of the 
number of beads per cell per NK cell, shown here as a percent of the NK cells in the 




bind to cells. Representative images are seen in Figure 5-3A. Finally, the number of anti-CD56 
Dynabeads per cell was quantified. It was found that there was an even spread between 0-10+ 
beads per cell, Figure 5-3B. It was not however known whether this would be sufficient beads 
attachment to capture cells using the magnet within the CellMag-CARWash system. 
5.5.2      NK isolation using CellMag-CARWash 
To determine the potential of the CellMag-CARWash system to isolate NK cells using 
the anti-CD56 Dynabeads™, we first used a pure population of NK-92MI cells. To start the 
experiment, NK cells were fluoresced using CellTracker before being incubated with the anti-
CD56 Dynabeads and fixed with PFA. The cells were processed through the droplet generator 
device before being sent through the CellMag-CARWash; both the product and waste streams 
were collected. As seen in Figure 5-4, NK cells with sufficient beads attachment are collected 
into the bottom, product stream.  
To determine how many beads are needed to successfully isolate NK-92MI cells, we 
quantified the number of NK cells in both product and waste streams, as well as the number of 
Figure 5-4 Images of NK-92MI cells isolation in the CellMag-CARWash device. 
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beads per cell in both streams. By first looking at solely the product stream, it was found that 3 
beads per cell led to an isolation rate of 37% ± 10 (n=5), with the rate increasing for each 
additional bead attached, Figure 5-5A.  We then calculated the percent recovery for all NK cells, 
regardless of the number of the beads attached, Equation 1. The overall percent recovery of the 
NK-92MI cells was 58% ± 7 (n=4), Figure 5-5B. However, for cells above the threshold of 3 
beads per cell, as found above, the recovery was 85% ±9 (n=4). We did find that for cells with 0-
2 beads, the recovery was a dismal 2% ± 3 (n=4). 
% 𝑟𝑟𝑎𝑎𝑐𝑐𝑟𝑟𝑟𝑟𝑎𝑎𝑟𝑟𝑟𝑟 = �
# 𝑟𝑟𝑜𝑜 𝑐𝑐𝑎𝑎𝑐𝑐𝑐𝑐𝐶𝐶 𝑡𝑡𝑎𝑎 𝑝𝑝𝑟𝑟𝑟𝑟𝑝𝑝𝑝𝑝𝑐𝑐𝑎𝑎
# 𝑐𝑐𝑎𝑎𝑐𝑐𝑐𝑐𝐶𝐶 𝑡𝑡𝑎𝑎 𝑝𝑝𝑟𝑟𝑟𝑟𝑝𝑝𝑝𝑝𝑐𝑐𝑎𝑎 + # 𝑐𝑐𝑎𝑎𝑐𝑐𝑐𝑐𝐶𝐶 𝑡𝑡𝑎𝑎 𝑤𝑤𝑎𝑎𝐶𝐶𝑎𝑎𝑎𝑎
� × 100 (1) 
We then investigated mathematically whether the system, as is, has a physical limitation 
of only capturing cells with 3+ beads. To perform this analysis, we used the framework laid out 
by Jack et al who was inspired by Derec et al, Kokkinis et al, and Schneider et al.273–276 The 
number of beads can be calculated based on the time it takes for a bead to traverse the width of 
Figure 5-5 Quantification of cells in product stream after CellMag-CARWash.  
A. Number of beads per cell in the product stream, shown as percent of cells with the given 
number of beads found in the product stream. B. Overall recovery of NK92-MI cells and 
recovery of NK cells split into cells with 0-2 beads and 3+ beads. Mean is shown, error bars are 
standard deviation, n=5 and n=4 experiments. 
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the CellMag-CARWash device and the time it takes for a cell to migrate the length of the 
CellMag-CARWash device.  
First, the residence time of unbound NK cells in the CellMag-CARWash is calculated by 
flowing clean cells, in droplets, through the CellMag-CARWash device. It was measured that the 
NK cells flow at a linear velocity, ux, of 111±8 µm/ms. Therefore, it takes an unbound cell 107±7 
ms to travel a length of 12mm through the CellMag-CARWash, or the typical residence time of a 
cell in CellMag-CARWash is 107 ms. The residence time is the maximum available time within 
which a target cell must be pulled from the top of the channel at the entrance of the CellMag-
CARWash to the bottom of the channel at the product outlet stream. Using the vertical distance 
of the device, Ly = 120 µm, we calculate that the linear y-velocity of a cell needs to be 1.02±0.07 
µm/ms for an NK cell to be captured.  
In the CellMag-CARWash, all linear y-velocity is achieved by the magnetic pull on the 
NK cells from the attached magnetic Dynabeads, FM.  Jack et al. state that the velocities of 
superparamagnetic microparticles are proportional to the magnetic field gradient.273 Assuming 
negligible electrostatic and Van der Waals forces, we can then say that the magnetic force FM, 
and the drag force FD acting on the particle are balanced. Applying Stokes law under laminar 
flow,  
3𝜋𝜋𝜋𝜋𝑝𝑝𝑡𝑡𝐷𝐷𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏 = 𝐹𝐹𝐷𝐷𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏 = 𝐹𝐹𝑀𝑀𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏 (2) 
where η is fluid viscosity, ut is terminal velocity in the y-direction, Dbead is particle particle 
diameter, and FD is drag force. If we assume that the beads do not significantly change the 
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diameter of the cell, then we can approximate the magnetic force on a cell as the sum of the 
magnetic beads attached to that cell.  
𝐹𝐹𝑀𝑀𝑀𝑀𝑏𝑏𝑀𝑀𝑀𝑀 = [𝑁𝑁 ×  𝐹𝐹𝑀𝑀𝑀𝑀𝑏𝑏𝑏𝑏𝑏𝑏] (3) 
By then applying Stokes law, Eq 2, we can state that 
�𝐷𝐷𝑀𝑀𝑏𝑏𝑀𝑀𝑀𝑀 ×  𝑝𝑝𝑦𝑦𝑀𝑀𝑏𝑏𝑀𝑀𝑀𝑀� =  �𝑁𝑁 ×  𝐷𝐷𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏 ×  𝑝𝑝𝑦𝑦𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏� (4) 
where Dcell is the diameter of the cell, uycell is the linear y-velocity needed to traverse the width of 
the channel as calculated above, Dbead is the diameter of the bead, and uybead is the linear y-
velocity of a Dynabead™. The final variable, uybead , was also calculated experimentally as 3.0 ± 
0.7 µm/ms; pure M-280 Dynabeads were flowed into the CellMag-CARWash and their y-
velocity was calculated by simply measuring the difference in y-distance between two 
timepoints.  
 Through our calculations we determined that 1.8 ± 0.4 M280 Dynabeads™ are needed 
per NK cell to achieve capture into the product stream. This is only ~1.2 beads fewer than we 
determined through our experiments, indicating that there are other factors affecting the 
collection of NK-cells in the CellMag-CARWash.  
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5.5.3      NK isolation using CellMag-CARWash from mixed cell sample  
To quantify the isolation specificity and purity of the CellMag-CARWash system, we then 
created a mixed sample of NK-92mi and Jurkat T-cells to mimic cells found in blood. First, we 
incubated anti-CD56 Dynabeads™ with the mixture of cells to ensure that the antibody is 
specific to NK cells. A representative image is seen in Figure 5-6A, with no beads found on the 
T-cells and the usual number of beads found on the NK-cells. Following bead attachment, the 
cells were processed into droplets and then through the CellMag-CARWash system. The input 
mixture was 55% ± 5 NK cells and 44% ± 5 T-cells. Following CellMag-CARWash, the product 
stream was an excellent 94% ± 2 NK cells and only 6% ± 2 T-cells, Figure 5-6B. The overall 
recovery of NK-cells was 42% ± 14, Figure 5-6C.    
5.5.4      Droplet stability and NK cell viability  
Following the isolation of pure NK cells, we then investigated the stability of those 
single-cell droplets. To image the droplets, it is necessary to load the droplets into single layers, 
Figure 5-6 Isolation of NK92-MI cells from a mixed NK and T-cell population. 
A. Brightfield and fluorescent images of the cell mixture after bead attachment. The NK cells 
have the usual number of beads while the T-cells have no beads. B. The components of the 
input and product stream, or before and after CellMag-CARWash processing. C. Percent 
recovery of NK and T-cell after CellMag-CARWash device. Mean is graphed, with error bars 
denoting standard deviation, n=4 experiments. 
A B C 
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otherwise the droplets overlap each other, making imaging impossible. We used the PDMS 
chamber (top) of the previously described GO chip, however here we simply bonded the 
chamber to a glass slide to form a chamber, called here an incubation device.  The droplets are 
loaded into the incubation device after first filling the device with oil to ensure smooth droplet 
loading.  
We first investigated two workflows for droplet incubation and loading. NK cells were 
processed into droplets through the CellMag-CARWash before either being (1) stored in the 
incubator in a 1.5 mL Eppendorf tube in suspension or (2) loaded into a primed incubation 
device. Both methods, in-tube and on-chip, were stored at 37℃, with no added CO2. At four time 
points a new incubation device was loaded using droplets stored in a tube and the droplets stored 
on-chip were imaged, Figure 5-7. At times 2 and 8 hours, the droplets are sturdy in both 
methods, with well-defined borders and filling approximately the same amount of the incubation 
Figure 5-7 Droplet stability in tube and on-chip.  
A time course of 2-24hrs (left to right) was performed for both droplets incubated in a tube 
(top) and droplets stored in an incubation device, on-chip (bottom), both were stored at 37℃. 
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device as at the first timepoint. However, by time 20 and 24 hours, the droplets stored in the tube 
were significantly more stable compared to the droplets stored on chip. Hence, the droplets will 
need to be stored elsewhere and then loaded into an incubation chamber.  
However, there were concerns about the viability of the cells; single cells are challenging 
to culture and the gas exchange through oil is already low before encapsulating the cells in a tube 
or device. To assess the viability of the cells in droplets, droplets were stored in a tube at 37℃. 
At 4, 9, and 24 hours after droplet generation, a portion of the droplets were removed from the 
tube and excess PBS was added to coalesce the droplets. The aqueous layer was then removed, 
and a live/dead viability assay was performed, Figure 5-8. 
Figure 5-8. Cell viability as tested with live/dead assay. 
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At 4 hours, the cells were either 
distinctly alive, green, or dead, red. This 
held true at 9 hours, where most of the cells 
were either dead or alive. However, at 24 
hours, there was a new population of cells: 
cells with compromised cell membranes, 
indicating recent cell death. This is shown in 
Figure 5-8 as the partially red, partially 
green cells. We then quantified the number of each population of cells: live, dead, and recently 
dead. We found that at 4 hours, 77% of cells were alive, but by 24 hours only 6% of the NK cells 
were alive, Figure 5-9. At 24 hours we do see a large portion of the cells we have termed 
recently dead cells, 42%, these cells indicate that there is room for improvement in incubation 
strategy that could lead to longer viability than 9 hours.   
The single NK cells were isolated into droplets of whole media following the CellMag-
CARWash system, meaning the cells have the necessary nutrients for growth. However, they 
were stored in a tube, and hence there was no gas exchanged. Cells are normally cultured with 
5% CO2. We think that altering the storage conditions of the droplets, maybe in a well plate or a 
culture dish, will allow us to incubate the droplets in a CO2 rich environment. Additionally, it has 
been shown that gasses diffuse more slowly through oil, so increasing the CO2 concentration 
may create a more aggressive gradient, allowing more CO2 penetration into the droplets. We 
hope that these changes will allow us to increase the viability of the cells in droplets.  
Figure 5-9 Live/dead results from NK cells 
following the CellMag-CARWash system. 
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5.5.5      EV quantification in droplets 
Finally, we began investigating the feasibility of quantifying EVs in droplets. We did not 
want to add anything to the droplets, such as a reporter, for fear of EV loss. Additionally, every 
additional processing step is more time that the cells are either off ice or out of the incubator—
leading to more potential cell death. We then turned to using dyed or stained cells, with the 
hypothesis that a dye found within the cytoplasm would naturally get excreted into the EVs. 
However, dyes can be shed from cells, making it almost impossible to determine what 
fluorescent signal was from EVs and what came from free dye in the droplets. As such, we have 
landed on using GFP-cells to excrete GFP-EVs, which has recently been demonstrated by Joshi 
et al.277  
 GFP-K562 cells were used to determine whether this method would be feasible for EV 
detection in droplets. Initial experiments were performed by isolating K562-GFP EVs using 
ultracentrifugation. The EVs were then loaded into droplets and into an incubation chamber. 
Fluorescence was then imaged and quantified using the Nikon Ti2 Eclipse microscope and 
analysis software, Figure 5-10. As a comparison, fluorescent 190nm polystyrene beads (Bangs 
Figure 5-10 Comparison of 190nm polystyrene beads with GFP-EVs.  
This comparison demonstrates the appearance of EV-sized fluorescent particles and confirm 
feasibility of the imaging method. 
190 nm Polystyrene Beads K562-GFP EVs 
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Lab), were processed into droplets, Figure 5-10. The comparison indicates the size range and 
appearance that the GFP-EVs should have, which we do see in the K562-GFP EVs.  
5. 6         Discussion  
 
In this work, we present the adaptation and application of the CellMag-CARWash droplet 
microfluidic device system for the isolation of pure NK-92MI cells. We then apply this device to 
begin understanding the heterogeneity of EV excretion among NK-92MI cells.  The original 
CAR-Wash system was highly effective at separating magnetic beads with bound protein; 
however, the system had never been used to isolate live cells. We harnessed the CellMag-
CARWash’s ability to isolate magnetic beads and attached anti-CD56 magnetic Dynabeads™ to 
NK-92mi cells and isolated them from both pure and mixed cell populations.  
 Preliminary testing found that NK cells with 3 or more anti-CD56 Dynabeads attached 
were able to be captured by the CellMag-CARWash system with 85% ± 9 efficiency. Using bead 
and cellular velocities measured experimentally in the CellMag-CARWash device, we were able 
to calculate that the system should capture cells with ~1.8 beads attached, which is slightly 
different than our empirical finding that we needed 3 beads per cell for capture. This difference 
could be for several reasons. First, the calculations assume that the cell with beads attached is 
essentially just a magnetic sphere the size of a cell with a magnetism corresponding to the 
number of beads attach. This assumption does not consider the location of the beads on the cell: 
if all the beads are evenly spread out, this cell may have less pull towards the magnet as some of 
the beads are blocked by the cell. Additionally, the presence of many beads on the surface of a 
cell will increase the apparent size of the cell, further decreasing the measured linear velocity of 
a cell across the channel. Another potential cause is blockages in the device. Because we are 
processing cells, there is always going to be cellular debris. One of the benefits of the CellMag-
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CARWash is the horizontal buffer exchange flow, however, cellular debris still occasionally 
becomes stuck to the device, causing cells to reroute to a suboptimal streamline, i.e. cells may be 
pushed away from the product stream along the bottom of the device.  
 Finally, for this system we used anti-CD56 conjugated Dynabeads, where CD56 is the 
hallmark protein marker for NK cells. However, it has been found that not all NK cell express 
CD56 at high level; Angelo et al. investigated NK cell phenotypes using flow cytometry and 
began by grouping NK cells into CD56 bright and CD56 dim.278 In the future, we could consider 
adding a second NK cell antibody to our Dynabeads, such as CD49b or NKp46279, allowing for 
bead attachment to cells that have lower expression of CD56. 
 We feel, however, that capturing only cells with 3+ beads may not be a problem, and in 
fact could even be beneficial. While we found very low nonspecific binding—in mixed cell 
populations T-cells rarely had beads attached, and if they did, it was always only one—the 
current system would allow these nonspecific cells to be released to the waste. Because of the 
high number of NK cells in the blood, accounting for ~10% of leukocytes in the blood, we are 
more concerned about the purity of the product sample and less about the recovery. In fact, we 
found that for mixed NK and T-cell populations, the purity of the product was 95%.  
 After validating the recovery of the system, we began investigating the stability of both 
the droplet and cells over 24 hours. We found that incubating droplets in an incubation device 
led to droplet destabilization and dissolvement whereas droplets stored in an Eppendorf tube 
remained stable and intact after 24 hours. Preliminary results show that after 24 hours, 
approximately 50% of the cells in droplets were dead while 45% were termed recently dead. This 
is a promising result, and we feel that with alterations to the droplet storage conditions, such as 
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storing them in a high concentration of gaseous CO2, we could achieve high cell viability during 
the 24-hour incubation time.  
 This project is ongoing with several main thrusts needing work. First, we need to further 
investigate optical methods for quantifying EV production from the single cells. We found that 
GFP tagged cells excrete GFP EVs, however, quantifying the EVs per droplet poses an 
interesting challenge. We will additionally need to validate that attaching the magnet beads does 
not significantly alter the cells’ ability to excrete EVs. Finally, we plan to use this system to 




Chapter 6 Conclusions 
6. 1         Research Summary 
In this work I present the development of workflows for the isolation and characterization 
of biomarkers from stage III and stage IV non-small cell lung cancer patients. In NSCLC, it can 
be challenging to know what treatment will be the most effective for patients, with the standard 
of care being largely patient-independent. There is a critical need for technologies that can be 
used to predict treatment outcomes to ensure patients receive the most precise, personal 
therapies. Liquid biopsies offer the potential to fill this need, with two of the most common 
biomarkers being circulating tumor cells (CTCs) and extracellular vesicles (EVs). The pathway 
to develop a liquid biopsy requires isolation of a biomarker, characterization of that biomarker, 
correlating the biomarker to clinical data, and finally validation in a larger cohort.  
 In the second chapter of my thesis, I describe the development of workflows to isolate 
and analyze EVs using microfluidics. Several microfluidic technologies were introduced that 
take advantage of different isolation strategies to isolate EVs from human plasma. One of the 
main benefits of using EVs, as opposed to ctDNA or CTCs, is that they are incredibly durable 
while still allowing for multianalyte testing, which we take advantage of in these microfluidic 
devices. The first described device, the newExoChip, uses the presentation of phosphatidylserine 
(PS) on the outer leaflet of tumor derived EVs (TDEVs) to capture TDEVs using Annexin V 
tethered to the device surface. This device steps outside of the bounds of typical EV capture, 
using a lipid as opposed to a tetraspanin protein as the target to capture EVs. We did have 
concerns, however, about the yield of this (and all) microfluidic device. Yield is incredibly 
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important in EV research because of the numerous characterizations that are needed to validate 
the presence of EVs. The newExoChip was the first system where we developed and validated 
workflows to characterize EVs following on-chip isolation and release, with a heavy focus on 
protein assays. The presence of specific proteins is the hallmark to identify specific 
subpopulations of EVs or validate the presence of EVs from a specific source. In this first work, 
I optimized assays for CD9 and FLOT1 using output of the newExoChip device, demonstrating 
the sufficient output of these technologies.  
We took advantage of the newly developed EV-Protein workflows in the second work 
described, the “On-Chip Biogenesis of NK-EVs”. In this system, we captured NK cells using the 
GO chip and incubated the captured, pure NK cells to generate NK-EVs which were then 
isolated using magnetic Dynabeads. In this system, I used western blots to demonstrate the 
presence of NK-EVs using CD56 (NK specific marker), FLOT1 and ALIX. This was 
significantly different than the proteins used for TDEVs, which contain the tetraspanin CD9, that 
is not expressed in NK cell derived EVs. In this work, the EVs were generated ex-vivo as 
opposed to direct capture, thereby testing our protein workflows again. 
Finally, I presented the DICE device, to isolate and characterize EV protein on-chi. This 
device was slightly different, where we biotinylated all the EVs before attaching them to the 
device. We then characterized the captured EVs for four common proteins (EGFR, EPCAM, N-
CAD, and PD-L1). The inter-person protein variability was corroborated using the Wes system, 
where quantified protein expression allows for easy comparison between samples. While these 
fundamental EV isolation and characterization methods are critical for EV research to move 
from benchtop to clinic, they are just the foundation and deeper characterizations are needed. 
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 In my third chapter I did just that, we moved beyond fundamental EV characterizations to 
investigate whether EVs contained EGFR mutations and whether these could be correlated to 
clinical outcomes. The presence of EGFR mutations in metastatic lung cancer allows for the use 
of specific therapies, however, testing for these mutations in the primary tumor is highly invasive 
and therefore minimally repeatable. Additionally, it has been shown that mutation profiles of a 
tumor can change through therapy; developing resistance mutations frequently necessitates a 
change in treatment. Liquid biopsies are the optimal technology to solve the need for a highly 
repeatable EGFR mutation profiling technology. In the third chapter of my thesis, I demonstrated 
the presence of EGFR mutations in EVs, quantified the mutations, and correlated the mutation 
burden to disease status. First, I established the assays for both activating, L858R and exon 19 
del, and resistance, T790M, mutations in EV-RNA using droplet digital PCR and activating 
mutations in EV-Protein using western blots. The assays had high specificity and sensitivity, as 
found using cell lines. The assays were then applied to a cohort of 10 metastatic NSCLC 
patients. EV-RNA mutations were found in 9/10 patients while EV-Protein was found in the four 
patients tested. Additionally, EV-RNA mutation burden, especially exon-19 deletion, was found 
to correlate to disease status; patients with increasing exon 19 del burden had progression and 
death, while patients with decreasing exon 19 del remained clinically stable. However, this was 
just a proof-of-concept study, demonstrating the potential of EVs for clinical use.  
 Compared to EVs, CTCs are significantly farther along in their path to clinical 
application. Because of the already FDA approved CellSearch™, their path to clinical utility is 
clearer and their use in clinical trials has already begun. CellSearch™ is not a perfect technology, 
and improvements are necessary, especially for investigating NSCLC CTCs which do not 
ubiquitously express the necessary EpCAM protein. In my fourth chapter, I present the use of the 
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GO Chip to isolate CTCs from treatment naïve stage III NSCLC patients. Here, CTCs were 
isolated from 26 NSCLC patients, before treatment, during radiation therapy, between therapies, 
and during immunotherapy. Two GO Chips were processed at each timepoint, with one being 
used to enumerate the number of CTCs per mL of blood and the second for microarray 
processing and differential gene analysis. The enumeration data allowed us to correlate the 
number of CTCs, change in number of CTCs, number of PD-L1+ CTCs and similar data to 
clinical metrics including gross tumor volume (GTV) and progression free survival (PFS). We 
found that between pre-treatment and week 4 of radiation having a percent change in CTCs 
therapy of less than 75% led to a significantly shorter PFS (7 mo. vs 21 mo. monitoring, p = 
0.0075, log-rank (Mantel-Cox) test). We additionally found that the patients with progression 
while on anti-PD-L1 immunotherapy, durvalumab, had >50% PD-L1+ CTCs at all timepoints. 
Using survival analysis, we found that having >50% PD-L1+ CTCs at pre-treatment led to a 
shorter PFS, though not quite statistically significantly (p < 0.06, log-rank (Mantel-Cox) test).  
While these metrics are incredibly exciting and offer the potential to screen patients 
either before treatment or very early during radiation therapy, we were additionally interested in 
the molecular profile of the CTCs. Previous GO Chip studies performed RT-qPCR to profile the 
CTC-RNA, however, in this study we moved to investigate whether a more comprehensive RNA 
profiling technique would be used. As such, we used the RNA isolated from the second GO chip 
to perform microarray analysis using ThermoFisher’s Clariom S PICO chip. We used the R 
programming language to develop a code to process the data, from raw data through quality 
control (QC) and resulting in differential gene analysis. After comparing unpaired to paired 
analysis, we used a paired analysis to identify a list of >300 genes that were significantly 
differentially expressed between pre-treatment and week 4 of radiation based on p < 0.05 and 
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false discovery rate < 0.05 as determined using the empirical Bayesian method in either a paired 
or unpaired t-test. While our analysis is a critical addition to the journey to bring CTCs to clinical 
use, this is still a bulk analysis, and research has shown that cellular heterogeneity is critical to 
understand.  
 One area of research in which cellular heterogeneity is still poorly understood is EV 
biogenesis. In the fifth, and final, chapter of my thesis, I collaborated with the Bailey Lab to 
adapt their droplet microfluidic CellMag-CARWash system to isolate single, live cells. Droplet 
microfluidics are systems that use oil to generate aqueous droplets, allowing for manipulations 
and reactions on a micro- and pico- scale. In this work, we first processed cells through the 
microfluidic droplet generator before putting the single-cell droplets through the microfluidic 
CellMag-CARWash system. Positively tagged cells were encapsulated into fresh droplets in the 
product stream, leading to a pure cell population in droplets. In this work, we used NK-92MI 
cells to investigate the heterogeneity of EV generation among NK cells. After demonstrating the 
antitumoral response of NK-EVs (“On-Chip EV Biogenesis”, Chapter 2), we aimed to 
understand the differences in EV generation. We found that the adapted CellMag-CARWash 
system isolates NK cells with 3+ anti-CD56 magnetic Dynabeads and using a previously 
developed mathematical framework to calculated that based on our system we should be able to 
capture cells with > 1.8 beads per cells.  We then moved to demonstrate that the CAR-Was 
system isolates NK cells with 95% purity from a mix of NK and T-cells. Finally, because we are 
interested in using this system to investigate EV biogenesis, it was critical to demonstrate the 
droplet stability and cell viability after the CAR-Wash. We found that droplets need to be stored 
in solution as opposed to in a microfluidic device.  However, while storing the droplets in an 
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Eppendorf tube led to droplet stability, there was minimal gas exchange which likely led to faster 
cell death.  
6. 2         Limitations and Future Work 
While the above work demonstrates the potential for introducing EVs and CTCs into 
clinical settings, there are still many challenges that need to be addressed before these 
biomarkers and subsequent technologies are adapted at a large scale.  
 EVs are definitively further away from clinical application, with no FDA approved 
isolation or characterization technologies being on the market. However, I feel that they offer 
more potential as prognostic and diagnostic biomarker in many cancers, especially lung cancer. 
The primary benefit of EVs is their robustness, their lipid bilayer makes them incredibly stable 
compared to other options. However, low concentration of target EVs in the background of non-
specific EVs, i.e. tumor-derived EVs in white blood cell EVs, or NK-derived EVs in white blood 
cell EVs, is a monumental hurdle. The most common solution to isolate a specific subpopulation 
of EVs is to perform antibody-based capture using a marker that should be cell-type specific. 
This is essentially the principle we used in Chapter 2 designing the newExoChip, however newer 
technologies, such as the EVHB-Chip screened several different glioblastoma specific markers to 
select the most effective for tumor-derived EV isolation, including EGFRvIII, one of the 
hallmarks proteins of glioblastoma.145 While this is a reasonable solution to isolate cell-type 
specific EVs, each cancer or cell type would need to have its own antibody validated, which 
becomes not feasible when looking at using EVs for diagnostics, where the cancer type is 
unknown. Additionally, some patients may not express the specific marker of interest, for 
instance only 24%-67% of glioblastoma patients have the EGFRvIII mutation, so an EGFRvIII-
specific test would be ineffective for those patients280. Similar advancements have led to the 
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generation of EV-protein screening assays to begin building knowledge about EV protein 
expression across cancers, however these efforts have been largely focused in lung cancer93,94. 
So while there has been much progress in finding tumor, or cell-type specific proteins, to target 
for EV isolation, there is still critical work that needs to be done before we have libraries of 
proteins to isolate or identify cancer type specific EVs.   
  A second option for a diagnostic or prognostic EV assay, besides isolating a tumor-
derived EVs, would be to instead target a specific molecule found within EVs that is known to be 
generated from the tumor, such as tumor-specific mutations. This was the approach we took in 
Chapter 3, where we profiled EGFR mutations. While we found that our assay had high 
sensitivity and specificity with a potentially clinically interesting finding, the methods are not 
suitable for clinical use. First, the EV isolation method here was ultracentrifugation, which takes 
~5 hours for EV isolation46, and the machine would likely not even exist at a non-research 
hospital. Instead, an isolation method would need to be used that was either already 
commercially developed or could be easily commercialized. Current commercial isolation 
methods, such as PEG precipitation kits suffer from high cost and lower purity47, while 
microfluidic technologies may not have a high enough yield to investigate rare mutations. 
Additionally, highly sensitive techniques are needed to profile these rare mutations if the isolated 
EVs are bulk EVs from blood. Droplet digital PCR, as used in Chapter 3, offers high sensitivity 
and the ability to achieve single-transcript resolution, but is minimally multiplexable, making it 
expensive and low throughput.281 Therefore, the combination of ultracentrifugation followed by 




 Where EVs are far from reaching clinical utility as diagnostic or prognostic technologies, 
CTCs are dramatically closer. The work in Chapter 4, using the GO chip to isolate CTCs across 
radiation therapy demonstrated prognostic potential early during treatment. There remain several 
challenges that need addressing before such a technology could be used in clinic. First, our 
findings were generated in a relatively small pilot cohort, a larger validation cohort is needed to 
ensure the accuracy of the data and power the study. However, the challenge in generating a 
larger cohort is additionally the second challenge for using this system in a clinical setting: 
fabricating and processing blood on a GO chip is a lengthy, hands on process.  
 Fabrication of the device is currently performed in 6 device batches, which would need to 
be significantly scaled up if used in a validation cohort. Of the two components of the device, the 
substrate is essentially a silicon wafer base with graphene oxide adhesion; this process is like 
other silicon fabrications used commercially and should be straightforward to scale up. The 
chamber is made of PDMS, which is an optimal material for this application282, and would likely 
need to be purchased from a company to achieve the throughput needed. Finally, the 
functionalization of these devices is time intensive, and automation would be needed to truly 
scale up this process. However, this process does mimic other microchip platforms, and could be 
done commercially in theory.  
 Even once scale-up challenges are alleviated for GO Chip manufacturing to allow for 
large cohort processing, the downstream analyses of GO Chip workflows need automating. The 
results found in Chapter 4 were largely based on counting the number CTCs bound to the GO 
Chip as DAPI+/CK+/CD45- cells based on immunofluorescent staining. And while this 
enumeration was performed quantitatively based on fluorescent intensity, it was done manually, 
with each cell being measured and decided upon by a human, similar to pathological 
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identification of tissues.  It has been shown that even among trained pathologists, human 
processing does added variability to these types of analyses.283 Automated counting will be a 
critical addition to a clinical GO Chip workflow. Easily available software includes ImageJ and 
even potentially Nikon’s proprietary NIS Elements software. However, these are still semi-
manual, with the user needing to alter many settings. This can become very challenging when 
working with immunofluorescent CTCs, where fluorescent intensity can have high variability 
patient to patient. Machine learning techniques offer a more robust method for automated CTC 
counting, with several groups making significant headway in this effort, however researchers still 
note the need to be incredibly diligent when choosing algorithms and defining training sets 
because of the inherently noisy data created from cellular variability.284,285  
 Finally, one of the main challenges when working with both EVs and primary cells is 
their heterogeneity. In Chapter 5, I present an approach to use the droplet microfluidic CellMag-
CARWash system to isolate NK cells into single-cell suspensions in droplets to investigate EV 
biogenesis. While this system offers many advantages for our application, there are several 
limitations to the setup. First, the system uses CD56 to bind magnetic beads to NK cells. 
However, if the goal is to investigate cellular heterogeneity, we have already preselected a 
population of NK cells that is likely to have a high expression of CD56; it has been shown that 
there are really two NK cell populations, CD56bright and CD56dim as shown by flow cytometry286. 
The creation of an NK cell-specific cocktail would enhance the variety of isolated NK cell 
phenotypes, and could include targets such as CD16 and NKp46.287 Adding additional NK cell 
antibodies would also help reduce the number of NK cells with 0-1 beads attached, which 
accounted for ~20% of NK-92MI cells. 
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 Besides increasing the heterogeneity of NK cells isolated, the post-CellMag-CARWash 
workflows face several limitations. First, the optical configuration of our EV-imaging is 
inherently challenging. Because of their small size, EVs are smaller than the wavelength of light, 
making their imaging extremely challenging. We are using fluorescence, which makes it 
possible, but imaging EVs is an on-going challenge in the field, especially when they are free to 
move about in a solution, causing them to be dilute and in many focus planes.288 Typically, in 
droplet microfluidic systems, researchers either use fluorescent microscopes using either lasers 
(like confocal microscope) or LED light sources, or they insert optical fibers into the device to 
increase detection289.  We feel that our Nikon Ti2 Eclipse microscope offers a sufficient 
combination of ease of use, low-background, and low-detection limit for this application as 
fluorescent microscopy has been used for single-cell cytokine detection290, and instead need to 
think about the geometry of our incubation chamber and the image analysis of the gathered data. 
One challenge is removing the fluorescence of the cell from the droplet to only count the 
fluorescence of the EVs, this could be done using the cell counting software described above, 
likely ImageJ. We also need to worry about the EVs being on different focus planes: the current 
incubation chamber is 50µm tall. As such, we need to consider taking a z-stack, or scanning the 
droplets in the z-direction, in addition to the x- and y- coordinates of the device.  
 A second limitation is that the current scheme of using fluorescent imaging to quantify 
EVs will essentially only be useful to answer questions about EV generation because we do not 
add or remove anything from the droplets. The addition of more complex droplet manipulation 
devices downstream will open our system up to a wide array of applications. To give a couple of 
examples, many droplet microfluidic systems use picoinjectors, first ideated by the lab of David 
Weitz, to inject droplets with small amount of liquid.291 Adding one or more picoinjectors to a 
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system vastly increases the applications of the system, with groups using picoinjectors to add 
reporter molecules to monitor reactions or the accumulation of secreted products.292 Another 
option to increase the versatility of this system would be to include a K-Channel, whereby 
droplets are split into two smaller droplets293, therefore the introduction of a magnet in one 
product stream would allow us to remove the tagged-cells, leaving droplets filled with only EVs 
for further analysis. 
6. 3         Conclusions 
In this work, I present several projects aiming to push the use of a blood-based liquid biopsy in 
lung cancer forward. From the development of EV isolation technologies and fundamental 
assays for EV characterization to the detection of EGFR mutations in EVs, this work helps move 
EVs towards clinical application. Then moving to CTCs, I demonstrate a direct clinical 
application of CTCs in stage III NSCLC, where changes in the number of CTCs predicts patient 
outcomes, but the technology would need to be overhauled for commercial scale-up to be 
reasonable. Finally, I introduce a droplet microfluidic technology to isolate pure cell populations 
using immunoaffinity magnet binding and am working to apply the technology to understand the 
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